Insights Fall 2024

Page 74


Canada’s voice for biotechnology / Le porte-parole canadien de la biotechnologie POLICY

Leading with Purpose: An Interview with Lori Lyons-Williams / Diriger avec détermination : Une entrevue avec Lori Lyons-Williams p. 54

BIONATION 2024: Showcasing the Power and Potential of Canada’s Biotech Ecosystem / BIONATION 2024 : révéler la richesse et le potentiel de l’écosystème biotechnologique canadien p.12

CONTENTS / TABLE DES MATIÈRES

09 MESSAGE FROM THE PRESIDENT AND CEO

11 MESSAGE DU PRÉSIDENT ET CHEF DE LA DIRECTION

Par Andrew Casey, BIOTECanada

DEPARTMENTS / SECTIONS

12 BIONATION

BIONATION 2024

Showcasing the Power and Potential of Canada’s Biotech Ecosystem

BIONATION 2024

Révéler la richesse et le potentiel de l’écosystème biotechnologique canadien

18 BIONATION

Celebrating the Best in Biotech: 2024 Gold Leaf Award Winners

Récompenser le meilleur de la biotechnologie : Les lauréats des Feuilles d’or 2024

26 BIONATION

All eyes on Canada at BIO 2024

Tous les regards tournés vers le Canada à l’occasion du congrès BIO 2024

38 KNOWLEDGE

Commercializing Women’s Health: Navigating a Blue Ocean Therapeutic Opportunity

Le marché de la santé des femmes : exploration de possibilités thérapeutiques inédites

By Erika Siren, CEO SeraGene Therapeutics

Par Erika Siren, chef de la direction de SeraGene Therapeutics

48 ECOSYSTEM

The State of Biotech and Biologic Manufacturing in Canada: A conversation with BIOTECanada Member, Pegasus Biotech

La situation des biotechs et de la fabrication biologique au Canada : Une rencontre avec Pegasus Biotech, une entreprise membre de BIOTECanada

DEPARTMENTS / SECTIONS

54 EXECUTIVE PROFILES / EXÉCUTIF

Leading with Purpose:

An Interview with Lori Lyons-Williams, President & CEO at Abdera Therapeutics, on Transforming Cancer Care

Diriger avec détermination : Une entrevue avec Lori Lyons-Williams, présidente et chef de la direction d’Abdera Therapeutics, sur la nouvelle approche des soins de cancérologie

60 KNOWLEDGE / CONNAISSANCE

Unlocking the Future of Alzheimer’s Treatment: An interview with Dr. Donald Weaver, Chief Medical Officer at Treventis

Découvrir de nouvelles pistes pour la recherche sur la maladie d’Alzheimer : Une entrevue avec le Dr Donald Weaver, chef des services médicaux de Treventis

Fall/Automne 2024

Published for / Publié pour :

410 – 410 Laurier Ave West Ottawa, ON K1R 1B7 Tel: 613-230-5585 info@biotech.ca www.biotech.ca

EDITOR IN CHIEF / RÉDACTRICE EN CHEF

Nina Lewis

TRANSLATION / TRADUCTION

Sophie Campbell

Published by / Publié par

ON THE COVER / EN COUVERTURE

Canada's biotech industry is clearly positioned for significant expansion. From the role of biomanufacturing in Canada, alongside the strategic roles of investment and policy, this issue explores how Canada is enhancing its regulatory capacity to support innovation and attract global pharmaceutical and biotech industries, bolstering its stance as a global leader in biotech. This edition is filled with insights into how these efforts are positioning Canada at the forefront of a transformative phase in healthcare, benefiting both national and global communities.

Le secteur canadien de la biotechnologie est en bonne voie de connaître une expansion considérable. Qu’il s’agisse du rôle de la biofabrication au Canada ou des fonctions stratégiques qu’assurent les investissements et les politiques, le présent numéro explore l’étoffement qu’effectue actuellement le Canada de sa capacité réglementaire à soutenir l’innovation et à attirer les multinationales pharmaceutiques et biotechnologiques, grâce auquel le pays renforce sa position de chef de file mondial des biotechs. Ce numéro est rempli d’informations sur le positionnement du Canada à la suite de ces efforts; notre pays se trouve en effet à l’avant-garde de la transformation qui touche les soins de santé, au bénéfice des populations de chez nous et d’ailleurs dans le monde.

ADVERTISERS DIRECTORY / RÉPERTOIRE DES ANNONCEURS

700 – 251 Bank Street Ottawa, ON K2P 1X3 Tel: 613-317-8945 reception@taag.ca www.taag.ca

GRAPHIC DESIGNER / GRAPHISTE

Leslie Miles

PROJECT MANAGER / DIRECTEUR DE PROJET

Danielle Valois

DIRECTOR OF ADVERTISING SALES / DIRECTEUR, VENTES PUBLICITAIRES

Stephan Pigeon

©2024 BIOTECanada insights. Any errors, omissions or opinions found in this magazine should not be attributed to the publisher. The authors, the publisher and the collaborating organizations will not assume any responsibility for commercial loss due to business decisions made based on the information contained in this magazine. No part of this publication may be reproduced, reprinted, stored in a retrieval system or transmitted in part or whole, in any form or by any means, electronic, mechanical, photocopying, recording or otherwise, without the prior written consent of the publisher.

©2024 BIOTECanada insights. Aucune erreur ou omission décelée dans ce magazine ou aucune opinion qui y est exprimée ne doit être imputée à l’éditeur. Les auteurs, l’éditeur et les organismes qui ont collaboré à la publication rejettent toute responsabilité à l’égard des éventuelles pertes commerciales pouvant découler de décisions d’affaires prises à la lumière des renseignements contenus dans ce magazine. Il est interdit de reproduire, de réimprimer, d’emmagasiner dans un système de recherche documentaire ou de transmettre cette publication en tout ou en partie, sous quelque forme ou par quelque moyen que ce soit (électronique, mécanique, photocopie, enregistrement ou autre), sans avoir obtenu au préalable le consentement écrit de l’éditeur.

TAAG is grateful for partial funding from the Canadian Periodical Fund, Department of Heritage. / TAAG est reconnaissante à Patrimoine canadien du financement partiel obtenu du Fonds du Canada pour les périodiques.

Funded by the Government of Canada Financé par le gouvernement du Canada

Publication Mail Agreement # / Numéro de convention de Poste-publication : #43136012 Return undeliverable Canadian addresses to: Retourner les numéros non distribuables à une adresse canadienne à : 700 – 251 Bank Street, Ottawa, ON K2P 1X3 Printed in Canada / Imprimé au Canada. Please recycle where facilities exist / Veuillez recycler là où ce service existe.

DÉCOUVREZ LE 18e FORUM DE L’INDUSTRIE DE LA SANTÉ DE QUÉBEC :

UN RENDEZ-VOUS MAJEUR EN SCIENCES DE LA VIE AU QUÉBEC!

PRESENTING THE 18TH QUÉBEC CITY HEALTHCARE INDUSTRY FORUM:

A MAJOR EVENT IN QUEBEC’S LIFE SCIENCES SECTOR!

Le 18e Forum de l’industrie de la santé de Québec (FISQ), organisé par Québec International et Québec VITAE, se tiendra les 4 et 5 décembre prochain au Centre des congrès de Québec. Véritable carrefour d’échanges et de découvertes, ce forum réunit les principaux acteurs de l’industrie, des gouvernements et du réseau de la santé autour des enjeux industriels face aux défis de la santé et des stratégies gouvernementales.

Les thématiques abordées cette année incluront la santé des femmes, le développement économique ainsi que des discussions sur la régionalisation des soins

Ne manquez pas cet événement incontournable qui façonne l’avenir de l’industrie de la santé depuis 17 ans. Plus d’info au fisq.ca

La région de Québec se distingue

• 216 entreprises ;

• 1 G$ de chiffre d’affaires pour le secteur en 2021 ;

• 3 hôpitaux spécialisés parmi les meilleurs au monde ;*

• Avantage coût de 30,1 % pour la R-D (inférieur à la moyenne des villes américaines).**

Avec un écosystème dynamique et diversifié en SVTS, la région de Québec offre un environnement propice à l’innovation, de la recherche fondamentale jusqu’au traitement des patients. Ses forces couvrent un large éventail de domaines incluant le biopharmaceutique, le diagnostic et les technologies médicales et de l’information liées à la santé. La région excelle aussi en cosméceutiques et nutraceutiques, renforçant son positionnement comme centre d’innovation.

Faites comme GSK, BD, Meridian Bioscience, Syneos Health et Aramis Biotechnologies et choisissez Québec pour votre croissance !

The 18th edition of the Québec City Healthcare Industry Forum hosted by Québec International and Québec VITAE will be held on December 4–5 at the Québec City Convention Centre. A meeting space for discussion and discovery, the Forum brings together major industry, government and healthcare network stakeholders to address industrial issues surrounding health challenges and government strategies.

This year’s themes include women’s health, economic development and the regionalization of healthcare

Do not miss this essential event that has been shaping the future of the industry for the past 17 years. More information at fisq.ca

The Québec City region stands out with:

• 216 businesses

• $1B in revenue in the sector in 2021

• 3 specialized hospitals among the best in the world*

• A cost advantage of 30.1% below the average of American cities for R&D**

With a dynamic and diverse business ecosystem in life sciences and health technology, the Québec City region provides an environment that fosters innovation, from basic research to patient care. With expertise in many fields including biopharmaceuticals, diagnosis, and medical and health information technologies, the region also excels in cosmeceuticals and nutraceuticals, strengthening its position as an innovation hub.

Follow the example of companies like GSK, BD, Meridian Bioscience, Syneos Health and Aramis Biotechnologies, and choose Québec City to boost your growth!

* Newsweek, 2021 ** KPMG, 2018

MESSAGE FROM THE PRESIDENT AND CEO

THE PANDEMIC’S ECONOMIC, SOCIAL, AND HEALTH impacts have highlighted the strategic importance of building a robust domestic life sciences industry and biomanufacturing capacity. Nearly four years after the pandemic’s onset, governments worldwide, including Canada, are preparing for future health emergencies, and this generational moment presents a unique opportunity for Canada’s biotech sector to establish a strong global presence.

While it makes strategic sense to prepare for another pandemic-like event, predicting the next health crisis or necessary technologies is nearly impossible. Canada’s best approach is to broadly strengthen its life sciences and biomanufacturing sectors to ensure multiple potential solutions are available. Fostering a competitive environment that attracts ideas, investors, and talent will support Canadian biotech companies capable of responding to diverse health challenges and driving innovation and economic growth even outside of crisis periods.

The federal Biomanufacturing and Life Sciences Strategy reflects the government’s recognition of the sector’s value. The strategy’s associated investments are accelerating company creation and expanding Canada’s life sciences and biomanufacturing capacity. By staying technology-agnostic, the government is establishing conditions that could enable Canadian discoveries to play a critical role in future global health solutions.

This approach builds from a position of strength. Canada’s life sciences ecosystem is renowned globally for excellence in scientific research, encompassing early-stage biotech companies, a strong pharmaceutical presence, and a national clinical trial network. Strategic competencies in regenerative medicine, artificial intelligence, vaccines, clinical trial expertise, and genomics further reinforce Canada’s position as a dynamic hub for life sciences innovation.

In recent years, Canada’s biotech sector has drawn over $26 billion in investment, a testament to the sector’s vitality and global appeal. This capital inflow includes significant exits and partnerships involving companies such as BELLUS, Inversago Pharma, and Fusion Pharmaceuticals, alongside ongoing investments from major global pharmaceutical companies. Companies like AbCellera,

Aspect Biosystems, and Repare Therapeutics showcase Canada’s capacity for growth, further underscoring investor confidence in Canadian biotechnology.

With this momentum, now is an important moment to strengthen Canada’s biotech foundation further. Enhanced investment in the sector will not only improve preparedness for future health challenges but also facilitate the growth of companies that can anchor and expand the Canadian biotech ecosystem. As other countries invest heavily in their life sciences sectors, global competition for biotech ideas, talent, and capital has never been more intense. Canada must establish a competitive environment that attracts the investment and expertise needed to support the scale-up of domestic biotech companies. New investors such as Canada’s lead pension funds would significantly grow the availability of investment capital in Canada and attract others from outside.

Canada has already proven its capacity for scientific discovery, entrepreneurship, and company creation. The logical next step is to establish a globally commercial biotech company rooted domestically. Translating this global moment into building Canadian companies capable of anchoring biotech clusters across the country will be critical for sustained growth. The establishment of such companies will not only secure Canada’s position on the global biotech stage but will also drive economic benefits, job creation, and innovation for decades to come. Given what is at stake, building anchor companies must be our common North Star.

A decade ago, the biotech sector was a ‘nice to have’ option for Canada. Today it is recognized as a ‘must have’ strategic asset. While there is clearly much to build on and leverage, there remains important work yet to be done. The year ahead represents a critical time to remain ambitious and continue to press forward to our North Star.

August and Marie Krogh

Arriving in Denmark after August’s lecture tour in the U.S., 1922

Driving change for generations

The founding of Novo Nordisk was a labour of love, driven by the tireless efforts of physiologist August Krogh and his wife Marie, a medical doctor. August and Marie dedicated their lives to expanding access to insulin treatment and their love for humankind continues to inspire us every day. Their belief that things can always be better drives us to make every improvement we can, even when the perfect solution isn’t yet at hand. Because today we know that even the smallest steps can make a meaningful difference for the people we exist to serve.

Discover more at novonordisk.ca

MESSAGE DU PRÉSIDENT ET CHEF DE LA DIRECTION

L’INCIDENCE ÉCONOMIQUE, SOCIALE ET SANITAIRE de la pandémie a mis en évidence l’importance stratégique de la mise en place d’une industrie nationale des sciences de la vie et d’une capacité de biofabrication solides. Près de cinq ans après le début de la pandémie, les gouvernements du monde entier, dont celui du Canada, se préparent à l’éventualité de nouvelles situations d’urgence sanitaire. On se trouve à une conjecture rare, et celle-ci offre au secteur canadien des biotechs l’occasion, tout aussi rare, de fermement établir sa présence à l’échelle internationale.

Il va de soi, de point de vue de la stratégie, qu’il faut se préparer à une nouvelle situation de type pandémique, mais prévoir la nature de la prochaine crise sanitaire et les technologies qu’elle exigera est pratiquement impossible. Ainsi, la démarche idéale pour le Canada consiste à renforcer de façon générale ses secteurs des sciences de la vie et de la biofabrication, afin de disposer de multiples solutions potentielles. La mise en place d’un milieu concurrentiel, un pôle apte à attirer les idées, les investisseurs et les personnes de talent, aidera les entreprises canadiennes de biotechnologie à relever une diversité de défis sanitaires, ainsi qu’à stimuler l’innovation et la croissance économique, même hors période de crise.

La Stratégie en matière de biofabrication et de sciences de la vie du gouvernement fédéral témoigne de la valeur que celui-ci accorde à ces secteurs. La combinaison de divers investissements que prévoit la stratégie accélère la création d’entreprises et vient étoffer la capacité du Canada en sciences de la vie et en biofabrication. En évitant de choisir une technologie en particulier, le gouvernement met en place les conditions propres à permettre aux découvertes canadiennes de jouer un rôle essentiel en ce qui concerne les futures solutions de santé à l’échelle mondiale.

La démarche choisie est forte d’une position déjà solide. En effet, l’écosystème canadien des sciences de la vie jouit d’une réputation internationale pour ce qui est de l’excellence en recherche scientifique, et il comprend aussi bien de jeunes pousses des biotechs que de grandes sociétés pharmaceutiques, ainsi qu’un réseau d’essais cliniques national. Des compétences stratégiques en médecine régénérative, en intelligence artificielle, et en matière vaccinale, ainsi qu’une expertise dans le domaine des essais cliniques et de la génomique renforcent encore davantage la position du Canada en tant que grand pôle de l’innovation en sciences de la vie.

Au cours des dernières années, le secteur canadien des biotechs a obtenu des investissements d’une valeur de 26 millions $, signe de la vitalité du secteur et de son pouvoir d’attraction. L’afflux de capitaux découle en partie des stratégies de sortie et des ententes de partenariats fructueuses ayant

notamment touché BELLUS, Inversago Pharma et Fusion Pharmaceuticals, ainsi que des investissements permanents de la part de multinationales pharmaceutiques. Des entreprises telles qu’AbCellera, Aspect Biosystems et Repare Therapeutics illustrent bien la capacité de croissance du Canada et mettent encore en évidence la confiance des investisseurs dans la biotechnologie canadienne.

Ces circonstances favorables offrent une importante occasion de renforcer davantage les fondements biotechnologiques du Canada. Des investissements accrus dans le secteur amélioreront l’état de préparation aux défis sanitaires futurs tout en favorisant la croissance d’entreprises capables de stabiliser et d’élargir l’écosystème canadien des biotechs. À l’heure où d’autres pays investissent massivement dans leur secteur des sciences de la vie, la concurrence mondiale pour l’obtention de l’innovation, des ressources de talent et des capitaux est d’une intensité inégalée. Le Canada doit mettre en place un milieu concurrentiel qui attire les investissements et l’expertise nécessaires à la croissance des sociétés nationales de biotechnologie. De nouveaux investisseurs, par exemple les grands fonds de pension canadiens, contribueraient considérablement à accroître les capitaux d’investissement disponibles au pays et susciteraient aussi des investissements de l’étranger.

La preuve des capacités du Canada sur les plans de la recherche scientifique, de l’entrepreneuriat et de la création d’entreprises n’est plus à faire. En toute logique, la prochaine étape consistera en l’établissement au pays d’une entreprise phare, commercialement et internationalement active en biotechnologie. Arriver à utiliser ce moment, unique à l’échelle mondiale, pour constituer des entreprises canadiennes capables de stabiliser des pôles biotechnologiques un peu partout au pays sera essentielle à la durabilité de la croissance. Cela garantira la position du pays sur la scène mondiale des biotechs, produira des bénéfices économiques, créera de l’emploi et stimulera l’innovation durant des décennies. L’enjeu est de taille, et la mise sur pied d’entreprises d’attache, « ancrées » au pays, doit être notre objectif commun.

Il y a dix ans, le secteur des biotechs constituait une option intéressante parmi d’autres pour le Canada. Aujourd’hui, il est un atout stratégique incontournable. Beaucoup reste néanmoins à bâtir et à exploiter. L’année à venir sera cruciale en ce qui a trait à nos ambitions, et nous devrons continuer d’avancer vers notre objectif commun.

BIONATION 2024

Showcasing

the Power and Potential

of Canada’s Biotech Ecosystem

BIONATION 2024

Révéler la richesse et le potentiel de l’écosystème biotechnologique canadien

Canada’s biotech ecosystem gathered in Ottawa for BIONATION 2024 showcasing the sector’s economic and social impact. Over the course of two days, BIONATION united leaders in science, innovation, and entrepreneurship with researchers, investors, policymakers, and the next generation of biotech professionals. The energy throughout the event highlighted not just Canada’s current potential, but also its collective ambition to establish world-class biotech companies on home soil.

Les représentants de l’écosystème biotechnologique canadien se sont réunis à Ottawa à l’occasion de BIONATION 2024 pour mettre en lumière les retombées socioéconomiques du secteur. L’événement de deux jours a permis à des leaders de la science, de l’innovation et de l’entrepreneuriat de rencontrer des chercheurs, des investisseurs, des décideurs et la prochaine génération de professionnels des biotechs. La fébrilité qui régnait tout au long de l’événement a fait ressortir le potentiel actuel du Canada, ainsi qu’une réelle ambition collective en vue de l’implantation au pays d’entreprises de biotech d’envergure mondiale.

BIONATION FEATURED FOUR INSIGHTFUL PANELS

ADDRESSING KEY THEMES VITAL TO CANADA’S BIOTECH ECOSYSTEM:

BIONATION PROPOSAIT QUATRE TABLES RONDES SUR DES ENJEUX ESSENTIELS POUR LE SECTEUR DES BIOTECHS AU CANADA :

EMBRACING & ACCELERATING BIOTECH INNOVATION: Colleen Coxson (Alnylam Pharmaceuticals), Peter Zandstra (University of British Columbia), Clarissa Desjardins (Congruence Therapeutics), Tamer Mohamed (Aspect Biosystems), and Rami Fayed (AbbVie Canada) discussed how Canadian scientific leadership is driving new global solutions for improve human health.

ENCOURAGER ET ACCROÎTRE L’INNOVATION DANS LE DOMAINE DE LA BIOTECHNOLOGIE : Colleen Coxson (Alnylam Pharmaceuticals), Peter Zandstra (University of British Columbia), Clarissa Desjardins (Congruence Therapeutics), Tamer Mohamed (Aspect Biosystems) et Rami Fayed (AbbVie Canada) ont évoqué le leadership scientifique canadien à l’origine de solutions qui améliorent la santé humaine à l’échelle mondiale.

ANCHORING CANADIAN EXCELLENCE: Gordon McCauley (adMare BioInnovations), Roberto Bellini (BSQUARED Capital), JP Devereaux (McMaster University), Anne Stevens (AbCellera), and Ed Morgan (Health Canada) explored the momentum behind Canada’s biotech sector, focusing on the aspirations, potential, and pan-Canadian opportunities for creating and growing anchor company creation and growth.

ENRACINER L’EXCELLENCE CANADIENNE : Gordon McCauley (adMare BioInnovations), Roberto Bellini (BSQUARED Capital), PJ Devereaux (McMaster University), Anne Stevens (AbCellera) et Ed Morgan (Santé Canada) ont montré à quel point le secteur biotechnologique canadien avait le vent en poupe grâce à ses ambitions claires, son potentiel et les possibilités pancanadiennes en matière de création et de croissance d’entreprises phares.

INVESTMENT ATTRACTION: Elizabeth Douville (Genome Canada), Maxime Pesant (Fonds de solidarité FTQ), Anne Woods (RBCx), Chuck LaFlèche (Viotika Life Sciences), and Jamie Stiff (Genesys Capital) examined global investment trends, how Canada measures up, and the opportunities ahead to capitalize on the investment momentum of recent years.

ATTIRER LES INVESTISSEMENTS : Elizabeth Douville (Génome Canada), Maxime Pesant (Fonds de solidarité FTQ), Anne Woods (RBCx), Chuck LaFlèche (Viotika Life Sciences) et Jamie Stiff (Genesys Capital) ont fait un tour d’horizon des tendances mondiales en matière d’investissement, de la situation du Canada à cet égard et des possibilités qui nous permettraient de tirer parti de l’effervescence qui a cours sur ce plan depuis quelques années.

PEOPLE POWERING THE ECOSYSTEM: Penny WalshMcGuire (CASTL), Rob Henderson (BioTalent Canada), François Ravenelle (Tarock Capital), and Geoff Evans (Eurofins) explored the growth and emergence of Canadian companies and innovations.

LES PERSONNES AU COEUR DE L’ÉCOSYSTÈME : Penny Walsh-McGuire (CASTL), Rob Henderson (BioTalent Canada), François Ravenelle (Tarock Capital) et Geoff Evans (Eurofins) ont dressé un portrait des possibilités de croissance qui s’offrent aux entreprises et aux innovations canadiennes, ainsi que des conditions favorables qui permettent leur émergence.

One of the many highlights of BIONATION were the one-on-one fireside chats led by BIOTECanada President & CEO Andrew Casey with the Hon. François-Philippe Champagne, Minister of Innovation, Science, and Industry, and the Hon. Mark Holland, Minister of Health. Both federal Ministers reaffirmed Canada’s commitment to creating favourable conditions for entrepreneurs, researchers, and experts.

In a pivotal announcement, exclusive to BIONATION 2024, Minister Champagne announced the creation of the Health Emergency Readiness Canada agency, a crucial step in bolstering the country’s pandemic preparedness and enhancing collaboration between healthcare and innovation sectors. This announcement emphasized the need for health and economic policy to work together to fully leverage Canada’s advances in science and innovation.

Les discussions en tête-à-tête menées par Andrew Casey, président-directeur général de BIOTECanada, avec l’honorable François-Philippe Champagne, ministre de l’Innovation, des Sciences et de l’Industrie, et l’honorable Mark Holland, ministre de la Santé, ont été l’un des nombreux temps forts de BIONATION. Les deux ministres fédéraux ont réaffirmé la volonté du Canada de créer des conditions favorables pour les entrepreneurs, les chercheurs et les experts.

Le ministre Champagne a profité de BIONATION 2024 pour faire une annonce exclusive : la création de l’agence Préparation aux crises sanitaires Canada, qui constitue une étape cruciale pour renforcer la préparation du pays en vue d’éventuelles pandémies et améliorer la collaboration entre les secteurs de la santé et de l’innovation. Le ministre a mis l’accent sur la nécessité d’harmoniser les réglementations en matière de santé et d’économie afin de tirer pleinement parti des avancées réalisées par le Canada en sciences et en innovation.

Andrew Casey (BIOTECanada) and the Hon. François-Philippe Champagne, Minister of Innovation, Science, and Industry

Andrew Casey et l’honorable François-Philippe Champagne, ministre de l’Innovation, des Sciences et de l’Industrie

Andrew Casey (BIOTECanada) and the Hon. Mark Holland, Minister of Health
Andrew Casey et l’honorable Mark Holland, ministre de la Santé

Legendary astronaut

Chris Hadfield delivered an inspiring keynote, urging the biotech sector to focus on purpose, communication, and celebrating successes to continue propelling the industry to new heights.

Wrapping up BIONATION 2024, Ritu Banerjee, Assistant Deputy Minister at Innovation, Science and Economic Development Canada delivered final remarks, reinforcing the momentum Canada has built in life sciences and biotech.

Le célèbre astronaute

Chris Hadfield a prononcé une allocution inspirante, exhortant le secteur des biotechs à se concentrer sur les finalités, la communication et la reconnaissance des réalisations afin de permettre à l’industrie d’atteindre de nouveaux sommets.

BIONATION 2024 s’est conclu par le discours de Ritu Banerjee, sous-ministre adjointe d’Innovation, Sciences et Développement économique Canada, qui est venue souligner l’élan que le Canada a donné aux sciences de la vie et à la biotechnologie.

Ritu Banerjee Assistant Deputy Minister at Innovation, Science and Economic Development Canada
Ritu Banerjee, sous-ministre adjointe d’Innovation, Sciences et Développement économique Canada
Colonel Chris Hadfield, Astronaut & Engineer
Colonel Chris Hadfield, astronaute et ingénieur

An insightful political panel titled “Ottawa Behind the Headlines,” featuring Susan Smith, Kathleen Monk, and Tim Powers, explored the future of Canada’s biotech industry and outlined strategies for continued success Un panel politique éclairé intitulé « Ottawa au-delà des manchettes », composé de Susan Smith, Kathleen Monk et Tim Powers, a discuté de l’avenir de l’industrie canadienne des biotechs et présenté des stratégies visant à garantir la prospérité du secteur

Thank you to Tim O’Loan, Founder of ReconciliActionS Speakers Bureau (RSB). As a Speaker on Reconciliation & mental health, Tim shared his valuable insights on land recognition as a vital aspect of long-term Reconciliation with Indigenous people in Canada

Merci à Tim O’Loan, fondateur de ReconciliActionS Speakers Bureau (RSB); en tant que conférencier spécialisé dans les questions de réconciliation et de santé mentale, il nous a fait part de ses réflexions approfondies sur la reconnaissance des terres en tant qu’aspect essentiel d’une réconciliation à long terme avec les peuples autochtones du Canada

BIONATION Builders: Gaby Bourbara (AstraZeneca Canada), Caroline Barber (Novartis Canada), Elizabeth Douville (Genome Canada), Gordon McCauley (adMare BioInnovations), Rob Henderson (BioTalent Canada), Cate Murray (Stem Cell Network), Penny Walsh-McGuire (Canadian Alliance for Skills and Training in Life Sciences, CASTL), Maxime Pesant (Fonds de solidarité FTQ), Andrew Casey (BIOTECanada)

BIONATION 2024 was a testament to the power of collaboration and the shared ambition within the ecosystem, proving that Canada has the tools, expertise, and vision needed to create a thriving global biotech hub. A special thank you to all BIOTECanada members, industry stakeholders, and the BIONATION Builders— including AbbVie, adMare BioInnovations, AstraZeneca Canada, BioTalent Canada, CASTL, Fonds de solidarité FTQ, Genome Canada, Novartis Canada, and the Stem Cell Network—who made this event a resounding success.

For a full recap of BIONATION 2024, including photos, scan the QR code.

Les Bâtisseurs BIONATION 2024 : Gaby Bourbara (AstraZeneca Canada), Caroline Barber (Novartis Canada), Elizabeth Douville (Génome Canada), Gordon McCauley (adMare BioInnovations), Rob Henderson (BioTalent Canada), Cate Murray (Réseau de cellules souches), Penny Walsh-McGuire (Alliance canadienne pour la formation et le développement de compétences en sciences de la vie [CASTL]), Maxime Pesant (Fonds de solidarité FTQ), Andrew Casey (BIOTECanada)

BIONATION 2024 a témoigné de la puissance de la collaboration et des ambitions communes au sein de l’écosystème et confirmé que le Canada dispose des outils, de l’expertise et de la vision nécessaires pour créer un pôle biotechnologique prospère à l’échelle mondiale.

Nous remercions tout particulièrement les membres de BIOTECanada, les intervenants de l’industrie et les Bâtisseurs BIONATION, notamment AbbVie, adMare BioInnovations, AstraZeneca Canada, BioTalent Canada, CASTL, Fonds de solidarité FTQ, Génome Canada, Novartis Canada et le Réseau de cellules souches, qui ont fait en sorte que cet événement connaisse un indéniable succès.

Pour un compte rendu complet de BIONATION 2024, notamment en images, scannez le code.

Celebrating the Best in Biotech 2024 GOLD LEAF AWARD WINNERS

Récompenser le meilleur de la biotechnologie LES LAURÉATS DES FEUILLES D’OR 2024

THE 2024 GOLD LEAF AWARDS were presented in September at BIONATION 2024, celebrating the remarkable achievements of leaders and innovators in Canada’s biotechnology sector. The awards recognize individuals and companies that have made significant contributions to advancing the biotech industry, positioning Canada as a global leader in life sciences innovation. From groundbreaking research to cutting-edge therapies, the winners exemplify the transformative potential of biotechnology.

This year’s awards featured four categories: Biotech Company of the Year, Promising Biotech Company of the Year, Industry Leadership (Ecosystem Builder) Award, and Community Leadership (Research & Innovation) Award.

LES FEUILLES D’OR 2024 ont été décernées en septembre à l’occasion de BIONATION 2024 : un témoignage de reconnaissance quant aux réalisations exceptionnelles des chefs de file et des innovateurs du secteur de la biotechnologie au Canada. En effet, ces prix récompensent les personnes et les entreprises qui ont contribué de manière considérable à faire évoluer le secteur de la biotechnologie et à positionner le Canada en tant que leader mondial de l’innovation en sciences de la vie. De la recherche de pointe aux traitements avant-gardistes, les lauréats illustrent le pouvoir de transformation de la biotechnologie.

Cette année, il y avait des prix dans quatre catégories : Entreprise biotechnologique de l’année, Entreprise biotechnologique prometteuse de l’année, Prix du leadership de l’industrie (bâtisseur de l’écosystème) et Prix du leadership de la communauté (recherche et innovation).

2024 Gold Leaf Awards
Les Feuilles d’or 2024

DISCOVER THE ACHIEVEMENTS OF THE 2024 WINNERS

BIOTECH COMPANY OF THE YEAR:

ASPECT BIOSYSTEMS

Aspect Biosystems, based in Vancouver, BC, was awarded Biotech Company of the Year for their work pioneering the development of bio printed tissue therapeutics. This award recognizes a company that has achieved groundbreaking advancements in biotechnology, bringing hope to patients facing some of the most challenging, currently incurable diseases.

Aspect Biosystems is at the forefront of developing therapies that have the potential to transform the treatment of conditions like diabetes, obesity, and congenital liver disorders. With a commitment to innovation and excellence, Aspect has not only made significant scientific breakthroughs but has also contributed to economic growth within Canada’s biotech sector. The company has grown to over 90 employees, doubled its facility size to more than 50,000 square feet, and secured over $200 million in funding. A recent partnership with Novo Nordisk, valued at US$2.6 billion, has set a new standard for Canadian biotech on the global stage.

DÉCOUVREZ LES RÉALISATIONS DES LAURÉATS DE 2024

ENTREPRISE BIOTECHNOLOGIQUE DE L’ANNÉE : ASPECT BIOSYSTEMS

Aspect Biosystems, établie à Vancouver, en ColombieBritannique, a reçu le prix de l’Entreprise biotechnologique de l’année pour son travail de précurseur dans la mise au point de produits tissulaires bio-imprimés. Ce prix récompense une entreprise qui a réalisé des avancées majeures dans le domaine de la biotechnologie, redonnant de l’espoir aux patients aux prises avec certaines des maladies les plus complexes, toujours incurables à ce jour.

Mohamed (Aspect

accepts the award for Biotech Company of the Year from Jenny Kwan, MP (Vancouver East, middle), Andrew Casey (CEO, BIOTECanada, far right)

Tamer Mohamed (Aspect Biosystems, gauche) reçoit le prix de l’Entreprise biotechnologique de l’année des mains de Jenny Kwan, députée (Vancouver-Est, au milieu); Andrew Casey (chef de la direction de BIOTECanada, à droite)

Under the visionary leadership of CEO Tamer Mohamed, Aspect is driving both scientific and economic impact, proving Canada’s capacity for world-class innovation.

PROMISING BIOTECH COMPANY OF THE YEAR: VENTUS THERAPEUTICS

Ventus Therapeutics received the Promising Biotech Company of the Year Award, a recognition reserved for companies demonstrating extraordinary innovation and significant business milestones, poised to shape the future of the biotech landscape.

A clinical-stage biopharmaceutical company, Ventus is transforming the future of immunology, inflammation, and neurology through its ReSOLVE™ computational chemistry platform. Ventus’ expertise in protein science is driving the discovery of therapies that offer new hope for patients with high unmet needs. Over the past year,

Aspect Biosystems occupe une place de premier plan dans la mise au point de traitements susceptibles de transformer la prise en charge de pathologies telles que le diabète, l’obésité et les troubles hépatiques congénitaux. Grâce à son approche axée sur l’innovation et l’excellence, Aspect a non seulement réalisé d’importantes percées scientifiques, mais a également contribué à la croissance économique du secteur biotechnologique au Canada. L’entreprise compte aujourd’hui plus de 90 employés, a doublé la superficie de ses installations, qui font maintenant plus de 50 000 pieds carrés, et a obtenu plus de 200 millions de dollars de financement. Récemment, elle a conclu avec Novo Nordisk un partenariat évalué à 2,6 milliards de dollars, qui constitue désormais l’étalon en ce qui concerne la biotechnologie canadienne sur la scène mondiale. Sous la direction visionnaire de son chef de la direction, Tamer Mohamed, Aspect Biosystems rayonne sur le plan tant scientifique qu’économique, attestant de la capacité du Canada à innover à l’échelle mondiale.

ENTREPRISE

BIOTECHNOLOGIQUE PROMETTEUSE DE L’ANNÉE : VENTUS THERAPEUTICS

Andrew Casey (BIOTECanada, far left) and Oliver Technow (CEO, BIOVECTRA and Board Chair, BIOTECanada, far right) present the award for Promising Biotech Company to Christine Ha (Ventus Therapeutics, centre)

Andrew Casey (BIOTECanada, à gauche) et Oliver Technow (chef de la direction de BIOVECTRA et président du conseil d’administration de BIOTECanada, à droite) remettent le prix de l’Entreprise biotechnologique prometteuse de l’année à Christine Ha (Ventus Therapeutics, au centre)

Ventus Therapeutics a été désignée Entreprise biotechnologique prometteuse de l’année, une reconnaissance réservée aux entreprises qui font preuve d’excellence en matière d’innovation, ont franchi des étapes importantes et

Tamer
Biosystems, far left)

Ventus has made impressive progress, advancing its lead programs into Phase 1 clinical trials and developing three candidates in just three years.

The company’s partnership with Novo Nordisk, which brought in $70 million, underscores Ventus’ strategic value in the global biotech community. With its commitment to translating cutting-edge science into impactful therapies, Ventus is a company on the verge of transformative breakthroughs in healthcare.

INDUSTRY LEADERSHIP (ECOSYSTEM BUILDER) AWARD: DR. CLARISSA DESJARDINS

The Industry Leadership (Ecosystem Builder) Award was presented to Dr. Clarissa Desjardins for her outstanding contributions to Canada’s biotechnology industry. This award honours leaders whose vision and impact extend beyond their own organizations, fostering innovation and growth across the entire biotech ecosystem.

With more than 25 years of experience in the field, Dr. Desjardins has founded and led four successful biotech companies, including her current venture, Congruence Therapeutics. At Congruence, she is pioneering therapies for protein misfolding diseases, combining computational and experimental drug discovery. Her innovative work is pushing the boundaries of biotech research and development.

sont prêtes à imprimer leur marque et à faire évoluer la biotechnologie.

Société biopharmaceutique au stade des essais cliniques, Ventus Therapeutics est en train de transformer l’avenir de l’immunologie, des maladies inflammatoires et de la neurologie grâce à sa plateforme de chimie computationnelle ReSOLVE™. L’expertise de Ventus dans le domaine de la science des protéines a conduit à la découverte de traitements qui offrent un nouvel espoir aux patients dont les besoins ne sont pas satisfaits. Au cours de la dernière l’année, l’entreprise a réalisé des progrès impressionnants en faisant passer ses principaux programmes à la phase 1 des essais cliniques et en mettant au point trois candidats-médicaments en l’espace de trois ans seulement.

Son partenariat avec Novo Nordisk, qui a rapporté 70 millions de dollars, met en évidence la valeur stratégique de Ventus au sein de la communauté biotechnologique mondiale. Ayant pour objectif de transformer la science de pointe en traitements efficaces, Ventus est une entreprise sur le point de réaliser des percées décisives dans le domaine des soins de santé.

Dr. Desjardins’ leadership extends beyond the lab, having co-founded Caprion Pharmaceuticals and led Clementia Pharmaceuticals, where she developed therapies for rare pediatric bone diseases. Her efforts have helped position Canada as a global leader in personalized medicine and healthcare innovation. Her dedication to fostering growth and attracting investment has had a lasting impact on Canada’s life sciences sector.

COMMUNITY LEADERSHIP (RESEARCH & INNOVATION) AWARD: DR. PETER ZANDSTRA

The Community Leadership (Research & Innovation) Award was awarded to Dr. Peter Zandstra, a visionary leader whose research and mentorship continue to shape the future of biotechnology in Canada and globally. This award recognizes individuals who have made significant contributions to research, innovation, and the development of future biotech leaders.

Dr. Zandstra’s pioneering work in stem cell biology has led to transformative advancements in tissue development and regenerative medicine. He serves as the Founding Director of

PRIX DU

LEADERSHIP

DE L’INDUSTRIE (BÂTISSEUR DE L’ÉCOSYSTÈME) :

CLARISSA DESJARDINS

Le Prix du leadership de l’industrie (bâtisseur de l’écosystème) a été décerné à Clarissa Desjardins pour sa contribution exceptionnelle à l’industrie biotechnologique canadienne. Ce prix récompense les dirigeants dont la vision et le rayonnement vont au-delà de leur propre organisation, et qui contribuent à l’innovation et à la croissance de l’ensemble de l’écosystème de la biotechnologie.

Avec plus de 25 ans d’expérience dans le domaine, Mme Desjardins a fondé et dirigé quatre entreprises de biotechnologie couronnées de succès; elle est toujours chef de la direction de Congruence Therapeutics. Chez Congruence, elle fait œuvre de pionnière en matière de traitements contre les maladies liées à protéines mal repliées; les travaux de Congruence s’appuient à la fois sur la recherche computationnelle et le développement expérimental de médicaments. Cet apport innovant repousse les limites de la recherche-développement dans le domaine de la biotechnologie.

L’expertise de Clarissa Desjardins dépasse le cadre du laboratoire, puisqu’elle a cofondé Caprion Pharmaceuticals et dirigé Clementia Pharmaceuticals, où elle a contribué à la mise au point de traitements contre des maladies osseuses pédiatriques rares. Ses travaux ont participé à faire du Canada un acteur de premier plan à l’échelle mondiale dans le domaine de la

Andrew Casey (BIOTECanada, far left) and Roberto Bellini (BSQUARED Capital, far left) present Gold Leaf Award to Dr. Clarissa Desjardins (centre)
Andrew Casey (BIOTECanada, à gauche) et Roberto Bellini (BSQUARED Capital, à droite) remettent sa Feuille d’or à Clarissa Desjardins (au centre)

UBC’s School of Biomedical Engineering and Director of the Michael Smith Laboratories, and his research has laid the groundwork for Canada’s next generation of biotech leaders.

Beyond academia, Dr. Zandstra serves as Chief Scientific Officer at CCRM and has co-founded innovative companies like ExCellThera and Notch Therapeutics. His leadership has fostered an environment where innovation thrives, and his commitment to nurturing future scientists ensures that Canada remains at the forefront of biotech innovation. In recognition of his exceptional contributions, Dr. Zandstra was appointed to the Order of Canada in 2021.

médecine personnalisée et de l’innovation en matière de soins de santé. Sa détermination à stimuler la croissance et à attirer les investissements a eu un retentissement durable sur le secteur des sciences de la vie au Canada.

PRIX DU LEADERSHIP AU SEIN DE LA COMMUNAUTÉ (RECHERCHE ET INNOVATION) : PETER ZANDSTRA

Le Prix du leadership au sein de la communauté (recherche et innovation) a été décerné à Peter Zandstra, un visionnaire dont les recherches et le mentorat continuent de modeler l’avenir de la biotechnologie au Canada et dans le monde. Ce prix récompense les personnes qui ont contribué de manière significative à la recherche, à l’innovation et au perfectionnement des futurs chercheurs en biotechnologie.

The Gold Leaf Awards shine a spotlight on the best in Canadian biotechnology, and this year’s winners exemplify the innovation, leadership, and dedication that continue to drive the industry forward. Congratulations to all the 2024 award recipients for their remarkable achievements and contributions to the global biotech landscape.

LOOKING AHEAD TO THE 2025 GOLD LEAF AWARDS

The Gold Leaf Awards shine a spotlight on the best in Canadian biotechnology, and this year’s winners exemplify the innovation, leadership, and dedication that continue to drive the industry forward. Congratulations to all the 2024 award recipients for their remarkable achievements and contributions to the global biotech landscape.

For more information about the Gold Leaf Awards and how to nominate, visit:

Les travaux précurseurs de M. Zandstra dans le domaine de la biologie des cellules souches ont permis de réaliser des progrès décisifs dans le domaine des tissus à usage thérapeutique et de la médecine régénérative. Il est le directeur fondateur de l’école d’ingénierie biomédicale de UBC et il dirige les laboratoires Michael Smith. Ses travaux ont permis de préparer le terrain à la formation de la prochaine génération de leaders en biotechnologie au Canada.

Au-delà du monde universitaire, Peter Zandstra est directeur scientifique du CCMR et il a cofondé des entreprises innovantes comme ExCellThera et Notch Therapeutics. Son action a favorisé l’émergence d’un environnement propice à l’innovation, et son désir de former de futurs scientifiques permet au Canada de rester à la pointe de l’innovation dans le domaine de la biotechnologie. Pour souligner ses contributions exceptionnelles, on a nommé Peter Zandstra membre de l’Ordre du Canada en 2021.

EN ATTENDANT LES LAURÉATS DES FEUILLES D’OR 2025

Les Feuilles d’or mettent en lumière le meilleur de la biotechnologie canadienne, et les lauréats de cette année illustrent l’innovation, le leadership et le professionnalisme qui continuent à faire évoluer l’industrie. Félicitations à tous les lauréats des prix 2024 pour leurs réalisations et contributions exceptionnelles au secteur de la biotechnologie à l’échelle mondiale.

Pour de plus amples renseignements sur les Feuilles d’or et sur les modalités de mise en candidature, scannez le code :

Oliver Technow (CEO, BIOVECTRA and Board Chair, BIOTECanada, far left) present Gold Leaf Award to Dr. Peter Zandstra (centre), Andrew Casey (CEO, BIOTECanada, far right)
Oliver Technow (chef de la direction de BIOVECTRA et président du conseil d’administration de BIOTECanada, à gauche) remet sa Feuille d’or à Peter Zandstra (au centre); Andrew Casey (chef de la direction de BIOTECanada, à droite)

Building Canada’s Biotech Future:

How the Biologics Manufacturing Centre is Driving Growth in Biomanufacturing

AS GLOBAL DEMAND FOR BIOLOGICS RISES, Canada’s life sciences sector is positioned to play a key role in biomanufacturing. Leading this effort is the Biologics Manufacturing Centre (BMC Inc.), a non-profit organization offering GMP contract manufacturing services for biologics, including vaccines and therapeutic proteins.

The BMC provides vital support to biotech companies, helping them navigate the complexities of biomanufacturing—from earlystage development to product completion. It’s more than just a facility; it’s a trusted partner for businesses looking to meet production needs through its specialized services.

A PARTNER IN BIOMANUFACTURING

The BMC provides vital support to biotech companies, helping them navigate the complexities of biomanufacturing—from early-stage development to product completion. It’s more than just a facility; it’s a

trusted partner for businesses looking to meet production needs through its specialized services.

COMPREHENSIVE SERVICES FOR BIOLOGICS PRODUCTION

The BMC offers a range of services, making it the ideal partner for both mammalian and insect cell-based biologics production. The facility specializes in vaccines, including viral vectors, protein subunits, and virus-like particles, as well as therapeutic proteins like antibodies and enzymes.

Whether a company needs end-to-end solutions or gap-filling services in its production process, the BMC can help. From tech transfer to drug substance production and analytical services, the BMC handles critical stages of manufacturing. While focused on small-scale production, its tailored solutions allow clients to respond quickly to project demands, without significant infrastructure investment.

ENSURING QUALITY AND COMPLIANCE

Meeting strict quality standards is crucial in biomanufacturing. The BMC offers comprehensive testing services that help mitigate risks for investors and partners by ensuring products meet regulatory requirements. These tests ensure that biologics adhere to high-quality benchmarks, minimizing costly delays.

With experienced quality assurance and regulatory compliance teams, the BMC offers peace of mind to its partners. Operating under GMP standards, the BMC adheres to international guidelines, ensuring excellence in every aspect of production.

This vision of readiness is essential as the world continues to face global health emergencies, making the BMC a key resource for Canada’s pandemic preparedness strategy.

EXPERT TEAM AND CONSULTING SERVICES

The organization is driven by seasoned professionals with years of experience in biomanufacturing, quality assurance, regulatory compliance, and project management. This ensures that each project—no matter how complex—is executed with precision.

The BMC also offers consulting services, guiding clients through the product development journey. From regulatory navigation to smooth tech transfers, the BMC’s consultants help biotech companies streamline their operations and achieve faster, more reliable outcomes.

ADDRESSING EMERGING HEALTH THREATS

The BMC has positioned itself as a crucial player in addressing emerging health threats. Aligned with Canada’s national goals for healthcare preparedness, the BMC’s infrastructure and expertise ensure the country is ready to respond to future health crises.

This vision of readiness is essential as the world continues to face global health emergencies, making the BMC a key resource for Canada’s pandemic preparedness strategy.

FOSTERING COLLABORATION IN CANADA’S LIFE SCIENCES ECOSYSTEM

The BMC actively promotes collaboration within the Canadian life sciences ecosystem. By forging connections with universities, startups, and larger pharmaceutical companies, it serves as a hub for biomanufacturing innovation. These partnerships are vital for strengthening Canada’s biotech industry and ensuring the country becomes a global leader in biomanufacturing.

Through these collaborations, the BMC is advancing its capabilities while contributing to a stronger, more resilient life sciences sector. Its role is not limited to serving clients but also to building biomanufacturing infrastructure that meets national and global needs.

SUPPORTING THE GROWTH OF CANADA’S BIOTECH INDUSTRY

For policymakers and industry leaders, the BMC highlights the importance of investing in biomanufacturing infrastructure. By supporting initiatives like the BMC, Canada can strengthen its biotech industry, create jobs, and ensure readiness for future health challenges.

The BMC’s vision of becoming a leader in addressing health threats and driving biotech manufacturing is about more than responding to today’s demands—it’s about shaping the future of healthcare. With its expert team, comprehensive services, and collaborative approach, the BMC is poised to drive the growth of Canada’s life sciences sector.

As the country seeks to establish itself in the global biomanufacturing landscape, the BMC will be a critical partner, offering the flexibility and expertise needed to meet the evolving demands of the biotech industry.

Advancing Canada’s Biomanufacturing Industry: A Study on Skills and Training Needs

THE CANADIAN ALLIANCE FOR SKILLS AND TRAINING IN LIFE SCIENCES (CASTL) released the highlights of a new study that provides critical insight into Canada’s biomanufacturing labour market over the next three to five years. The study’s findings will play a key role in helping CASTL—and the broader training community—to strategically adapt and scale up initiatives that align to the sector’s emerging needs.

“A skilled workforce is the single most important element for ensuring our national biomanufacturing industry is resilient, competitive, and responsive to the perpetually changing landscape of global health,” says Penny WalshMcGuire, CASTL’s CEO. “This study provides the framework to position our resources to address future demands.”

Funded by Future Skills Centre and conducted in partnership with BioTalent Canada, the Identifying the skills and training needed to advance Canadian biomanufacturing study surveyed and interviewed biomanufacturing employers across the country to better understand near-future priorities for the sector’s workforce. In addition to emerging developments around artificial intelligence, Industry 5.0 technologies, and carbonreducing manufacturing, the study’s findings focus on hiring forecasts, essential competencies, and gaps in current training curricula.

Specifically, 74 percent of study participants reported significant hiring projections in the next three years, with 50 percent of new hires expected to go to technician roles in manufacturing, production, and laboratory environments. Study participants heavily weighted technical skills, including Good Manufacturing Practices (GMP), laboratory skills, and manufacturing and production techniques, as a key consideration in hiring decisions. They also emphasized the importance of balancing theoretical knowledge with practical experience.

“CASTL’s training model successfully addresses the issues identified in the study,” says Sven Ansorge, CASTL’s Director of Technical Training. “Delivered to students and

industry employees through a combination of online, in-class and hands-on training at our state-of-the-art, pilot-scale GMP-simulated facilities, our programs are designed to meet industry needs, complementing the strong scientific programs provided by Canadian universities.”

The full study will be available in the coming weeks at castlcanada.ca

CASTL is a national organization that provides training and skills development specific to Canada’s fast-growing biomanufacturing sector. It is the exclusive provider of the National Institute for Bioprocessing Research and Training (NIBRT) licensed training programs in Canada.

All eyes on Canada at BIO 2024

Tous les regards tournés vers le Canada à l’occasion du congrès BIO 2024

(Back row) Jamie Moses, Minister of Economic Development, Investment & Trade (Government of Manitoba), Michelle Thompson, Minister for Health & Wellness (Government of Nova Scotia), Andrew Parsons, Minister of Industry, Energy, & Technology (Government of Newfoundland & Labrador), Andrew Casey, President & CEO, BIOTECanada, Nate Glubish, Minister of Technology & Innovation (Government of Alberta), Christopher Skeete, Ministère de l’Économie (Government of Québec), Mayor of Laval, Stéphane Boyer (Québec) (Front row) Adriana LaGrange, Minister of Health (Government of Alberta), Premier Dennis King (Prince Edward Island), Victor Fedeli, Minister of Economic Development, Job Creation & Trade (Government of Ontario), Bruce Fitch, Minister of Health (Government of New Brunswick), Gilles Arsenault Minister of Economic Development, Innovation & Trade (Government of Prince Edward Island)

(Rangée arrière) Jamie Moses, ministre du Développement économique, de l’Investissement et du Commerce (gouvernement du Manitoba), Michelle Thompson, ministre de la Santé et du Mieux-être (gouvernement de la Nouvelle-Écosse), Andrew Parsons, ministre de I’Industrie, de I’Énergie et de la Technologie (gouvernement de Terre-Neuve-et-Labrador), Andrew Casey, président et chef de la direction de BIOTECanada, Nate Glubish, ministre de la Technologie et de l’Innovation (gouvernement de l’Alberta), Christopher Skeete, ministre délégué à l’Économie (gouvernement du Québec), Maire de Laval, Stéphane Boyer (Québec) (Rangée de devant) Adriana LaGrange, ministre de la Santé (gouvernement de l’Alberta), Premier ministre Dennis King (Île-du-Prince-Édouard), Victor Fedeli, ministre du Développement économique, de la Création d’emplois et du Commerce (gouvernement de l’Ontario), Bruce Fitch, ministre de la Santé (gouvernement du Nouveau-Brunswick), Gilles Arsenault, ministre du Développement économique, de l’Innovation et du Commerce (gouvernement de l’Île-du-Prince-Édouard)

The Canada Pavilion at BIO 2024 in San Diego was nothing short of impressive. Spanning 3,000 square feet, it featured digital exhibits, bustling meeting spaces, and engaging stage events, showcasing a dynamic display of what Canada has to offer the biotechnology ecosystem.

Le pavillon du Canada au congrès BIO 2024 à San Diego était tout simplement impressionnant. D’une superficie de 3 000 pieds carrés, il proposait des expositions numériques, des espaces de réunion animés et des présentations attrayantes, illustrant de manière dynamique ce que le Canada peut offrir à l’écosystème de la biotechnologie.

With nearly 1000 delegates—including biotech leaders, researchers, entrepreneurs, elected officials, and senior public servants—the Canadian life sciences ecosystem was well represented. The Canadian delegation at BIO continues to grow in size and diversity each year, expanding both in numbers and in its wide-ranging expertise. The energy was evident as attendees engaged in discussions, built partnerships, and highlighted Canada’s contributions to the global biotech industry.

BIO was a remarkable showcase of Canada’s thriving biotech sector, with BIOTECanada spearheading the organization of the Canadian Pavilion alongside partners from across the country. This gathering of the Canadian biotech ecosystem highlighted Canada’s dynamic contributions to the global biotechnology landscape. With the second-largest international delegation at BIO 2024, all eyes were on Canada as it made its mark on the world stage.

BIOTECanada curated and delivered a program lineup that showcased Canada’s leadership in biotechnology. Along with provincial Accord members, the Government of Canada and the Quebec provincial government, the

Près de 10 00 délégués, parmi lesquels des dirigeants du seteur de la biotechnologie, des chercheurs, des entrepreneurs, des élus et des hauts fonctionnaires, ont permis à l’écosystème canadien des sciences de la vie d’être bien représenté. La délégation canadienne à BIO continue de croître en taille et en diversité chaque année, avec de plus en plus d’intervenants et un niveau d’expertise accru. Les participants se sont prêtés à des discussions, ont travaillé à des partenariats et ont souligné les contributions du Canada à l’industrie mondiale de la biotechnologie, faisant preuve d’une belle énergie.

BIO a été une vitrine remarquable pour le secteur canadien de la biotechnologie, en plein essor, le tout notamment grâce à BIOTECanada, qui a orchestré de main de maître les activités du pavillon canadien avec des partenaires de tout le pays. Ce rassemblement de spécialistes canadiens de la biotechnologie a permis de mettre en lumière les contributions remarquables du Canada à l’échelle mondiale. Notre pays, dont la délégation internationale était la deuxième en importance à BIO 2024, a été sous le feu des projecteurs et s’est ainsi imposé sur la scène mondiale.

Left to right: Ritu Banerjee, Assistant Deputy Minister, Innovation, Science and Economic Development Canada, Michael Willmott, Consulate General of Canada, Los Angeles, Heather Delage, BIOVECTRA , John Snowden, Amgen Canada, Jose Rodriguez, Vaccine and Infectious Disease Organization (VIDO), Andrew Casey, BIOTECanada, Karen Heim, Alexion Canada
De gauche à droite : Ritu Banerjee, sous-ministre adjointe, ministère de l’Innovation, des Sciences et du Développement économique du Canada, Michael Willmott, consul général du Canada à Los Angeles, Heather Delage, BIOVECTRA , John Snowden, Amgen Canada, Jose Rodriguez, Vaccine and Infectious Disease Organization (VIDO), Andrew Casey, BIOTECanada, Karen Heim, Alexion Canada

BIOTECanada a présenté un programme qui a mis en évidence le leadership du Canada dans le domaine de la biotechnologie. Le pavillon canadien proposait une programmation extraordinaire grâce aux membres provinciaux de l’Accord national de biotechnologie, au gouvernement du Canada et au gouvernement du Québec.

Le programme d’activités tournait autour des initiatives stratégiques prises par le Canada pour mettre en valeur la capacité d’innovation et de recherche qui est à l’origine de son succès économique.

Canada Pavilion offered fantastic Canadian programming, and the agenda of activities built on the policy initiatives Canada has established to showcase the innovation and research capacity driving economic success.

The Canada Pavilion serves as a vital platform to highlight the significance of industry-government collaboration in driving the growth of Canada’s biotech sector. The pavilion also serves as a central hub of activity, showcasing groundbreaking innovations and facilitating hundreds of meetings that connected Canadian companies with global partners. Recognizing the vast opportunities for partnership, Canada remains committed to improving health outcomes for patients and families.

As Canada took the spotlight at BIO 2024, the country’s reputation as a leader in biotech innovation was further solidified. From cutting-edge research to next-generation therapeutics, Canada demonstrated why it remains a top destination for biotech investment and collaboration. BIO highlighted the valuable role of policy and government support in driving this success, reflecting Canada’s strong commitment to the life sciences sector.

Le pavillon du Canada fut une vitrine essentielle pour souligner l’importance de la collaboration entre l’industrie et le gouvernement, qui contribue à stimuler la croissance du secteur de la biotechnologie au pays. Le pavillon a également servi de centre d’activités, où étaient présentées des innovations révolutionnaires et où étaient organisées des centaines de réunions, qui ont mis des entreprises canadiennes en contact avec des partenaires mondiaux. Conscient des vastes perspectives en matière de partenariat, le Canada reste déterminé à améliorer les résultats dans le domaine de la santé pour les patients et les familles.

Le pays a ainsi été au centre de l’attention lors de BIO 2024, ce qui a renforcé sa réputation de leader en ce qui a trait à l’innovation en biotechnologie. De la recherche de pointe aux traitements de nouvelle génération, le Canada a prouvé qu’il restait un lieu de prédilection pour les investissements et les collaborations dans le domaine de la biotechnologie. Le congrès BIO a aussi mis en évidence le rôle précieux des politiques et du soutien des pouvoirs publics dans les avancées et témoigné de l’engagement résolu du Canada à l’égard du secteur des sciences de la vie.

BIOTECanada remercie les partenaires canadiens du pavillon : Investir au Canada, Affaires mondiales Canada,

Panel discussion on Canadian Biomanufacturing : “Building for the World”: showcased Canada’s biomanufacturing growth, industry leadership, investment success, and highlighting the role of federal policy in driving global competitiveness and innovation. (L-R Andrew Casey, Heather Delage, John Snowden, Jose Rodriguez) Table ronde sur la biofabrication au Canada : « Building for the World » (Pour l’avenir de tous) : présentation de l’évolution du secteur de la biofabrication au Canada, du leadership de l’industrie canadienne, du dynamisme en matière d’investissement et du rôle joué par la réglementation fédérale en vue de stimuler la compétitivité et l’innovation à l’échelle mondiale. (De gauche à droite : Andrew Casey, Heather Delage, John Snowden, Jose Rodriguez)

BIOTECanada thanks fellow Canadian Pavilion partners: Invest in Canada, Global Affairs Canada, Innovation, Science, and Economic Development (ISED), Invest Ontario, Investissement Québec, Atlantic Canada Bio Industries Alliance: Bounce Health Innovation, Life Sciences Nova Scotia, Research New Brunswick, Prince Edward Island BioAlliance, BioAlberta, Life Sciences BC, and BioTalent Canada. Their commitment and hard work were instrumental in creating an impactful presence for Canada at this year’s event.

BIO 2024 was a milestone moment for Canada, showcasing not just the sector’s strengths but its potential for future growth. With eyes now set on Boston for BIO 2025, BIOTECanada and its partners are poised to continue driving the Canadian biotech ecosystem forward, building on the successes of this year.

Scan the QR code to view our photo gallery and access the BIOTECanada Canadian Delegation Directory.

“The capacity of our sector is incredible. We’re proud to present to the world the expertise driving the growth of the Canadian biomanufacturing sector and its emerging companies who are making remarkable strides in precision medicine, drug development, and cell and gene therapy to name a few examples.”

Innovation, Sciences et Développement économique Canada (ISDE), Investissements Ontario, Investissement Québec et l’Atlantic Canada Bio Industries Alliance, soit Bounce Health Innovation, Life Sciences Nova Scotia et RechercheNB, ainsi que la Prince Edward Island BioAlliance, BioAlberta, Life Sciences BC et BioTalent Canada. Leur engagement et leur travail acharné ont joué un rôle déterminant dans la présence remarquée du Canada au congrès de cette année.

Le congrès BIO 2024 a été marquant pour le Canada, car il a mis en évidence non seulement les atouts actuels du secteur, mais aussi son potentiel de croissance future. Maintenant que les regards se tournent vers Boston, où se déroulera le congrès BIO 2025, BIOTECanada et ses partenaires sont prêts à continuer à faire évoluer l’écosystème biotechnologique canadien, sur la base du succès de cette année.

Scannez le code pour voir notre galerie de photos et accéder au répertoire des participants de la délégation canadienne qui sont membres de BIOTECanada.

Panel discussion: “Let’s Talk People” featuring Canadian Alliance for Skills and Training in Life Sciences (CASTL), BioTalent Canada, Applied Pharmaceutical Innovation (API), and Stem Cell Network: Explored job training opportunities in bioscience and biomanufacturing, this panel also highlighted how organizations are addressing challenges within Canada’s biotech ecosystem. (L-R: Rob Henderson, Penny Walsh-McGuire, Andrew MacIssac, Cate Murray) Table ronde de la CASTL : Description : « Let’s Talk People » (Parlons des gens) avec l’Alliance canadienne pour la formation et le développement de compétences en sciences de la vie (CASTL), BioTalent Canada, Applied Pharmaceutical Innovation (API) et le Réseau des cellules souches : Il a été question lors de cette table ronde des perspectives de formation professionnelle dans le domaine des biosciences et de la biofabrication. Les panélistes ont également mis en lumière la manière dont les organisations s’attaquent aux défis propres à l’écosystème biotechnologique du Canada. (De gauche à droite : Rob Henderson, Penny Walsh-McGuire, Andrew MacIssac, Cate Murray)

« Notre secteur dispose d’une incroyable capacité d’action. Nous sommes on ne peut plus fiers de révéler au monde la qualité de l’expertise qui stimule la croissance du secteur canadien de la biofabrication et ses entreprises émergentes, qui font des progrès remarquables dans les domaines de la médecine de précision, du développement de médicaments et de la thérapie cellulaire et génique, pour ne citer que quelques exemples. »

– ANDREW CASEY, PRÉSIDENT ET CHEF DE LA DIRECTION, BIOTECANADA

Join BIOTECanada Today

Meet!

By joining BIOTECanada, your company becomes part of an effective advocacy and regulatory voice representing the collective interests of the Canadian biotechnology industry. BIOTECanada has the tools to help your business reach its full potential through government relations, communications, marketing and membership services.

Advantages of becoming a BIOTECanada member:

Advocating and representing the collective interests of the Canadian biotechnology industry.

BIOTECanada is committed to the objective of ensuring that savings offered will, at a minimum, offset the cost of membership, depending on the membership category.

Opportunities to connect with colleagues and build new relationships.

Joignez-vous

à BIOTECanada

aujourd’hui

À la croisée de l’innovation et des nouvelles occasions

En devenant membre de BIOTECanada, votre entreprise joint sa voix à celle d’un organisme de réglementation et de revendication qui défend efficacement les intérêts collectifs de l’industrie canadienne des biotechnologies. BIOTECanada propose un éventail d’outils et de services – relations gouvernementales, communications, marketing et services aux membres – qui aideront votre entreprise à atteindre son plein potentiel.

Avantages réservés aux membres de BIOTECanada :

DÉFENSE DES INTÉRÊTS

BIOTECanada milite en faveur des intérêts collectifs de l’industrie canadienne des biotechnologies.

BIOTECanada veille à ce que les économies réalisées par ses membres compensent, au minimum, le coût de l’adhésion, selon la catégorie d’adhésion.

BIOTECanada offre à ses membres de nombreuses occasions d’échanger avec leurs collègues et de bâtir de nouvelles relations professionnelles.

Numérisez le code QR pour en savoir plus sur les avantages aux membres de BIOTECanada et l’adhésion.

Eisai Leading Fight for Early Alzheimer’s Treatment Eisai mène le combat pour un traitement de la maladie d’Alzheimer légère

EISAI LIMITED HAS SCORED a major victory in the fight against the ravages of Alzheimer’s by developing an effective new therapy for early stages patients.

“It’s an extremely exciting time for Alzheimer’s patients and their families,” says Pat Forsythe, general manager of Eisai in Canada. “There is a lot of excitement in the medical community with Health Canada currently reviewing this new disease modifying therapy for Alzheimer’s Disease (AD).”

EISAI LIMITED A REMPORTÉ une victoire majeure dans la lutte contre les ravages de la maladie d’Alzheimer en développant une nouvelle thérapie efficace pour les patients en phase précoce.

« C’est une période extrêmement excitante pour les patients atteints de la maladie d’Alzheimer et leurs familles », affirme Pat Forsythe, directeur général d’Eisai au Canada. « Il y a beaucoup d’enthousiasme dans la communauté médicale alors que Santé Canada examine actuellement ce nouveau traitement modificateur de la maladie d’Alzheimer (MA). »

Eisai’s Leqembi, which received approval by the U.S. Food and Drug Administration in 2023, will slow further decline in patients who have mild cognitive impairment or mild AD. This new therapy is timely because many patients with early AD are waiting with hope.

He says these new innovations create interest in obtaining an AD diagnosis, particularly at the mild stages when those impacted by Alzheimer’s are still functioning

Eisai’s Leqembi, which received approval by the U.S. Food and Drug Administration in 2023, will slow further decline in patients who have mild cognitive impairment or mild AD.

well, living at home, and contributing to society. The goal is to slow down the progression of this disease so that they can maintain their independence and continue to enjoy living fulfilling lives with their families.

Eisai is working with all key AD centres in Canada to support their efforts to develop a pathway to enable patients access to innovations. “We’re listening and defining how we can get this done by working with the health care professionals, health systems and governments to try to improve the situation,” Forsythe elaborates.

Using a collaborative approach to better understand the experience of people impacted by AD, Eisai has worked with a diverse group of patients, caregivers, advocates, and primary care networks, all of whom have a shared desire to improve the diagnosis and care pathway for people living with early AD. “We’re coming in with an open mind to really understand how we can make a difference for them. We think first about patients and their families,” says Forsythe.

He says Eisai would like to roll out its therapy to the Canadian healthcare system in a sustainable way, once it receives approval by Health Canada. The company is working with provincial health systems to innovate and secure access for these patients.

“Cognitive decline is a ticking clock, and we’re aware of that. So we’ll do our best to make sure that any patient who can benefit from this we’re able to help,” he stresses.

Leqembi, qui a reçu l’approbation de la Food and Drug Administration des États-Unis en 2023, ralentira le déclin des patients qui ont un trouble cognitif léger ou une MA légère. Cette nouvelle thérapie est opportune parce que de nombreux patients atteints de MA précoce attendent avec espoir.

Il affirme que ces nouvelles innovations suscitent de l’intérêt pour le diagnostic de MA, en particulier aux stades précoces où les personnes touchées par la maladie

Leqembi, qui a reçu l’approbation de la Food and Drug Administration des

États-Unis en 2023, ralentira le déclin

des patients qui ont

un trouble cognitif léger ou une MA légère.

fonctionnent toujours bien, vivent à la maison et contribuent à la société. L’objectif est de ralentir la progression de cette maladie afin qu’ils puissent conserver leur indépendance et continuer à vivre une vie épanouissante avec leur famille.

Eisai travaille avec les centres de soins au Canada pour soutenir leurs efforts visant à développer une voie permettant aux patients d’accéder aux innovations. « Nous sommes à l’écoute et travaillons avec les professionnels, les systèmes de santé et les gouvernements pour tenter d’améliorer la situation », explique Forsythe.

Par une approche collaborative pour mieux comprendre l’expérience des personnes touchées, Eisai a travaillé avec des patients, des soignants, des professionnels et réseaux de soins primaires, qui ont tous un désir d’améliorer le diagnostic et les soins pour les personnes vivant avec la MA. « Nous arrivons avec un esprit ouvert pour vraiment comprendre comment nous pouvons faire une différence pour eux. Nous pensons d’abord aux patients et à leurs familles », explique Forsythe.

Il affirme qu’Eisai aimerait déployer sa thérapie au Canada de façon durable, une fois qu’elle aura reçu l’approbation règlementaire. L’entreprise collabore déjà avec les provinces pour innover et assurer l’accès des patients. « Le déclin cognitif continue, et nous en sommes conscients. Nous ferons donc de notre mieux pour nous assurer que les patients puissent en bénéficier », souligne-t-il.

Advancing Beyond the Lab: The New Environment for Biotech M&A and Capital Raising

HOW MANY POTENTIALLY WORLD-CHANGING discoveries never get beyond the lab? There’s a big gap between pathbreaking R&D and its commercialization, and even the most impressive science can struggle to reach a market. Making that leap requires a broad and deep set of capabilities, and capital—a lot of capital. Many companies find the best way to bring these threads together is through a strategic partnership or by being acquired.

As with research and development, this too is more complex than it may seem. In a small market like Canada, the natural strategic partners and acquirors of promising Canadian biotech companies are typically from abroad.

At a time when the Canadian government, like others around the world, is taking a much keener interest in the long-term national security implications of these technologies, this presents certain fundamental challenges for any company seeking foreign investment, especially in sensitive sectors like critical minerals or biotech.

Specifically, even before commencing a review of potential strategic alternatives, such as a partnership or sale, Canadian companies would be well advised to gain an expert understanding of a host of domestic and sometimes international political, regulatory and national security considerations that could inform, alter or block their path to success.

NAVIGATING REGULATORY COMPLEXITY, INCLUDING GEOPOLITICS

While the versatility and potential of biotechnology make it exciting, these same qualities are inviting scrutiny by governments. The U.S., Canada and many European states all consider biotech a critical technology area vital to national security. The result is that an area of research historically inclined towards international collaboration is now running up against national security imperatives that put partnerships and investment decisions under a regulatory microscope.

The Investment Canada Act allows the Canadian government to examine foreign investment, not just takeovers, to ensure it represents a benefit to, and poses no risk for, the country. This has significant implications for Canadian companies.

IDENTIFYING VIABLE PARTNERS AND COMPLETABLE TRANSACTIONS

The time has passed where a suitable investor can be judged solely by the price they are willing to pay and their ability to advance a company’s development. A front-end analysis today requires broad consideration of how a range of stakeholders would view the partnership. Most fundamentally, regulators need to be assured that the technology will be advanced in a way they can accept. Increasingly, the government’s prime consideration is national security—particularly who will have access to these applications and any related discoveries. Governments today also require precise details on plans like where scientific activity will be conducted, who will be involved, and even about the locations of the servers where data will be stored.

The scrutiny of foreign investors can go beyond the specific project at hand. Governments are undertaking comprehensive reviews of the ownership and control structures of foreign investors and their other holdings, and will carefully examine the supply and customer intentions that are part of investment transactions.

A company can be subject to a months’ long National Security Review when entering into a minority private placement. The Canadian government has gone so far as to block transactions even where the assets being acquired were located outside of Canada, and has also prevented a re-domiciling to work around these types of reviews.

As a result, Boards and management teams must have their eyes wide open to potential risks long before a deal materializes, and they must pay close attention to transaction structuring. They must also have a welldeveloped plan on how to navigate this rapidly shifting terrain before entering any formal agreement.

To create the conditions for success, a broader lens must be adopted on who has a stake in the future of the company, and how they will, or will not, be affected by a transaction. This takes more than a compelling story.

Maintaining strong relationships with key elected officials and members of the public service can be as critical to closing a transaction as communications with investors and employees. Aligning these critical stakeholders requires up-front identification of risks and potential issues, and carefully executed internal and external communications, government relations, and regulatory strategies.

Done right, raising outside capital can be the catalyst for growth and new discoveries. Mishandled, it can invite new and varied risks, create distractions, and waste precious capital on dead end pathways, throttling the scientific mission. A biotech executive today must know the science, but also how to navigate an ever-more complicated political, regulatory and stakeholder environment. Careful planning, clear-eyed risk analysis, and a thoughtful approach to managing stakeholders are essential to growing Canada’s next success story, and to avoid becoming a cautionary tale.

Phil Harwood is a partner at FGS Longview, a leading Canadian strategic advisory firm, helping organizations navigate mission-critical strategic communications and public affairs scenarios, including corporate strategy and reputation; media relations, crisis and issues management; government affairs, policy and advocacy; and transaction and financial communications. In the last three years the firm has advised on over 35 transactions that have undergone national security reviews under the Investment Canada Act.

Commercializing Women’s Health:

Navigating a Blue Ocean Therapeutic Opportunity

Le marché de la

santé

des femmes : exploration de possibilités thérapeutiques inédites

WOMEN’S HEATH IS FINALLY HAVING ITS MOMENT—in recent years, the emergence of research priorities, focused funds, and policy changes has brought new momentum to a greatly underserved area of human health. Most notably, a 2024 report from McKinsey highlighted that investments addressing the women’s health gap could boost the global economy by $1 trillion annually by 20401, cementing the notion that Women’s Health isn’t just a “feel-good” issue, but one that can also deliver significant commercial rewards. With identified unmet needs across a range of indications, Women’s Health is a certifiable Blue Ocean opportunity for therapeutics. However, these waters remain largely uncharted, and the biotech sector faces a monumental task in carving out viable commercialization pathways for therapies in this space.

Our company, SeraGene Therapeutics, is currently dipping our toes in these uncharted waters. SeraGene is a preclinical stage, therapeutics company based in Vancouver Canada advancing first and best-in-class treatments for bleeding and thrombotic disorders. As a female-founded company developing technology created by women scientists, SeraGene is actively pursuing pathways that can better address Women’s Health. During our initial exploration of rare bleeding disorders, we found that women, girls, and people who menstruate (WGPM) are disproportionately burdened through heavy menstrual bleeding. Heavy menstrual bleeding is experienced by over

LA SANTÉ DES FEMMES REÇOIT ENFIN L’ATTENTION qu’elle mérite. Ces dernières années, l’émergence de priorités de recherche, de fonds spécialisés et de changements réglementaires a donné un nouvel élan à un domaine de la santé humaine qui avait été grandement négligé. Le rapport 2024 de McKinsey souligne notamment que les investissements visant à combler le déficit dans le domaine de la santé des femmes pourraient stimuler l’économie mondiale à raison de 1 000 milliards de dollars par an d’ici à 2040,1 ce qui confirme l’idée selon laquelle la santé des femmes n’est pas seulement une question de bien-être, mais peut aussi générer d’importantes retombées commerciales. Compte tenu des besoins non satisfaits pour toute une série d’indications thérapeutiques, la santé des femmes offre en matière de produits thérapeutiques un extraordinaire potentiel que l’on pourrait qualifier d’« océan bleu ». Cependant, cette mer de possibilités demeurant en grande partie inexplorée, le secteur de la biotechnologie se trouve devant la tâche monumentale de devoir définir des voies de commercialisation viables pour les traitements.

Notre société, SeraGene Therapeutics, est en train de plonger dans ces eaux inconnues. SeraGene est une société biotechnologique de Vancouver, au Canada, qui en est à l’étape des essais précliniques dans la mise au point de traitements visant des troubles hémorragiques et thrombotiques devant être les premiers et les meilleurs de leur catégorie. En tant qu’entreprise fondée par des femmes

Photo courtesy of SeraGene Therapeutics Crédit photo : avec l’aimable autorisation de SeraGene Therapeutics

SeraGene is a preclinical stage, therapeutics company based in Vancouver Canada advancing first and best-in-class treatments for bleeding and thrombotic disorders.

80% of WGPM diagnosed with bleeding disorders, yet there remain only a handful of treatment options with outcome efficacies so suboptimal that almost one-third of WGPM will opt for a hysterectomy as a last ditch effort to free themselves from the burden of chronic, uncontrolled bleeding.2 Our lead asset—SG-001—is a RNAi therapy that targets a universal driver of uncontrolled bleeding in patients with bleeding disorders. With the potential to address a broad spectrum of bleeding disorders, SG-001 gains appeal as a novel treatment option for heavy menstrual bleeding—the first in over 15 years. Recent animal data studying SG-001 in demonstrated significantly reduced duration of menses and blood volume, an important milestone for both SeraGene and the wider bleeding disorder community.

However, promising efficacy data is often not enough for Women’s Health. Despite its prevalence, heavy menstrual bleeding is poorly understood compared to other indications with a similar population size. This is true for many indications in Women’s Health and according to a 2023 report from Silicon Valley Bank (SVB), a suspected reason for this relative lack of data is due to the fact that women’s health companies are typically valued at a fifth of generalist health companies.3 This lack of scientific and market data on women’s health conditions creates a high-risk investment play, wherein opportunities become difficult to value and commercialization pathways to capture these opportunities remain murky. To de-risk investment in Women’s Health will not only require (1) a significant commitment to research funding, but also (2)

et qui met au point des technologies créées par des femmes scientifiques, SeraGene recherche activement des moyens de mieux prendre en charge la santé des femmes. Lors de notre exploration préliminaire des troubles hémorragiques rares, nous avons constaté que les femmes, les filles et les autres personnes qui ont des règles (FFAPR) subissent un stress disproportionné en cas de saignements menstruels abondants. Les saignements menstruels abondants sont le lot de plus de 80 % des FFAPR qui ont reçu un diagnostic de troubles de saignement. Pourtant, il n’existe qu’une poignée d’options thérapeutiques, dont l’efficacité est tellement faible que près d’un tiers des femmes FFAPR opteront pour une hystérectomie dans un ultime effort pour se libérer du problème des saignements chroniques et incontrôlés. 2 Notre principal actif (SG-001) est un traitement par ARNi qui cible un mécanisme de saignement incontrôlé chez les patientes souffrant de troubles de saignement. Le SG-001, qui pourrait potentiellement traiter un large éventail de troubles hémorragiques, est intéressant puisqu’il s’agit d’une nouvelle option thérapeutique pour les saignements menstruels abondants, soit la première en plus de 15 ans. Les données de récents essais du SG-001 sur des animaux ont démontré une réduction significative de la durée des menstruations et du volume sanguin, une étape importante pour SeraGene et l’ensemble de la communauté des troubles hémorragiques.

Toutefois, de simples données prometteuses suffisent rarement à améliorer la santé des femmes. Les saignements menstruels abondants, malgré leur prévalence, sont mal compris par rapport à d’autres problèmes qui touchent des populations d’ampleur comparable. Une telle insuffisance des explications touche de nombreux problèmes dans le domaine de la santé des femmes. De plus, selon un rapport de 2023 de la Silicon Valley Bank (SVB), l’une des raisons possibles de ce manque relatif de données est que l’évaluation financière des entreprises du secteur de la santé des femmes s’établit généralement à un cinquième de celle des entreprises généralistes du secteur de la santé. 3 Le manque de données scientifiques et commerciales concernant les problèmes de santé des femmes fait en sorte que les investissements dans ce secteur présentent un risque élevé. Les possibilités s’avèrent ainsi plus difficiles à valoriser, et les voies de commercialisation permettant de saisir ces occasions restent donc incertaines. Pour réduire les risques liés aux investissements dans le domaine de la santé des femmes, il faudra : 1) un engagement important en matière de financement de la recherche et 2) des solutions créatives de la part des entreprises qui s’efforcent d’introduire de nouveaux traitements dans un domaine où les précédents commerciaux sont rares.

Heureusement, le financement destiné à la santé des femmes a connu quelques avancées majeures au cours des dernières années. Le mois dernier, le ministère américain de la Défense a annoncé un investissement de 500 millions de dollars dans la recherche sur la santé des femmes, dans le cadre de l’initiative de la Maison-Blanche relative à la

SeraGene Therapeutics CEO, Erika Siren at BIO International, June 2024
Erika Siren, chef de la direction de SeraGene Therapeutics, au congrès international BIO en juin 2024

Panelists at entrepeneurship@UBC’s Women’s Health Translation and Investment Mini-Symposium in September 2024. Left to right: Nicole Prestley, Manager, Research + Knowledge Translation at Women’s Health Research Institute; Jesse Coleman, Manager, Programs at Digital; Dr. Lori Brotto, Professor of Obstetrics and Gynaecology at UBC, Canada Research Chair in Women’s Sexual Health, and Executive Director of the Women’s Health Research Institute

Les panélistes au mini-symposium sur les applications et les investissements dans le domaine de la santé des femmes organisé par entrepeneurship@UBC en septembre 2024. De gauche à droite : Nicole Prestley, directrice des applications de la recherche et du savoir au Women’s Health Research Institute; Jesse Coleman, directeur des programmes chez Digital; Lori Brotto, professeure d’obstétrique et de gynécologie à UBC, titulaire de la chaire de recherche du Canada sur la santé sexuelle des femmes et directrice générale du Women’s Health Research Institute

creative solutions by companies who endeavor to bring new therapies forward in a space with limited market precedents.

Fortunately, there have been some major achievements in funding for Women’s Health in recent years. Last month, the US Department of Defense recently announced the commitment of $500 Million for Women’s Health Research, part of the $12 billion White House Initiative on Women’s Health Research. In 2021, Canada announced their own efforts to impact this space through the Women’s Health Research Initiative, where the federal government committed to allocating $20 million to fund research and knowledge mobilization for Women’s Health over the course of 4 years.4 Though Canada’s recognition of Women’s Health is something to be celebrated, experts believe a commitment similar to our neighbours south of the border is required to significantly move the needle. In a recent panel session on Women’s Health held by entrepreneurship@UBC, Dr. Lori Brotto (Executive Director of the Women’s Health Research Institute at BC Women’s Hospital) challenged institutions to think of the bigger picture: “20 million dollars over the course of two years is barely going to make a dent at the end of the road.5,6 I hope our funding bodies get inspired by what’s happening in the US to say it’s not just about adding years to life, but life to years also, and with the economic savings there’s a huge return on investment when you invest in Women’s Health research.”

A group that has no issue in seeing the “bigger picture” is patient organizations, who have played a critical role in filling funding gaps for Women’s Health in Canada. This is especially the case in the bleeding disorder community with organizations including (but certainly not limited to) the Canadian Hemophilia Society, who recently funded a two-year project with Drs. Paula James and Mackenzie Bowman at Queen’s University.7 The goal of this specific project is to investigate the mechanisms underlying heavy menstrual bleeding in Von Willebrand Disease.

recherche sur la santé des femmes, qui représente un budget de 12 milliards de dollars. En 2021, le Canada a lui aussi annoncé un investissement en ce sens en lançant l’Initiative nationale de recherche sur la santé des femmes, dans le contexte de laquelle le gouvernement fédéral s’est engagé à allouer 20 millions de dollars au financement de la recherche et de la mobilisation des connaissances sur la santé des femmes sur une période de quatre ans.4 La reconnaissance par le Canada de l’importance de prendre en compte la santé des femmes est une chose dont il faut se réjouir, mais les experts estiment qu’un engagement semblable à celui de nos voisins du sud est nécessaire pour faire avancer les choses de manière significative. Lors d’une récente table ronde sur la santé des femmes organisée par entrepreneurship@UBC, Lori Brotto (directrice générale de l’Institut de recherche sur la santé des femmes au BC Women’s Hospital) a mis les institutions au défi de réfléchir à la situation dans son ensemble : « 20 millions de dollars sur deux ans, c’est à peine si cela va faire une petite différence au bout du compte. 5,6 J’espère que nos organismes de financement s’inspireront de ce qui se passe aux États-Unis et reconnaîtront qu’il ne s’agit pas seulement d’ajouter des années à la vie, mais aussi de la vie aux années, et qu’avec les économies réalisées, on obtient un énorme retour sur investissement lorsqu’on investit dans la recherche sur la santé des femmes. »

Les associations de patients, qui ont joué un rôle essentiel en comblant les déficits de financement dans le domaine de la santé des femmes au Canada, sont un groupe qui voit déjà la situation dans son ensemble. C’est particulièrement le cas dans la communauté des troubles de saignement, avec des organisations telles que (un exemple parmi d’autres) la Société canadienne de l’hémophilie, qui a récemment financé un projet de deux ans dirigé par Paula James et Mackenzie Bowman à l’Université Queen’s.7 L’objectif de ce projet était d’étudier les mécanismes qui sous-tendent les saignements menstruels abondants dans la maladie de von Willebrand.

En l’absence de précédents au sein du marché dans le domaine de la santé des femmes, la mise au point de traitements au-delà de la recherche fondamentale nécessitera des stratégies créatives de réduction des risques. Certains experts suggèrent que la réaffectation de candidats utilisés pour des indications non liées à la santé des femmes et pour lesquels le risque a dont été éliminé peut constituer une stratégie prometteuse pour ce qui est d’accélérer le développement clinique et le retour sur investissement dans

In lieu of a strong market precedent in Women’s Health, therapeutic development beyond basic research will require creative strategies to offload risk. Some experts suggest that repurposing de-risked targets from non-women’s health indications can serve as a promising strategy to carve faster paths towards clinical development and reimbursement in Women’s Health. Alternatively, companies can follow a trajectory similar to SeraGene, where a new molecular entity is first explored in an established indication (i.e. Hemophilia), followed by a second indication that focuses on Women’s Health in a subpopulation of the first indication (i.e. Hemophilic women with heavy menstrual bleeding). In both strategies, these (relatively) quick wins will increase the abundance of clinical trial data on Women, allowing all ships in the Women’s Health industry to rise.

It is worth noting that Women’s Health is not the first to reside in uncharted waters. As stated by Naseem Sayani, Co-founder and Managing Director of Women’s Healthfocused fund Emmeline Ventures: “Early investors in Google and Facebook didn’t have proof points on social networks and search engines, but they understood emerging trends and behaviors.8 The same mentality should be how investors now approach women’s health. The emerging trends and behaviors are clear and we should all be running after it. The proof points will come. Big bets that can unlock an arbitrage opportunity are the longstanding strategy of venture.”

The future of women’s health is promising, but it will require a shift in perspective from multiple stakeholders to fully realize the potential opportunity. Ultimately, time will reveal the best path forward to commercialization—but as long as there are women, there will always be an opportunity in Women’s Health.

1. K. Ellingrud, L. Pérez, A. Petersen, V. Sartori, Closing the women’s health gap: A $1 trillion opportunity to improve lives and economies. McKinsey & Company (2024). Available at: https://www.mckinsey.com/mhi/our-insights/closing-the-womens-health-gap-a-1-trillion-dollar-opportunity-to-improve-lives-and-economies Accessed October 2024.

2. Author links open overlay panel H.P. Eising a c et al., Prophylactic and therapeutic strategies for intraoperative bleeding in women with von Willebrand disease and heavy menstrual bleeding: A systematic review. Blood Reviews (2023). Available at: https://www.sciencedirect.com/science/article/abs/pii/S0268960X23000929#:~:text=Heavy%20menstrual%20bleeding%20(HMB)%20occurs,5%5D%2C%20 %5B6%5D%5D. . Accessed October 2024.

3. J. Spencer et al., Innovation in women’s health: Silicon Valley Bank. Silicon Valley Bank a Division of First Citizens Bank. Available at: https://www.svb.com/trends-insights/reports/womens-health-report/ . Accessed October 2024.

4. C. I. of H. R. Government of Canada, Pre-announcement: National Women’s Health Research initiative: Pan-Canadian Women’s Health Coalition. CIHR (2022). Available at: https://cihr-irsc.gc.ca/e/53098.html . Accessed October 2024.

5. L. Brotto, Immersion Week 2024: ENTREPRENEURSHIP@UBC. Immersion Week2024 | entrepreneurship@UBC. Available at: https://entrepreneurship.ubc.ca/ latest-updates/marquee-events/immersion-week-2024 . Accessed October 2024.

6. Home. Women’s Health Research Institute. Available at: https://whri.org/ . Accessed October 2024.

7. CHS Dream Of A Cure Research Program. Hemophilia (2024). Available at: https:// www.hemophilia.ca/chs-dream-of-a-cure-research-program/. Accessed October 2024.

8. Innovation in women’s health: Silicon Valley Bank. Silicon Valley Bank a Division of First Citizens Bank. Available at: https://www.svb.com/trends-insights/reports/ womens-health-report/ . Accessed October 2024.

le domaine de la santé des femmes. Les entreprises peuvent également adopter une trajectoire similaire à celle de SeraGene, qui consiste à explorer une nouvelle entité moléculaire pour une indication établie (l’hémophilie), puis pour une seconde indication axée sur la santé des femmes dans une sous-population de la première indication (les femmes hémophiles ayant des saignements menstruels abondants). Ces deux stratégies permettront des gains (relativement) rapides qui augmenteront la quantité de données provenant des essais cliniques réalisés sur les femmes, ce qui contribuera à l’essor de l’ensemble des traitements en santé des femmes.

Il convient de noter que le secteur de la santé des femmes n’est pas le premier à s’aventurer en terrain inconnu. Comme l’a déclaré Naseem Sayani, cofondatrice et directrice générale du fonds Emmeline Ventures, spécialisé dans la santé des femmes : « Les premiers investisseurs dans Google et Facebook n’avaient pas de données probantes sur les réseaux sociaux et les moteurs de recherche, mais ils comprenaient les tendances et les comportements émergents. 8 C’est avec la même attitude que les investisseurs devraient désormais envisager la santé des femmes. Les tendances et les comportements émergents sont parlants et nous avons tous intérêt à nous en inspirer. Ensuite, les éléments de preuve viendront. Les investissements importants qui peuvent mener à un pari sûr sont depuis longtemps une stratégie employée dans le secteur du capital-risque ».

L’avenir de la santé des femmes est prometteur, mais il faudra un changement de perspective de la part des multiples parties prenantes pour la pleine réalisation des possibilités qu’il recèle. En fin de compte, le temps nous montrera la meilleure voie à suivre pour la commercialisation, mais tant qu’il y aura des femmes, il y aura des perspectives dans le domaine de la santé des femmes.

1. K. Ellingrud, L. Pérez, A. Petersen, V. Sartori, Closing the women’s health gap: A $1 trillion opportunity to improve lives and economies. McKinsey & Company (2024). Communiqué (en anglais) consultable à l’adresse : https://www.mckinsey.com/mhi/ our-insights/closing-the-womens-health-gap-a-1-trillion-dollar-opportunity-to-improve-lives-and-economies. Consulté en octobre 2024.

2. H. P. Eising a c et al., Prophylactic and therapeutic strategies for intraoperative bleeding in women with von Willebrand disease and heavy menstrual bleeding: A systematic review. Blood Reviews (2023). Article (en anglais) consultable à l’adresse : https://www.sciencedirect.com/science/article/abs/pii/S0268960X23000929#:~:text=Heavy%20menstrual%20bleeding%20(HMB)%20occurs,5%5D%2C%20 %5B6%5D%5D. Consulté en octobre 2024.

3. J. Spencer et al., Innovation in women’s health: Silicon Valley Bank. Silicon Valley Bank a Division of First Citizens Bank. Rapport (en anglais) consultable à l’adresse : https://www.svb.com/trends-insights/reports/womens-health-report/. Consulté en octobre 2024.

4. Instituts de recherche en santé du Canada, gouvernement du Canada, Annonce préalable : Initiative nationale de recherche sur la santé des femmes : coalition pancanadienne pour la santé des femmes. IRSC (2022). Communiqué consultable à l’adresse : https://cihr-irsc.gc.ca/f/53098.html. Consulté en octobre 2024.

5. L. Brotto, Immersion Week 2024: ENTREPRENEURSHIP@UBC. Immersion Week2024 | entrepreneurship@UBC. Communiqué (en anglais) consultable à l’adresse : https://entrepreneurship.ubc.ca/latest-updates/marquee-events/immersion-week-2024. Consulté en octobre 2024.

6. Home. Women’s Health Research Institute. Communiqué (en anglais) consultable à l’adresse : https://whri.org/. Consulté en octobre 2024.

7. Le rêve d’une guérison : programme de recherche de la SCH. Société canadienne de l’hémophilie (2024). Communiqué consultable à l’adresse : https://www.hemophilia.ca/fr/le-reve-dune-guerison-programme-de-recherche-de-la-sch/. Consulté en octobre 2024.

8. Innovation in women’s health: Silicon Valley Bank. Silicon Valley Bank a Division of First Citizens Bank. Communiqué (en anglais) consultable à l’adresse : https://www. svb.com/trends-insights/reports/womens-health-report/. Consulté en octobre 2024. knowledge connaissance

CPDC: Pioneering Global Radiopharmaceuticals from Canada CPDC : Le Canada, pionnier des produits radiopharmaceutiques à l’échelle mondiale

IN THE HEART OF SOUTHWESTERN ONTARIO, a quiet revolution has been unfolding within the burgeoning nuclear medicine industry—and the world is starting to take notice. At the centre of the transformation stands the Centre for Probe Development and Commercialization (CPDC), a pioneering force in the global radiopharmaceutical landscape. Founded in 2008 at McMaster University by Dr. John Valliant as a not-for-profit Centre of Excellence for Commercialization and Research (CECR), CPDC has grown into a leader in company creation and innovation, cementing its position as a significant player in radiopharmaceuticals worldwide.

AU COEUR DU SUD-OUEST DE L’ONTARIO, une révolution tranquille s’opère au sein de l’industrie florissante de la médecine nucléaire—et le monde commence à s’en apercevoir. Au cœur de cette transformation se trouve le Centre for Probe Development and Commercialization (CPDC), une force pionnière dans le paysage radiopharmaceutique mondial. Fondé en 2008 à l’Université McMaster par le Dr John Valliant en tant que Centre d’excellence en commercialisation et en recherche (CECR) à but non lucratif, le CPDC est devenu un chef de file en matière de création d’entreprises et d’innovation, consolidant sa position d’acteur important du secteur radiopharmaceutique à l’échelle mondiale.

AN INDUSTRY REACHING CRITICAL MASS

CPDC started with a mission to advance probe research and development, focusing on the creation of molecules that carry medical isotopes to precise targets in the body for diagnostic or therapeutic use. Over the last 16 years, CPDC has been a driving force behind radiopharmaceutical innovation, positioning Southwestern Ontario as a thriving hub for the industry.

“We have been building an invaluable ecosystem, bringing together the right talent, expertise, and state-of-the-art facilities, and we will continue to solidify this region’s standing as a global radiopharma center,” says CPDC CEO Owen Roberts. “The world has been watching, recognizing the value of our breakthroughs, and attracting international investments to our region. As the industry has taken off in recent years, it is now a transformative time for CPDC as we work to strengthen Canada’s leadership in radiopharmaceuticals.”

CREATING INNOVATIVE COMPANIES WITH GLOBAL IMPACT

Through leadership, partnerships, and collaborations between academia and industry, CPDC has fostered the creation of multiple companies that are making waves worldwide. Most notably, Fusion Pharmaceuticals, a clinical-stage oncology company focused on developing next-generation radioconjugates, was acquired earlier this year by AstraZeneca for up for US$2.4 billion. ARTMS, a leader in cost-effective, large-scale cyclotron-based medical isotope production, was bought by Telix Pharmaceuticals in April 2024. CanProbe, a joint venture between CPDC and the University Health Network, saw its technology licensed to POINT Biopharma, which was acquired by Eli Lilly for US$1.4 billion last year.

And in 2022, CPDC spun out AtomVie, a contract development and manufacturing organization which is building a cutting-edge 64,000 sq. ft. facility in Hamilton. CPDC’s impact on the industry is undeniable, with its influence reverberating far beyond Canada’s borders.

UN SECTEUR QUI ATTEINT UNE MASSE CRITIQUE

Le CPDC s’est donné pour mission de faire progresser la recherche et le développement de sondes, en se concentrant sur la création de molécules qui transportent des isotopes médicaux vers des cibles précises dans l’organisme à des fins diagnostiques ou thérapeutiques. Au cours des 16 dernières années, le CPDC a joué un rôle moteur dans l’innovation radiopharmaceutique, faisant du sud-ouest de l’Ontario un centre prospère pour l’industrie.

« Nous sommes en train de construire un écosystème inestimable, en réunissant les talents, l’expertise et les installations de pointe nécessaires, et nous continuerons à consolider la position de cette région en tant que centre radiopharmaceutique mondial », a déclaré Owen Roberts, PDG du CPDC. « Le monde nous observe, reconnaît la valeur de nos percées et attire des investissements internationaux dans notre région. L’industrie ayant pris son essor au cours des dernières années, le CPDC vit actuellement une période de transformation et s’efforce de renforcer le leadership du Canada dans le domaine radiopharmaceutique. »

CRÉER DES ENTREPRISES INNOVANTES AYANT UN IMPACT MONDIAL

Grâce à son leadership, à ses partenariats et à ses collaborations entre le monde universitaire et l’industrie, le CPDC a favorisé la création de nombreuses entreprises qui font parler d’elles dans le monde entier. Nottament, Fusion Pharmaceuticals, une entreprise d’oncologie au stade clinique axée sur le développement de radioconjugués de nouvelle génération, a été rachetée au début de l’année par AstraZeneca pour un montant allant jusqu’à de 2,4 milliards de dollars américains. ARTMS, leader dans la production rentable et à grande échelle d’isotopes médicaux par cyclotron, a été rachetée par Telix Pharmaceuticals en avril 2024. CanProbe, une coentreprise entre le CPDC et l’University Health Network, a vu sa technologie concédée sous licence à POINT Biopharma, qui a été rachetée par Eli Lilly pour 1,4 milliard de dollars américains l’année dernière.

En 2022, le CPDC a créé AtomVie, une organisation de développement et de fabrication sous contrat qui construit une installation de pointe de 64 000 pieds carrés à Hamilton. L’impact du CPDC sur l’industrie est indéniable, et son influence se répercute bien au-delà des frontières du Canada.

ASSURER UNE PRODUCTION RADIOPHARMACEUTIQUE NATIONALE

La croissance de l’industrie radiopharmaceutique s’est accompagnée d’une demande de fabrication dans des conditions rigoureuses de bonnes pratiques de fabrication (BPF). Depuis sa création, le CPDC a joué un rôle crucial en apportant son soutien pour garantir que les produits radiopharmaceutiques fabriqués au Canada respectent les normes BPF. Le CPDC continue de travailler en étroite collaboration avec les universités et les hôpitaux de recherche de tout le pays, contribuant ainsi à mettre à la disposition des patients canadiens des médicaments nucléaires importants.

As CPDC looks to the future, it is actively seeking collaborations with industry, academia, and government. Whether through funding opportunities, company creation, joint ventures or strategic partnerships, CPDC remains dedicated to advancing the radiopharmaceutical field in Canada and around the world.

ENSURING NATIONAL RADIOPHARMA PRODUCTION

As the radiopharmaceutical industry has grown, so too has the demand for manufacturing under rigorous Good Manufacturing Practice (GMP) conditions. Since its inception, CPDC has played a crucial role in providing support to ensure that Canadian-made radiopharmaceuticals meet GMP standards. CPDC continues to work closely with universities and research hospitals across the country, helping to make available important nuclear medicines to patients across Canada.

LOOKING AHEAD: GROWTH AND COLLABORATION OPPORTUNITIES

CPDC’s groundbreaking contributions are transforming the radiopharmaceutical industry, but the organization is far from done. As a self-funding entity, CPDC is committed fostering partnerships both within Canada and globally. Through its investments of time and capital, CPDC is looking ahead to building new companies and advancing innovative radiopharmaceutical technologies that will benefit patients worldwide.

Returning to its foundational research focus, CPDC is now involved in company creation efforts, collaborations and the in-licensing radiopharma assets for further development along with direct early-stage equity investments which bolster the national ecosystem. A key part of these efforts is CPDC’s role as co-lead of the Canadian Medical Isotope Ecosystem (CMIE). Through the CMIE Development Fund, CPDC administers grants of up to $500K to Canadian SMEs in the radiopharmceutical industry to help these companies complete critical proof-ofconcept studies which will advance their technologies towards commercialization.

Tourné vers l’avenir, le CPDC recherche activement des collaborations avec l’industrie, les universités et les gouvernements. Qu’il s’agisse d’opportunités de financement, de création d’entreprises, de coentreprises ou de partenariats stratégiques, le CPDC reste déterminé à faire progresser le secteur radiopharmaceutique au Canada et dans le monde entier.

REGARDER VERS L’AVENIR

: POSSIBILITÉS DE CROISSANCE ET DE COLLABORATION

Les contributions révolutionnaires du CPDC transforment l’industrie radiopharmaceutique, mais l’organisation est loin d’avoir terminé son travail. En tant qu’entité autofinancée, le CPDC s’engage à favoriser les partenariats au Canada et dans le monde. Grâce à ses investissements en temps et en capital, le CPDC envisage de créer de nouvelles entreprises et de faire progresser les technologies radiopharmaceutiques innovantes qui profiteront aux patients du monde entier.

Revenant à son objectif de recherche fondamental, le CPDC participe désormais à des efforts de création d’entreprises, à des collaborations et à l’octroi de licences pour des actifs radiopharmaceutiques en vue d’un développement ultérieur, ainsi qu’à des prises de participation directes à un stade précoce qui renforcent l’écosystème national. Un élément clé de ces efforts est le rôle du CPDC en tant que co-responsable de l’écosystème canadien des isotopes médicaux (CMIE). Par l’intermédiaire du Fonds de développement du CMIE, le CPDC administre des subventions pouvant aller jusqu’à 500 000 dollars à des PME canadiennes de l’industrie radiopharmaceutique afin d’aider ces entreprises à mener à bien des études de validation de principe essentielles qui feront progresser leurs technologies vers la commercialisation.

Tourné vers l’avenir, le CPDC recherche activement des collaborations avec l’industrie, les universités et les gouvernements. Qu’il s’agisse d’opportunités de financement, de création d’entreprises, de coentreprises ou de partenariats stratégiques, le CPDC reste déterminé à faire progresser le secteur radiopharmaceutique au Canada et dans le monde entier.

As CPDC looks to the future, it is actively seeking collaborations with industry, academia, and government. Whether through funding opportunities, company creation, joint ventures or strategic partnerships, CPDC remains dedicated to advancing the radiopharmaceutical field in Canada and around the world.

ADVANCING CANADA’S DISTINCT LEADERSHIP IN GLOBAL RADIOPHARMACEUTICALS

“There has never been a more exciting time to be part of this dynamic industry,” says Roberts. “There is a growing demand for radiopharma diagnostics and therapeutics, and these technologies have advanced to the point where we will soon see more groundbreaking medicines emerging from Canada for patients worldwide. Canada has created significant momentum in the global radiopharma space, and we need to encourage all our partners to continue to build on our successes.”

CPDC’s journey exemplifies the power of innovation, collaboration, commitment, and strategic investment. As CPDC forges ahead in the fast-evolving radiopharmaceutical industry, the company invites potential collaborators to explore opportunities for partnership.

To learn more about CPDC and explore funding and collaborations opportunities, contact info@cpdc.ca .

PROMOUVOIR LE LEADERSHIP DISTINCTIF DU CANADA DANS LE DOMAINE DES PRODUITS RADIOPHARMACEUTIQUES À L›ÉCHELLE MONDIALE

« Il n’y a jamais eu de période plus excitante pour faire partie de cette industrie dynamique », déclare Roberts. « La demande de diagnostics et de thérapies radiopharmaceutiques ne cesse de croître, et ces technologies ont progressé à un point tel que nous verrons bientôt d’autres médicaments révolutionnaires émerger du Canada pour les patients du monde entier. Le Canada a créé un élan important dans l’espace radiopharmaceutique mondial, et nous devons encourager tous nos partenaires à continuer à tirer parti de nos succès. »

Le parcours de CPDC illustre le pouvoir de l’innovation, de la collaboration, de l’engagement et de l’investissement stratégique. Alors que CPDC va de l’avant dans l’industrie radiopharmaceutique en pleine évolution, la société invite les collaborateurs potentiels à explorer les possibilités de partenariat.

Pour en savoir plus sur le CPDC et explorer les possibilités de financement et de collaboration, contactez info@cpdc.ca.

Owen Roberts, CEO/Chef de la direction

The role of public policy in promoting translational research: The IRICoR example

Le rôle des politiques publiques dans la valorisation de la recherche translationnelle : L’exemple

d’IRICoR

TRANSLATIONAL RESEARCH, which aims to translate fundamental discoveries into tangible therapies available to patients, is an essential component in the development of new medicines. Some organizations, such as IRICoR, play a crucial role in this field. However, public policy support through appropriate programs is essential to enable these organisations to deploy all their know-how and transform this academic research into concrete solutions that meet patients’ needs and stimulate the economy.

THE ROLE OF PUBLIC POLICY AND INVESTMENT MEASURES

Public policies and strategic investments through relevant programs play a crucial role in the valorisation of translational life sciences research. Incentives such as R&D tax credits and the Biomanufacturing and Life Sciences Strategy (BLSS) have gone a long way to support innovation in Canada.

However, gaps remain, including under-funding of the intermediate stages of development between basic research and commercialization, and limited access to funds for start-ups. There is a need to improve public-private partnerships, adapt policies to the needs of small businesses and increase the range of programs and investments between basic research and clinical validation.

LA RECHERCHE TRANSLATIONNELLE, qui vise à traduire les découvertes fondamentales en thérapie tangible disponible pour les patients, est une composante essentielle du développement de nouveaux médicaments. Certains acteurs, comme IRICoR, jouent un rôle crucial dans ce domaine. Toutefois, le soutien des politiques publiques via des programmes adaptés est indispensable pour permettre à ces organisations de déployer tout leur savoir-faire et transformer cette recherche académique en solutions concrètes, répondant aux besoins des patients et stimulant l’économie.

LE

RÔLE

DES POLITIQUES PUBLIQUES ET DES MESURES D’INVESTISSEMENT

Les politiques publiques et les investissements stratégiques via des programmes pertinents jouent un rôle décisif dans la valorisation de la recherche translationnelle en sciences de la vie. Des mesures incitatives telles que les crédits d’impôt pour la R&D et la Stratégie de biofabrication et de sciences de la vie, ont permis de supporter l’innovation au Canada.

Cependant, des lacunes subsistent, notamment le sousfinancement des étapes intermédiaires du développement entre la recherche fondamentale et la commercialisation, et l’accès limité aux fonds pour les startups. Il est nécessaire d’améliorer les partenariats public-privé, d’adapter les politiques aux besoins des petites entreprises et d’augmenter l’offre de programmes et les investissements entre la recherche fondamentale et la validation clinique.

IRICOR: ASSET CATALYST AND VALORIZATION DRIVER

Through its business model, centered on collaboration between academic research and private partners, IRICoR plays a key role in the creation of innovative biopharmaceutical companies, supporting the development of cancer treatments, as demonstrated by ExCellThera, with its UM171 molecule for the expansion of stem cells to treat patients with leukaemia, Epitopea, which is developing therapeutic vaccines against cancer, and RejuvenRx, which is advancing precision therapies in the field of cancer and ageing.

These companies are the direct outcome of initiatives to translate and commercialize discoveries made in university laboratories. By capitalizing on a network of industrial and financial partners, IRICoR succeeds in bridging the gap between academic innovations and market needs, while maximizing the return on investment of public funds. By supporting the critical stages of preclinical development, IRICoR strengthens the international competitiveness of Canadian innovations and stimulates the national entrepreneurial and economic ecosystem.

By supporting the critical stages of preclinical development, IRICoR strengthens the international competitiveness of Canadian innovations and stimulates the national entrepreneurial and economic ecosystem.

STRENGTHENING POLICIES FOR A FLOURISHING ECOSYSTEM

IRICoR’s success demonstrates that with the appropriate policies and programs, academic research projects can lead to major scientific and economic breakthroughs. To unlock Canada’s full potential in the life sciences, it is essential to continue along this path, by strengthening public-private partnerships and creating a regulatory framework that encourages innovation, supported by the appropriate programs.

IRICOR : CATALYSEUR D’ACTIFS ET MOTEUR DE VALORISATION

Par son modèle d’affaires axé sur la collaboration entre la recherche académique et les partenaires privés, IRICoR joue un rôle clé dans la création de compagnies innovantes, soutenant le développement de traitements contre le cancer, comme en témoignent ExCellThera, avec sa molécule UM171 pour l’expansion des cellules souches pour traiter les personnes atteintes de leucémie, Epitopea, qui développe des vaccins thérapeutiques ciblant le cancer ou encore RejuvenRx qui travaille au développement de thérapies de précision dans le domaine du cancer et du vieillissement .

Ces entreprises sont le résultat direct des efforts de valorisation et commercialisation des découvertes universitaires. En capitalisant sur un réseau de partenaires industriels et financiers, IRICoR fait le lien entre l’innovation académique et les besoins du marché, tout en maximisant le retour sur investissement et bénéfices sociaux économiques des fonds publics. En soutenant les étapes critiques du développement préclinique, IRICoR renforce la compétitivité des innovations canadiennes à l’échelle internationale, et stimule l’écosystème entrepreneurial et économique national.

En soutenant

les

étapes

critiques

du développement préclinique,

IRICoR renforce la compétitivité des innovations canadiennes à l’échelle internationale, et stimule l’écosystème entrepreneurial et économique national.

DES POLITIQUES À RENFORCER POUR UN ÉCOSYSTÈME FLORISSANT

Le succès d’IRICoR démontre que, lorsqu’ils sont soutenus par des politiques et des programmes appropriés, les projets issus de la recherche académique peuvent aboutir à des avancées scientifiques et économiques majeures. Pour que le Canada puisse pleinement exploiter son potentiel en sciences de la vie, il est essentiel de poursuivre dans cette voie, en renforçant les partenariats entre le public et le privé, et en créant un cadre réglementaire favorable à l’innovation avec des programmes ciblés.

The State of Biotech and Biologic Manufacturing in Canada: A conversation with BIOTECanada Member, Pegasus Biotech

La situation des biotechs et de la fabrication biologique au Canada : Une rencontre avec Pegasus

Biotech, une entreprise membre de BIOTECanada

CAN YOU PROVIDE AN OVERVIEW OF PEGASUS BIO’S CONTRIBUTIONS TO THE CANADIAN BIOLOGIC MANUFACTURING LANDSCAPE, INCLUDING ITS KEY STRENGTHS AND CHALLENGES, AND HOW ITS WORK IN ADVANCING BIOLOGIC THERAPIES IMPACTS CANADA’S STANDING IN THE GLOBAL BIOTECH SECTOR?

Canada boasts a highly educated workforce and a reputable regulatory framework. However, the country’s biotech manufacturing sector faces economic challenges, particularly a lack of private investment compared to other more investment-friendly regions, which hampers its potential for expansion and growth.

Another significant obstacle to the sector’s growth is the scarcity of suitable biocontainment-rated laboratory facilities available for lease. This issue is especially pronounced in smaller provinces like Prince Edward Island (PEI), where innovative start-up biotech companies struggle to secure containment level 2 or 3 laboratories essential for developing and manufacturing vaccines and biologic products involving infectious organisms. Setting up new facilities often requires substantial additional investment, leading to considerable delays in the commencement of development work.

Founded in 2019 in Charlottetown, Pegasus Biotech, led by Dr. Yimy Mena (CEO), Daniel Wilson (COO), and Jonathan Wilts (CFO), has contributed to the success of the Canadian vaccine and biologics sector by providing their extensive experience to clients at critical premanufacturing and manufacturing stages of development for biologics and DNA vaccines. Committed to addressing the need for Canadian-based vaccine manufacturing expertise, Pegasus Biotech has focused on three key areas: upstream processing (e.g., fermentation and animal cell culture), downstream processing (purification and formulation), and analytical test development for autogenous vaccines, DNA vaccines, and biologic products.

Over the past five years, Pegasus Biotech has significantly contributed to the advancement of numerous biologics and vaccine projects in Canada and internationally and has amplified the global impact of Canadian biotech companies.

POUVEZ-VOUS NOUS DONNER UN APERÇU DES CONTRIBUTIONS DE PEGASUS BIO DANS LE SECTEUR CANADIEN DE LA FABRICATION DE PRODUITS BIOLOGIQUES? QUELLES SONT SES PRINCIPALES FORCES, ET À QUELS ENJEUX DOIT-ELLE FAIRE FACE?

POURRIEZ-VOUS AUSSI NOUS EXPLIQUER COMMENT SON APPROCHE DES TRAITEMENTS BIOLOGIQUES INFLUE SUR LA PLACE DU CANADA DANS LE SECTEUR DE LA BIOTECHNOLOGIE À L’ÉCHELLE MONDIALE?

Le Canada est fier de disposer d’une main-d’œuvre hautement qualifiée et d’un cadre réglementaire reconnu. Il n’en reste pas moins que le secteur de la fabrication biotechnologique du pays est aux prises avec des difficultés économiques, notamment un manque d’investissements privés par rapport à d’autres pays où il est plus attrayant d’investir, ce qui entrave son potentiel d’expansion et de croissance.

La croissance du secteur est également ralentie par la rareté des installations de laboratoire à louer qui sont adaptées et conformes aux normes de confinement biologique, ce qui constitue un autre obstacle important. Le problème est particulièrement criant dans les petites provinces comme l’Île-du-Prince-Édouard, où les jeunes entreprises biotechnologiques innovantes peinent à accéder à des laboratoires de confinement de niveau 2 ou 3, indispensables au développement et à la fabrication de vaccins et de produits biologiques à base d’organismes infectieux. L’aménagement de nouvelles installations nécessite souvent des investissements importants, ce qui entraîne des retards considérables dans la mise en œuvre du travail de mise au point.

Pegasus Biotech a été créée en 2019 à Charlottetown, avec à sa tête Yimy Mena (PDG), Daniel Wilson (directeur de l’exploitation) et Jonathan Wilts (directeur financier).

L’entreprise a contribué au succès du secteur canadien des vaccins et des produits biologiques en mettant sa vaste expérience au service des clients aux étapes cruciales de la préfabrication et de la fabrication de vaccins biologiques et de vaccins à ADN. Soucieuse de répondre au besoin d’expertise en matière de fabrication de vaccins au Canada, Pegasus Biotech s’est concentrée sur trois domaines clés : le traitement en amont (fermentation et culture de cellules animales), le traitement en aval (purification et formulation) et la mise au point d’analyses pour les vaccins autogènes, les vaccins à ADN et les produits biologiques.

INNOVATION IN BIOLOGIC MANUFACTURING

HOW IS PEGASUS BIO DRIVING INNOVATION IN BIOLOGIC MANUFACTURING?

In response to the growing Canadian and global demand for more efficient and cost-effective biologics and vaccine production methods, Pegasus Biotech invented and developed a groundbreaking, high-yield, ultra-low-cost plasmid manufacturing platform known as the BPE. This innovative platform is selection marker-free and leverages a combination of advanced technologies, including a de-novo bacterial origin, a genetically engineered host bacterium, and thermoregulated plasmid replication. These features enabling ultra-high plasmid yields in an environment free of antimicrobial agents.

At the core of the BPE technology platform is a highly efficient plasmid backbone designed for robust replication and temperature stability, containing minimal bacterial sequences and no selection marker. This results in a platform with an exceptional safety profile and industryleading expression levels.

In addition, Pegasus Biotech has integrated their plasmid technology within a comprehensive suite of optimized manufacturing processes for fermentation, purification, and formulation, and have combined these with a set of fully developed and validated analytical tests. This complete manufacturing package makes previously cost-prohibitive DNA vaccines commercially viable, opening up new opportunities in the marketplace.

REGULATORY AND POLICY IMPACT

TELL US MORE ABOUT HOW THE CANADIAN REGULATORY ENVIRONMENT AFFECTS PEGASUS BIO’S BIOLOGIC MANUFACTURING OPERATIONS.

With extensive experience in manufacturing under Canada’s current regulatory framework, the founders of Pegasus Biotech are well aware of the challenges biotech innovators face when bringing new products to market, particularly in the animal health sector. The regulatory hurdles, especially in biologics manufacturing, are notably stringent, with Canadian standards among the most demanding globally.

Pegasus Biotech views a critical area for improvement in the Canadian regulatory environment is in the transparency of the approval pathway for autogenous and other vaccine products. Additionally, the growing

L’apport de Pegasus Biotech au cours des cinq dernières années est considérable. Il a permis à de nombreux projets relatifs à des produits biologiques et à des vaccins au Canada et à l’étranger de voir le jour, ce qui a accru la présence des entreprises canadiennes de biotechnologie sur la scène internationale.

L’INNOVATION DANS LA FABRICATION DE PRODUITS BIOLOGIQUES

DE QUELLE MANIÈRE PEGASUS BIO STIMULE-T-ELLE

L’INNOVATION DANS LE DOMAINE DE LA FABRICATION DE PRODUITS BIOLOGIQUES?

En réponse à la demande croissante, au Canada et dans le monde, relative à des méthodes de production de produits biologiques et de vaccins plus efficaces et plus rentables, Pegasus Biotech a créé BPE, une plateforme novatrice à haut rendement et à très faible coût pour la fabrication de plasmides. Cette plateforme est exempte d’agent de sélection spécifique et s’appuie sur une combinaison de technologies avancées, dont l’assemblage de génome bactérien de novo, la modification génétique de la bactérie hôte et la réplication plasmidique à régulation thermique. Ces caractéristiques permettent d’obtenir des rendements plasmidiques très élevés dans un environnement exempt d’agents antimicrobiens.

La plateforme technologique BPE a été conçue autour d’un système plasmidique avancé, qui permet une réplication très efficace et qui offre une température stable, avec seulement un minimum de séquences bactériennes et sans agent de sélection spécifique. La plateforme présente ainsi un profil d’innocuité exceptionnel et des niveaux d’expression inégalés dans l’industrie.

De plus, la technologie plasmidique de Pegasus Biotech fait partie d’un ensemble complet de procédés de fabrication optimisés pour la fermentation, la purification et la formulation, qui sont associés à une série d’analyses dont la mise au point est terminée et qui sont dûment validées. Cette plateforme complète de fabrication assure la viabilité commerciale de vaccins à ADN dont le coût était jusqu’à présent prohibitif, ce qui ouvre de nouvelles perspectives sur le marché.

LES RÉPERCUSSIONS DE LA RÉGLEMENTATION ET DES POLITIQUES

EXPLIQUEZ-NOUS QUELS SONT LES EFFETS DE L’ENVIRONNEMENT RÉGLEMENTAIRE CANADIEN SUR LES ACTIVITÉS DE FABRICATION DE PRODUITS BIOLOGIQUES DE PEGASUS BIO.

Forts d’une vaste expérience de la fabrication au sein du cadre réglementaire canadien, les fondateurs de Pegasus Biotech sont bien conscients des défis que doivent relever les entreprises d’innovation en biotechnologie lorsqu’elles souhaitent mettre de nouveaux produits sur le marché, en particulier dans le secteur de la santé animale. Les exigences réglementaires, notamment dans le domaine de la fabrication de produits biologiques, sont spécialement strictes, les normes canadiennes étant parmi les plus exigeantes au monde.

Pegasus Bio Team / L’équipe de Pegasus Bio

Since reforming the Canadian regulatory process would require significant time and political will, Pegasus Biotech is proactively addressing the existing challenges.

bureaucracy in other federal areas such as the tariffs collection system (CARM) for cross-border purchases of equipment, consumables, and reagents—has further complicated operations for small biotech companies like Pegasus. In this particular example, we believe the previous system, where customs brokers managed and were reimbursed for duties and taxes, was simpler and more efficient.

Since reforming the Canadian regulatory process would require significant time and political will, Pegasus Biotech is proactively addressing the existing challenges. Our platform of optimized manufacturing processes and comprehensive suite of analytical tests (BPE platform) was designed to meet the strictest global standards, with the goal to simplify and expedite the regulatory approval timelines for Canadian vaccine and biologic manufacturers.

PUBLIC-PRIVATE PARTNERSHIPS AND COLLABORATIONS

CAN YOU PROVIDE INSIGHTS INTO THE PUBLIC-PRIVATE PARTNERSHIPS PEGASUS BIO HAS ENGAGED IN TO ACCELERATE INNOVATION, ALONG WITH EXAMPLES OF SUCCESSFUL COLLABORATIONS THAT HAVE POSITIVELY IMPACTED BIOLOGIC MANUFACTURING?

To drive innovation, Pegasus Biotech has formed multiple public-private partnerships focused on developing DNA vaccine products using the BPE platform. One notable collaboration is with the Vaccine and Infectious Disease Organization (VIDO) in Saskatchewan, aimed at accelerating vaccine innovation in Canada and enhancing the nation’s manufacturing readiness for emerging infectious diseases. Pegasus Biotech views governmentsupported organizations like VIDO, with its currently rare combination of CL3 containment facilities for animal testing and GLP manufacturing capabilities, as vital to

Pegasus Biotech estime que la transparence de la procédure d’approbation des vaccins autogènes et des autres produits vaccinaux est essentielle à l’amélioration de l’environnement réglementaire canadien. Par ailleurs, les démarches administratives dans d’autres structures fédérales, tels que le système de gestion des cotisations et des recettes de l’Agence des services frontaliers du Canada (GCRA) pour les achats transfrontaliers d’équipement, de consommables et de réactifs, a considérablement compliqué les opérations des petites entreprises de biotechnologie telles que Pegasus. Nous pensons que le système antérieur, dans lequel les courtiers en douane géraient et se faisaient rembourser les droits et les taxes, était plus simple et plus efficace.

Étant donné que la réforme du processus réglementaire canadien nécessiterait beaucoup de temps et de volonté politique, Pegasus Biotech œuvre à surmonter les difficultés existantes de manière proactive. Notre plateforme optimisée pour les processus de fabrication et notre vaste gamme d’analyses (plateforme BPE) ont été conçues pour répondre aux normes mondiales les plus strictes, dans le but de simplifier et d’accélérer les délais d’approbation réglementaire pour les fabricants canadiens de vaccins et de produits biologiques.

LES PARTENARIATS ET LES COLLABORATIONS PUBLIC-PRIVÉ

POUVEZ-VOUS NOUS PARLER DES PARTENARIATS PUBLIC-PRIVÉ DANS LESQUELS PEGASUS BIO S’EST ENGAGÉE POUR STIMULER L’INNOVATION, ET NOUS

DONNER AUSSI DES EXEMPLES DE COLLABORATIONS RÉUSSIES QUI ONT EU UN EFFET POSITIF SUR LA FABRICATION DE PRODUITS BIOLOGIQUES?

Pour stimuler l’innovation, Pegasus Biotech a établi plusieurs partenariats public-privé axés sur la mise au point de produits vaccinaux à base d’ADN à partir de la plateforme BPE. Une des collaborations les plus remarquables est celle avec la Vaccine and Infectious Disease Organization (VIDO) de la Saskatchewan, qui vise à stimuler l’innovation en matière de vaccins au Canada et à améliorer la préparation de l’industrie au pays en vue d’éventuelles nouvelles maladies infectieuses. Pegasus Biotech considère que les organismes recevant des fonds du gouvernement comme la VIDO, avec sa combinaison exceptionnelle d’installations de confinement de niveau 3 permettant l’expérimentation sur les animaux et de capacités de fabrication selon les BPL, sont essentiels à la croissance du secteur de la fabrication de vaccins et de produits biologiques au Canada.

L’AVENIR DE LA FABRICATION DE PRODUITS BIOLOGIQUES AU CANADA

QUELLES SONT LES PRINCIPALES TENDANCES QUI SE DESSINENT POUR L’AVENIR DE LA FABRICATION DE PRODUITS BIOLOGIQUES AU CANADA, ET EN QUOI LA POSITION STRATÉGIQUE DE PEGASUS BIO LUI PERMETTRA-T-ELLE DE JOUER UN RÔLE DE PREMIER

Pegasus Bio Founders / Les fondateurs de Pegasus Bio

strengthening and growing Canada’s vaccine and biologics manufacturing sector.

FUTURE OF BIOLOGIC MANUFACTURING IN CANADA

WHAT KEY TRENDS ARE SHAPING THE FUTURE OF BIOLOGIC MANUFACTURING IN CANADA, AND HOW IS PEGASUS BIO STRATEGICALLY POSITIONED TO LEAD IN THIS EVOLVING LANDSCAPE, PARTICULARLY IN THE CONTEXT OF POLICY ALIGNMENT AT BOTH THE PROVINCIAL AND FEDERAL LEVELS?

As the world prepares for the next pandemic and faces an increasing number of significant international disease threats—like African Swine Fever and Avian Influenza— that impact global food supplies and pose risks to human health through cross-species transmission, the development of vaccines is critical to the Canadian and global biotechnology sector. Canada has a unique, albeit limited, opportunity to establish a significant leadership role on the world stage by effectively aligning provincial and federal policies and incentives to promote the growth of biologics and vaccine manufacturing. A positive example of this is the recently announced Canada-UK: Biomanufacturing of Biologics and Advanced Therapies Initiative, driven by the federal government, which brings together Canadian and UK companies to collaborate in the development of new biomanufacturing platforms that increase pandemic preparedness.

In this context, Pegasus Biotech has strategically invested in innovative technologies like BPE, with support from IRAP and SRED, to expedite the development of vaccines and biologics while streamlining the production processes for these vital products.

GLOBAL PERSPECTIVE

HOW DOES CANADA’S APPROACH TO BIOLOGIC MANUFACTURING COMPARE TO OTHER COUNTRIES, WHAT LESSONS CAN BE LEARNED FROM INTERNATIONAL BEST PRACTICES, AND CAN YOU PROVIDE AN OVERVIEW OF GLOBAL PARTNERSHIPS OR TRENDS THAT PEGASUS BIO IS INVOLVED IN THAT COULD SHAPE THE FUTURE OF BIOLOGIC MANUFACTURING IN CANADA?

The global biologics industry is becoming increasingly internationally interconnected and the leaders at Pegasus Biotech believe Canada should move to further align its regulatory requirements with those of the FDA and USDA in the U.S. and the EMA in Europe to streamline the international product approval process. Furthermore, additional efforts should be made to incentivize private sector investment in the Canadian biotech industry to drive necessary growth.

Also, it is well known that U.S. government agencies and private biotech investors are significantly less risk-averse

PLAN DANS CE SECTEUR EN ÉVOLUTION, EN PARTICULIER PAR RAPPORT À L’HARMONISATION DES POLITIQUES PROVINCIALES ET FÉDÉRALES?

À l’heure où le monde se prépare à la prochaine pandémie et fait face à un nombre croissant de menaces sanitaires importantes à l’échelle mondiale, telles que la peste porcine africaine et la grippe aviaire, qui ont un impact sur l’approvisionnement alimentaire mondial et présentent des risques pour la santé humaine en raison de la transmission d’infections interspécifiques, la mise au point de vaccins est cruciale pour le secteur canadien et mondial de la biotechnologie. Le Canada dispose d’une fenêtre d’opportunité unique, bien qu’étroite, de jouer un rôle de premier plan sur la scène mondiale en harmonisant les politiques et les mesures d’incitation provinciales et fédérales afin de promouvoir la croissance de la production de produits biologiques et de vaccins. Un exemple favorable de cela est le programme de collaboration entre le Canada et le RoyaumeUni dans le secteur de la biofabrication de produits thérapeutiques et biologiques, récemment annoncé. Mené par le gouvernement fédéral, il réunit des entreprises canadiennes et britanniques en vue de la création de nouvelles plateformes de biofabrication qui permettront de mieux nous préparer aux futures pandémies.

Dans ce contexte, Pegasus Biotech a réalisé des investissements stratégiques dans des technologies innovantes telles que la plateforme BPE, grâce au PARI et aux encouragements fiscaux à la RS&DE, afin d’accélérer les processus de mise au point de vaccins et de produits biologiques tout en veillant à simplifier les processus de production de ces produits essentiels.

PERSPECTIVE MONDIALE

COMMENT L’APPROCHE DU CANADA EN MATIÈRE DE FABRICATION DE PRODUITS BIOLOGIQUES SE COMPARET-ELLE À CELLE D’AUTRES PAYS? QUELLES LEÇONS PEUT-ON TIRER DES MEILLEURES PRATIQUES INTERNATIONALES? POUVEZ-VOUS DONNER UN APERÇU DES PARTENARIATS INTERNATIONAUX DANS LESQUELS PEGASUS BIO EST ENGAGÉE ET DES TENDANCES QUI POURRAIENT INFLUENCER L’AVENIR DE LA FABRICATION DE PRODUITS BIOLOGIQUES AU CANADA?

L’industrie mondiale des produits biologiques est de plus en plus interconnectée et les dirigeants de Pegasus Biotech estiment que le Canada devrait faire en sorte que ses exigences réglementaires soient davantage en phase avec celles de la FDA et de l’USDA aux États-Unis et de l’EMA en Europe afin de simplifier le processus d’approbation des produits à l’échelle internationale. Par ailleurs, on devrait prendre des mesures supplémentaires pour encourager les investissements du secteur privé dans l’industrie canadienne de la biotechnologie afin de stimuler la croissance attendue. Il est également bien établi que les organismes gouvernementaux et les investisseurs privés du domaine de la

compared to those in Canada. This approach allows U.S. biologics manufacturing companies to invest in innovation at levels surpassing those of their Canadian counterparts. As a result, the U.S. holds a significant advantage in fostering innovation and growth in this sector, a challenge that Canada struggles to match. To remain competitive, it is imperative for Canada to adopt policies that encourage greater investment in biotech innovation.

Although the federal and provincial governments were a driving force supporting the Canadian biotech sector during the COVID-19 pandemic, funding was quickly and quietly reduced once the crisis subsided. In a field where it can take over a decade to bring a biologic product to market, sustained private investment enabled by effective federal and provincial government policies and programs is essential to position Canada at the forefront of the biotech and biologics industry globally.

As an example of global interconnectedness, Pegasus Biotech has established strategic partnerships with other biotech organizations in both the UK and Argentina to develop new vaccines for both human and animal health. These initiatives have been supported by the federal/ provincial government, the Canadian Trade Commissioner service and through support of private organizations such as PEI BioAlliance’s Emergence Bioscience Business Incubator program.

LOOKING AHEAD

CAN YOU SUMMARIZE PEGASUS BIO’S CONTRIBUTIONS TO ADVANCING BIOLOGIC MANUFACTURING IN CANADA, AND OUTLINE THE KEY STEPS NEEDED TO FOSTER GROWTH AND INNOVATION IN THE COUNTRY’S BIOLOGIC MANUFACTURING ECOSYSTEM?

Pegasus Biotech exemplifies an innovative Canadian biotech firm that, with the backing of crucial provincial and federal government partners, has successfully developed and commercialized a new vaccine development and manufacturing technology vital for the industry. Pegasus Biotech advocates for increased financial support directed toward provincial initiatives like the PEI BioAlliance and Innovation PEI, as well as federal R&D programs such as IRAP and SRED. They believe that promoting private sector investment is essential for driving growth and innovation within Canada’s biologics manufacturing ecosystem.

biotechnologie des États-Unis craignent nettement moins les risques que ceux du Canada. Cette stratégie permet aux entreprises américaines de fabrication de produits biologiques d’investir dans l’innovation à un rythme supérieur à celui de leurs homologues canadiennes. Par conséquent, là où les États-Unis disposent d’un avantage considérable favorisant l’innovation et la croissance dans ce secteur, le Canada, lui, s’en tire moins bien. Si le Canada veut rester dans la course, il est impératif qu’il adopte des politiques qui encouragent l’investissement dans le secteur de l’innovation biotechnologique.

Si les gouvernements fédéral et provinciaux ont joué un rôle moteur dans le financement du secteur biotechnologique canadien pendant la pandémie de COVID-19, les aides ont rapidement, et sans avertissement, diminué après la crise. Dans un domaine où la mise sur le marché d’un produit biologique peut nécessiter plus d’une décennie de travail, des investissements privés continus, favorisés par des politiques et des programmes efficaces des gouvernements fédéral et provinciaux, sont essentiels pour positionner le Canada à l’avant-garde de l’industrie de la biotechnologie et des produits biologiques à l’échelle mondiale.

À titre d’exemple de relations internationales, Pegasus Biotech a établi des partenariats stratégiques avec d’autres organisations biotechnologiques au Royaume-Uni et en Argentine afin de mettre au point de nouveaux vaccins à la fois pour la santé humaine et pour la santé animale. Ces initiatives ont été menées avec le soutien des gouvernements fédéral et provinciaux, du Service des délégués commerciaux du Canada et d’organisations privées telles que le programme d’incubateur d’entreprises de biosciences de PEI BioAlliance.

PERSPECTIVES D’AVENIR

COMMENT POURRIEZ-VOUS RÉSUMER LES CONTRIBUTIONS DE PEGASUS BIO À L’ÉGARD DE L’ÉVOLUTION DU SECTEUR DE LA FABRICATION DE PRODUITS BIOLOGIQUES AU CANADA ET DÉCRIRE LES PRINCIPALES ÉTAPES NÉCESSAIRES À LA CROISSANCE ET À L’INNOVATION DANS L’ÉCOSYSTÈME DE FABRICATION DE PRODUITS BIOLOGIQUES DU PAYS? En bref, Pegasus Biotech est un exemple d’entreprise biotechnologique canadienne innovante qui, avec le soutien de partenaires essentiels que sont les gouvernements provinciaux et fédéral, a réussi à concevoir et à commercialiser une nouvelle technologie de mise au point et de fabrication de vaccins, une avancée cruciale pour l’industrie. Pegasus Biotech recommande d’accroître le soutien financier aux initiatives provinciales telles que PEI BioAlliance et Innovation PEI, ainsi qu’aux programmes fédéraux de R.-D. tels que le PARI et le RS&DE. Elle estime que favoriser les investissements du secteur privé est essentiel pour stimuler la croissance et l’innovation au sein de l’écosystème de la fabrication de produits biologiques au Canada.

Transforming Patients’ Lives with High-Quality Radiopharmaceuticals: How AtomVie Global Radiopharma is Shaping the Future of Radiopharmaceuticals

WITH OVER A DECADE of experience in radiopharmaceuticals, AtomVie Global Radiopharma (AtomVie) has established itself as a global leader in the development, manufacturing and global distribution of radiopharmaceuticals. As the most recent spinout of the Centre for Probe Development & Commercialization (CPDC) and with its successful series

A funding of $90M, AtomVie is uniquely positioned to be a forefront leading CDMO in the thriving radiopharma industry, ultimately serving patients by manufacturing high quality drugs.

What sets AtomVie apart is its deep expertise in taking its partners’ assets from initial development, all the way towards commercial success, together with its skilful work force equipped with unparalleled knowledge in working with an array of radioisotopes, including Lu-177, Ac-225, I-131, Y-90, In-111 and more, process & analytical development,

quality, regulatory as well as logistics. By offering comprehensive, end-to-end high caliber services, AtomVie has proven to succeed in developing, scaling up and supplying clinical phases 1 to 3 with utmost reliability, ultimately resulting in the delivery of final drug products, with short shelf lives, in time to be injected into patients globally.

To meet the rising global demand for radiotherapeutics, AtomVie is currently building a cutting-edge, purpose-built 72,300-square-foot manufacturing facility, scheduled to open in early 2025. Equipped with over 18 GMP production lines and offering scalable solutions, this expansion will increase the company’s production capacity by more than

tenfold, enabling support for an expanding pipeline of radiopharmaceuticals while staying flexible for future innovations.

Partnering with AtomVie also provides a distinct strategic advantage. Located in proximity to 2 international airports and the US border, AtomVie has access to delivery routes that cover a wide distribution network, currently covering 25 countries, spanning 6 continents, ensuring logistics capabilities, a key ingredient in AtomVie’s success.

AtomVie’s unwavering commitment to quality and rapid logistics remains central to its mission of transforming patient lives with reliable manufacturing and on-time delivery of radiopharmaceuticals. As the company continues to grow, its ability to navigate complex global operations solidifies its position as a leader in the future of radiopharmaceuticals.

Bruno Paquin, CEO of AtomVie Global Radiopharma

Leading with Purpose:

An Interview with Lori Lyons-Williams, President & CEO at Abdera Therapeutics,

on Transforming Cancer Care

Diriger avec détermination :

Une entrevue avec Lori Lyons-Williams, présidente et chef de la direction d’Abdera Therapeutics, sur la nouvelle approche des soins de cancérologie

PERSONAL VISION AND PASSION

YOU’VE BEEN AT THE HELM OF ABDERA DURING A TIME OF RAPID GROWTH AND INNOVATION. WHAT INSPIRED YOU TO PURSUE LEADERSHIP IN SUCH A CHALLENGING AND COMPETITIVE FIELD, AND HOW DO YOU STAY GROUNDED AND MOTIVATED IN YOUR MISSION?

Over the past decade, the landscape for oncology drug development has been fast moving with many different companies and approaches. I believe radiopharmaceuticals are one of the most innovative areas of oncology drug development and hold enormous promise for patients, offering the potential to transform the treatment of a variety of cancer types. This is our common motivation at Abdera—we are purpose-built to attack cancer, inspire hope and restore life. We always think of patients first and how to leverage our unique next-generation radiopharmaceutical-based technology program to design, engineer and develop the best medicines for them. We aim to develop our medicines as rapidly as possible because we believe they have the potential to truly impact patients lives, which fuels our sense of urgency. We are excited to advance our lead program, ABD-147, for certain neuroendocrine carcinomas like small-cell lung cancer into a first-in-human study in 2024. These are aggressive

UNE VISION PERSONNELLE ET DE LA PASSION

VOUS AVEZ PRIS LA TÊTE D’ABDERA À UN MOMENT DE CROISSANCE RAPIDE ET D’INNOVATION. QU’EST-CE QUI VOUS A INCITÉE À EXERCER DES FONCTIONS DE DIRECTION DANS UN DOMAINE AUSSI DIFFICILE ET COMPÉTITIF, ET COMMENT FAITES-VOUS POUR DEMEURER MOTIVÉE VIS-À-VIS DE VOTRE MISSION?

Au cours de la dernière décennie, le secteur de la mise au point de médicaments oncologiques a connu une évolution rapide. Les entreprises et les approches sont nombreuses. Je pense que les produits radiopharmaceutiques comptent parmi les candidats-médicaments les plus innovants en oncologie et qu’ils sont extrêmement prometteurs pour les patients, car ils sont susceptibles de transformer le traitement de divers types de cancer. C’est notre motivation première chez Abdera et ce qui fait que nous sommes déterminés à nous attaquer au cancer, à inspirer l’espoir et à faire renaître la vie. Nous pensons toujours d’abord aux patients et à la manière de mettre à profit notre programme technologique unique basé sur les produits radiopharmaceutiques de nouvelle génération lorsque vient le moment de concevoir et de mettre au point les meilleurs médicaments pour eux. Nous visons à élaborer nos médicaments aussi rapidement que possible. Nous pensons en effet qu’ils ont le potentiel d’avoir un véritable effet sur la vie des patients, ce qui renforce notre

cancers and challenging to treat—and ABD-147 has the potential to make a significant impact.

ABDERA’S FOCUS ON PRECISION RADIOPHARMACEUTICALS IS GROUNDBREAKING. WHAT PERSONALLY DRIVES YOUR PASSION FOR DEVELOPING THESE NEXT-GENERATION CANCER THERAPIES, AND HOW DOES THIS PASSION INFLUENCE THE CULTURE AND DIRECTION OF THE COMPANY?

My passion is rooted in the immense impact we aim to make for patients and I believe everyone who works at Abdera shares the same sense of urgency. What keeps us going is that we very much believe we will someday meet people living with cancer who live longer lives because of the medicines we discover and develop. Together, we are relentless in our focus to offer new hope to families facing devastating diagnoses. Targeted radiation therapies are one of the most cutting-edge and highly promising areas of oncology drug development. Abdera is built on a proprietary modular technology platform optimized for the delivery of radioisotopes to selectively destroy tumor cells while sparing healthy cells. We are using this platform to enable the rapid development of therapies serving a broad range of cancer patients with limited treatment options. Our culture and direction are grounded in innovative science, agility and dedication. We are building an exciting and fast-paced company that is passionate about advancing tomorrow’s most innovative cancer therapies.

I

believe radiopharmaceuticals are one of the most innovative areas of oncology drug development and hold enormous promise for patients, offering the potential to transform the treatment of a variety of cancer

types.

CANADIAN BIOTECH AND LEADERSHIP REFLECTIONS

AS A LEADER OPERATING IN BOTH CANADA AND THE U.S., WHAT DO YOU BELIEVE ARE THE UNIQUE STRENGTHS THAT CANADA OFFERS TO THE BIOTECH INDUSTRY? HOW HAVE YOUR EXPERIENCES IN CANADA SHAPED YOUR APPROACH TO BUILDING A GLOBALLY RECOGNIZED COMPANY?

Our platform is based on the work of a group of Canadian scientists who collaborated to design a more targeted delivery system, custom-engineered for novel radiopharmaceuticals. Our heads of biology, chemistry and

sentiment d’urgence. Nous sommes ravis de faire passer notre programme phare, ABD-147, à une première phase d’essais chez l’humain en 2024 pour certains carcinomes neuroendocriniens tels que le cancer du poumon à petites cellules. Un tel cancer est agressif et difficile à traiter, et l’ABD-147 pourrait potentiellement jouer un rôle très important dans ce cas précis.

LE FAIT QU’ABDERA SE CONCENTRE SUR LES PRODUITS RADIOPHARMACEUTIQUES DE PRÉCISION EST NOVATEUR. QU’EST-CE QUI VOUS POUSSE PERSONNELLEMENT À DÉVELOPPER CES TRAITEMENTS ANTICANCÉREUX DE NOUVELLE GÉNÉRATION ET COMMENT CETTE CONVICTION INFLUE-T-ELLE SUR LA CULTURE ET L’ORIENTATION DE L’ENTREPRISE?

Ce qui me motive, c’est l’immense effet escompté sur les patients, et je pense que toutes les personnes qui travaillent chez Abdera partagent ce sentiment d’urgence. Ce qui nous pousse à continuer, c’est que nous croyons fermement que nous permettrons un jour à des personnes atteintes d’un cancer de vivre plus longtemps grâce aux médicaments que nous découvrons et mettons au point. Ensemble, nous nous efforçons sans relâche de redonner de l’espoir aux familles qui reçoivent des diagnostics bouleversants. Les radiothérapies ciblées constituent l’un des domaines les plus avancés et les plus prometteurs de la mise au point de médicaments oncologiques. Abdera a été conçue autour d’une plateforme technologique modulaire exclusive, optimisée pour l’administration de radio-isotopes devant détruire sélectivement les cellules tumorales tout en épargnant les cellules saines. Cette plateforme nous permet de concevoir rapidement des traitements destinés à un large éventail de patients atteints d’un cancer et dont les options thérapeutiques sont pour l’heure limitées. Notre philosophie et notre ligne de conduite sont guidées par l’innovation scientifique, l’agilité et le dévouement. Notre entreprise en évolution est dynamique, et ses membres sont motivés par la perspective d’arriver à créer les traitements anticancéreux les plus novateurs de demain.

RÉFLEXIONS SUR LA BIOTECHNOLOGIE CANADIENNE ET LE LEADERSHIP

EN TANT QUE DIRIGEANTE D’UNE ENTREPRISE OPÉRANT À LA FOIS AU CANADA ET AUX ÉTATS-UNIS, QUELS SONT, SELON VOUS, LES ATOUTS UNIQUES DU CANADA DANS LE DOMAINE DE LA BIOTECHNOLOGIE? COMMENT VOS EXPÉRIENCES AU CANADA ONT-ELLES INFLUENCÉ VOTRE APPROCHE DE LA CRÉATION D’UNE ENTREPRISE MONDIALEMENT RECONNUE?

Notre plateforme a été créée à partir des travaux d’un groupe de scientifiques canadiens, qui ont collaboré à la conception d’un système d’administration plus ciblé, conçu sur mesure pour de nouveaux produits

pharmacology have played instrumental roles in the company since the earliest days. Each of these leaders and their teams are based in our Vancouver location, alongside Lana Janes, our co-founder and chief operating officer. Having run multi-national teams for prior companies, what impresses me most about our Canadian colleagues is their depth of expertise, the rigor of their work, and their clear dedication to Abdera’s mission. In my experience, great scientists are primarily motivated by doing great work and our scientific leadership team exemplifies that spirit every Our culture and direction are grounded in innovative science, agility and dedication. We are building an exciting and fastpaced company that is passionate about advancing tomorrow’s most innovative cancer therapies.

radiopharmaceutiques. Les responsables de la biologie, de la chimie et de la pharmacologie ont joué un rôle déterminant dans l’entreprise dès le départ. Ces personnes et leurs équipes sont en poste dans nos locaux de Vancouver, aux côtés de Lana Janes, cofondatrice et directrice de l’exploitation. Ayant par le passé dirigé des équipes multinationales pour d’autres sociétés, ce qui m’impressionne le plus chez nos collègues canadiens, c’est la profondeur de leur expertise, la rigueur de leur travail et leur dévouement évident à la mission d’Abdera. Mon expérience m’a appris que les grands scientifiques sont avant tout motivés par l’excellence, et notre équipe de direction scientifique incarne cet esprit au quotidien. Notre équipe canadienne s’est agrandie au cours des dernières années, tout comme notre équipe américaine, qui peut désormais compter sur des compétences en matière de fabrication, d’élaboration de processus, d’activités cliniques et de réglementation. Nous formons ensemble une équipe formidable.

LEADERSHIP ET PERSPECTIVES DE CARRIÈRE

LORSQUE VOUS VOUS REMÉMOREZ VOS DÉBUTS DANS LA BIOTECHNOLOGIE, Y A-T-IL QUELQUE CHOSE QUE VOUS AURIEZ AIMÉ SAVOIR À L’ÉPOQUE ET QUE VOUS AVEZ APPRIS GRÂCE À VOTRE EXPÉRIENCE AU SEIN D’ABDERA? COMMENT CES CONNAISSANCES ONT-ELLES INFLUENCÉ VOTRE MANIÈRE DE DIRIGER AUJOURD’HUI?

J’ai déjà siégé au conseil d’administration de sociétés d’oncologie, mais c’est la première fois que j’ai des fonctions de dirigeante au sein de l’une d’entre elles. Les fonctions que j’ai occupées précédemment concernaient d’autres domaines thérapeutiques. Ce qui m’a incitée à rejoindre Abdera, c’est que ce poste m’offrait la possibilité de changer le secteur et la vie des personnes atteintes d’un cancer. Le fait que je sois si profondément attachée à la mission de l’entreprise, qui est d’inspirer l’espoir

Abdera team accepts prestigious “Fierce 15” award from FierceBiotech, September 2024. Team, left to right: Lori Lyons-Williams ( President & CEO), Kelly Parker ( SVP HR), Kawa Chiu (CTO), Lana Janes (Co-Founder & COO), Philippe Bishop (CMO) L’équipe d’Abdera reçoit le prestigieux prix « Fierce 15 » de FierceBiotech, septembre 2024. De gauche à droite : Lori Lyons-Williams (présidente et chef de la direction), Kelly Parker (vice-présidente principale des ressources humaines), Kawa Chiu (directrice de la technologie), Lana Janes (cofondatrice et directrice de l’exploitation), Philippe Bishop (médecin chef)

day. As our Canadian team has grown over the last few years, so has our U.S. based team, where we have added expertise in manufacturing, process development, clinical operations and regulatory. Together we make a formidable team.

LEADERSHIP AND CAREER INSIGHTS

WHEN YOU REFLECT ON YOUR EARLY DAYS IN BIOTECH, IS THERE SOMETHING YOU WISH YOU HAD KNOWN THEN THAT YOU’VE SINCE LEARNED THROUGH YOUR EXPERIENCES AT ABDERA? HOW HAS THAT KNOWLEDGE INFLUENCED YOUR LEADERSHIP STYLE TODAY?

While I had previously served on boards of oncology companies, this is the first time I’m working as an operator in one. My previous roles were in other therapeutic areas. What inspired me to join Abdera was the opportunity I saw to make a difference that could be industry-altering and life changing for people living with cancer. To be so passionately connected to the mission of the company, to inspire hope and restore life to people living with cancer, makes every decision, every hire, every meeting seem important in much more consequential ways. I often say that I feel like a fish in water in this role and am forever grateful that the founders of the company, the board of directors and each Abdera employee offers me the grace to play any role I can to help shape Abdera’s tomorrows.

ABDERA’S FUTURE AND YOUR ROLE AS A LEADER

YOU MADE THE DECISION TO BRING ON A CHIEF TECHNICAL OFFICER EARLY ON, WHICH REFLECTS YOUR FORWARD-THINKING LEADERSHIP. HOW DO YOU APPROACH MAKING KEY LEADERSHIP DECISIONS, AND HOW ARE THESE CHOICES SHAPING THE DIRECTION OF ABDERA’S GROWTH?

In my experience, companies can run into catastrophic issues when they think about manufacturing and process development too late in their company-building efforts, which has sometimes cratered otherwise promising scientific advancements. In the case of radiotherapeutics, where isotopes are some of the rarest substances on earth, and where a just-in-time manufacturing process is required because isotopes decay rapidly, I felt strongly that we needed to prioritize building our manufacturing expertise in the earliest days of scaling the company. Our CTO, Kawa Chiu, brings more than 26 years of global manufacturing, supply chain and Chemistry, Manufacturing and Controls (CMC) experience across broad modalities. In her previous role, Kawa built out and oversaw CMC programs that enabled three IND approvals in two years. Getting these functions in place early allows us to speed up the rate at which we can get our medicines into the clinic and deliver them to patients who need them.

aux personnes atteintes d’un cancer et d’améliorer leur vie, fait que chaque décision, chaque embauche, chaque réunion semble importante à bien plus d’un titre. Je dis souvent que je me sens comme un poisson dans l’eau dans ce rôle et je suis à jamais reconnaissante aux fondateurs de la société, au conseil d’administration et à chaque employé d’Abdera de m’offrir la chance de contribuer, dans la pleine mesure de mes moyens, à façonner les lendemains d’Abdera.

L’AVENIR D’ABDERA ET VOTRE RÔLE DE LEADER

VOUS AVEZ PRIS LA DÉCISION DE RECRUTER TRÈS TÔT UNE DIRECTRICE DE LA TECHNOLOGIE, CE QUI TÉMOIGNE DE VOTRE CLAIRVOYANCE. COMMENT ABORDEZ-VOUS LES DÉCISIONS CLÉS EN MATIÈRE DE LEADERSHIP ET COMMENT CES CHOIX INFLUENT-ILS SUR LA CROISSANCE D’ABDERA?

Mon expérience m’a appris que les entreprises peuvent se heurter à des problèmes catastrophiques lorsqu’elles envisagent la fabrication et le développement de procédés trop tard dans leurs efforts de croissance; cela a parfois réduit à néant des avancées scientifiques pourtant prometteuses. Dans le cas de la radiothérapie, où les isotopes font partie des substances les plus rares sur terre et où un processus de fabrication « au moment adéquat » est nécessaire parce que les isotopes se désintègrent rapidement, j’étais convaincu que nous devions donner la priorité au savoir-faire en matière de fabrication dès les premiers jours de la phase d’expansion de l’entreprise. Notre directrice de la technologie, Kawa Chiu, compte plus de 26 ans d’expérience à l’échelle mondiale dans les domaines de la fabrication, des chaînes d’approvisionnement et de la « CMC » (chimie, fabrication et contrôles), et ce, dans de nombreux secteurs. Dans ses fonctions précédentes, Mme Kawa a élaboré et supervisé des programmes de CMC qui ont permis que trois demandes d’autorisation de nouveau médicament de recherche en deux ans soient approuvées. La mise en place précoce de ces mécanismes nous permet d’accélérer la disponibilité de nos médicaments dans les cliniques et de les administrer aux patients qui en ont besoin. Dans d’autres secteurs thérapeutiques, nous constituerions au moins deux ans de stocks de médicaments. Dans le secteur de la radiothérapie, chaque lot doit être fabriqué en fonction du patient, car les isotopes se désintègrent très rapidement. Réussir sur ce plan est évidemment essentiel à notre avantage concurrentiel.

In other therapeutic modalities, we would be building at least a two-year supply of our medicines. In radiotherapeutics, you must make each batch on a per-patient basis because the isotopes so rapidly decay. It’s obviously critical to get that right, as a competitive advantage.

LOOKING AHEAD

AS YOU LOOK TOWARDS THE FUTURE OF ABDERA AND THE BIOTECH INDUSTRY, WHAT PERSONAL GOALS AND ASPIRATIONS DO YOU HAVE AS A LEADER? WHAT IMPACT DO YOU HOPE TO MAKE, NOT ONLY IN ADVANCING RADIOPHARMACEUTICALS BUT IN LEAVING A LASTING LEGACY IN THE BIOTECH WORLD?

Without a doubt, I hope the legacy of our team becomes one that changes the way cancer is treated. We hold ambitions that are as audacious as they are daunting. We are propelled forward, even on the tough days, because of the promise we see to leave our mark by helping people live longer lives. It is rare to get to work for a company that has so much potential, and it is the honor of my career to play a role in what we’re doing at Abdera. Lots of companies are formed around one or two programs; some scientific advancements are incremental. What is groundbreaking at Abdera is that our platform enables us to rapidly design radiopharmaceuticals that have the potential to address many different cancer types and groups of patients. Our approach offers the ability to design radiotherapeutics against virtually any cancer target expressed on the cell surface. We see ourselves as pioneers in radiotherapeutics and aim to build a leading company in this space. With such potent activity, such a precise and predictable delivery, and such an impressive team, I like our chances.

LORI LYONS-WILLIAMS is a Chief Executive Officer and Board Director with more than 20 years of experience building companies, franchises, and teams in both large and emerging organizations. In addition to driving corporate, financial, operational, and commercial strategy, she has led large capital raises and guided teams through business development deals and R&D pipeline advancement for biotech assets across therapeutic areas, from oncology, immunology, and neuroscience to dermatology and urology.

LORSQUE VOUS ENVISAGEZ L’AVENIR D’ABDERA ET DE L’INDUSTRIE BIOTECHNOLOGIQUE, QUELS SONT VOS OBJECTIFS PERSONNELS ET VOS ASPIRATIONS EN TANT QUE DIRIGEANTE? QUEL EST VOTRE OBJECTIF POUR CE QUI EST DE FAIRE ÉVOLUER LES PRODUITS RADIOPHARMACEUTIQUES ET DE LAISSER UN HÉRITAGE DURABLE DANS LE MONDE DE LA BIOTECHNOLOGIE?

Je souhaite assurément que la contribution de notre équipe permette de changer la façon dont le cancer est traité. Nous nourrissons des ambitions aussi audacieuses que vertigineuses. Ce qui nous pousse à aller de l’avant, même dans les moments difficiles, c’est la perspective de laisser notre marque en aidant les gens à vivre plus longtemps. Il est rare de pouvoir travailler pour une entreprise qui a autant de potentiel, et c’est un honneur inégalé pour moi de jouer un rôle au sein d’Abdera. De nombreuses entreprises sont structurées autour d’un ou deux programmes seulement, et certaines avancées scientifiques sont graduelles. Ce qui est novateur chez Abdera, c’est que notre plateforme nous permet de concevoir rapidement des produits radiopharmaceutiques qui ont le potentiel de traiter de nombreux types de cancer et groupes de patients différents. Notre approche permet de concevoir des radiothérapies contre pratiquement toutes les cibles cancéreuses qui s’expriment à la surface des cellules. Nous nous considérons comme des pionniers dans le domaine de la radiothérapie et avons l’ambition de devenir une entreprise de premier plan dans ce domaine. Avec une activité aussi intense, une réalisation aussi précise et prévisible et une équipe aussi impressionnante, nous avons toutes les chances de notre côté.

LORI LYONS-WILLIAMS agit à titre de chef de la direction et d’administratrice. Elle a plus de 20 ans d’expérience dans la création d’entreprises, de franchises et d’équipes au sein de grandes organisations et d’entreprises en phase de démarrage. En plus d’avoir mis en œuvre des stratégies d’entreprise, financières, opérationnelles et commerciales, elle a dirigé d’importantes collectes de fonds et guidé des équipes dans le cadre d’opérations de développement commercial et d’avancement du processus de recherche-développement pour des actifs biotechnologiques dans différents domaines thérapeutiques, dont l’oncologie, l’immunologie, les neurosciences, la dermatologie et l’urologie.

Disrupting Cancer Care: The Commitment of BeiGene Canada

THE BATTLE AGAINST CANCER is indeed dynamic, with ongoing advancements in treatment options largely propelled by pharmaceutical innovators. BeiGene Canada stands out as a disruptor, challenging the status quo to ensure innovative cancer therapies are accessible to all Canadians.

As we recently recognized Blood Cancer Awareness Month, it’s essential to highlight BeiGene’s leadership in this area. Since entering the Canadian market in 2021, the company has made significant strides in addressing the needs of these cancer patients. With Health Canada’s approval of five indications for its BTK inhibitor for B-cell malignancies—including adult patients with Waldenström’s Macroglobulinemia (WM), mantle cell lymphoma (MCL), marginal zone lymphoma (MZL), chronic lymphocytic leukemia (CLL), and in combination with obinutuzumab for relapsed or refractory grade 1, 2, or 3a follicular lymphoma (FL)—BeiGene is on a mission to make its novel therapies affordable and accessible.

The principle of “patients first” is central to BeiGene’s mission. The company believes effective therapies must be within reach for everyone, regardless of location. In a landscape where access to treatments can be limited, BeiGene fosters partnerships with healthcare providers, advocacy groups, and policymakers to create a more inclusive environment that prioritizes patient access. This approach enhances treatment availability and empowers patients with the resources they need to navigate their cancer journeys.

Peter Brenders, General Manager of BeiGene Canada, articulates the vision: “Our goal is to ensure that every Canadian has access to the treatments they need when they need them. No patient should have to fight for access to innovative therapies. And with our robust pipeline we have plans for better, safer, and more affordable options.”

Moreover, BeiGene recognizes that effective cancer treatment extends beyond physical health; mental wellbeing is critical to patient outcomes. Acknowledging the emotional toll of cancer, the company raises awareness about the importance of mental health support throughout the cancer journey. BeiGene stands behind patients, families and caregivers through active involvement in the cancer care community through participation in and sponsorship of organizations like Gilda’s Toronto, whose purpose is to help people live, while living with cancer, along with fundraising events such as Lymphoma Canada’s Laps for Lymphoma, and Leukemia & Lymphoma Canada’s Light the Night.

As BeiGene reshapes cancer care in Canada, its focus on innovation and accessibility offers hope for patients, caregivers, and healthcare professionals alike. But turning that hope into reality presents a challenge that BeiGene is leading. Brenders emphasizes, “It will take collective effort—companies, drug plans, governments and clinicians must work together. Evolution happens when the system encourages new treatments and people demand change. We all need to influence the care we receive.”

With a steadfast commitment to collaboration and a vision that knows no borders, BeiGene is not just participating in the fight against cancer; it is driving transformative change to improve outcomes for all.

Unlocking the Future of Alzheimer’s Treatment

An interview with Dr. Donald Weaver, Chief Medical Officer at Treventis

Découvrir de nouvelles pistes pour la recherche sur la maladie d’Alzheimer

Une entrevue avec le Dr Donald Weaver, chef des services médicaux de Treventis

THE FUTURE OF ALZHEIMER’S RESEARCH

IN YOUR OPINION, WHAT ARE THE MOST PROMISING AREAS OF RESEARCH CURRENTLY IN THE FIGHT AGAINST ALZHEIMER’S DISEASE?

Alzheimer’s disease (AD) is certainly target rich when it comes to promising research directions. Although there are many unanswered questions about AD, a wealth of ongoing fundamental research is providing tantalizing clues that point to possible answers. Thus, there is no shortage of research ideas that need to be pursued.

First, there is the issue of diagnostics. The timehonoured practice of mental status “neuropsych” testing is mercifully being slowly surpassed by the realization that we need useful biomarkers—and these biomarkers need to be meaningful, practical and easy to implement. Cerebrospinal fluid biomarkers, though undoubtedly useful, are difficult and unpleasant to obtain. Easily acquired serum biomarkers will soon be revolutionizing the diagnostic approach to AD. Research into measuring blood levels of β-amyloid (A β) and tau (the two misfolding proteins historically implicated as being the causes of AD) and correlating this with AD presence and progression is exciting and full of promise. Augmenting this work on A β and tau biomarkers, is work on identifying and developing other complementary biomarkers such as indicators of neuroinflammation. In future, we hopefully will be able to offer a battery of diagnostic tests that will enable a precision medicine approach to AD.

Second, there is the issue of therapeutics. For decades, research has focussed on the two misfolding protein culprits: A β and tau. Although this direction has failed to yield a curative or disease modifying agent, recent clinical studies on lecanemab and donanemab (biologics targeting A β aggregates) suggests that this is an area worthy of ongoing research. However, protein misfolding is not the only target deserving of attention. Neuroinflammation is now recognized as a key contributor to AD, and the design of therapeutics targeting activated microglial cells and pro-inflammatory cytokines within brain is an active and promising area of research. Mitochondrial dysfunction, synaptotoxicity, membrane lipid metabolism and metal dyshomeostasis represent other pathogenic contributors to AD with untapped potential as drug targets.

Third, there is the issue of better understanding AD. Is it one disease or a collection of related diseases? We need to better clarify AD as a clinical entity, in order to better design drugs that can possibly be tailored to specific clinical subtypes.

L’AVENIR DE LA RECHERCHE SUR LA MALADIE D’ALZHEIMER

SELON VOUS, QUELS SONT LES DOMAINES DE RECHERCHE LES PLUS PROMETTEURS ACTUELLEMENT DANS LA LUTTE CONTRE LA MALADIE D’ALZHEIMER?

De nombreuses cibles offrent des perspectives de recherche prometteuses en ce qui concerne la maladie d’Alzheimer. Bien que beaucoup de questions demeurent sans réponse au sujet de cette maladie, de nombreux travaux de recherche fondamentale en cours offrent des pistes intéressantes et laissent entrevoir des solutions. Il est clair que les pistes de recherche ne manquent pas.

Tout d’abord, il y a la question du diagnostic. La pratique bien connue des tests « neuropsychiques » de l’état mental commence heureusement à céder la place à l’étude des biomarqueurs pertinents, car on se rend compte de l’utilité de ces derniers, en particulier ceux dont l’analyse est facile à mettre en œuvre. Les biomarqueurs présents dans le liquide céphalorachidien, bien qu’indubitablement utiles, sont difficiles à obtenir. Des biomarqueurs sériques, plus faciles à obtenir, vont bientôt révolutionner l’approche diagnostique de la maladie d’Alzheimer. La recherche sur la mesure des taux sanguins de peptide β-amyloïde (A β) et de tau (les deux protéines présentant des problèmes de repliement généralement impliquées dans la maladie d’Alzheimer) et leur corrélation avec la présence et l’évolution de la maladie d’Alzheimer est pleine de promesses. Ces travaux sur les biomarqueurs que sont le peptide A β et la protéine tau s’effectuent en lien avec ceux visant à définir et à utiliser d’autres biomarqueurs complémentaires, tels que des indicateurs de la neuroinflammation. À l’avenir, nous espérons être en mesure de proposer une batterie de tests diagnostiques qui permettront une médecine de précision pour ce qui est de cette maladie.

Ensuite, il y a la question des traitements. Pendant des décennies, la recherche a été axée sur les deux protéines mal repliées fautives : le peptide ß-amyloïde (A β) et la protéine tau. Bien que cette piste n’ait pas permis de trouver un agent apte à guérir la maladie ou à tout le moins à agir sur elle, des études cliniques récentes sur le lécanemab et le donanemab (des produits biologiques agissant sur les plaques A β) laissent à penser qu’il s’agit d’un domaine qui mérite des recherches approfondies. Cependant, les protéines mal repliées ne sont pas la seule cible qui mérite notre attention. Il est maintenant avéré que la neuroinflammation est un facteur clé de la maladie d’Alzheimer, et la conception de traitements ciblant les cellules microgliales activées et les cytokines proinflammatoires dans le cerveau est un domaine de recherche dynamique et prometteur. Le dysfonctionnement mitochondrial, la synaptotoxicité, le métabolisme des lipides membranaires et la dyshoméostasie des métaux sont d’autres facteurs pathogènes de la maladie d’Alzheimer qui présentent un potentiel en tant que futures cibles de médicaments.

TREVENTIS’ COLLABORATION WITH TAKEDA

WHAT GOALS HAVE YOU SET FOR YOUR COLLABORATION WITH TAKEDA, AND HOW DO YOU ENVISION THIS PARTNERSHIP UNFOLDING TO UNLOCK THE POTENTIAL OF YOUR TAU-TARGETING PRODUCT AND ADVANCE EXCITING NEW DEVELOPMENTS?

Treventis Corporation entered an option, collaboration, and license agreement with Takeda for the further research, development, and commercialization of small molecules that target tau, a key protein in AD. This therapeutic strategy aims to reduce tau misfolding and is a potential disease-modifying mechanism in AD as well as in other tauopathies. Targeting tau using a small molecule has proven difficult because it is an “intrinsically disordered protein”, a class of proteins that have many conformations and resist attempts to experimentally document their three-dimensional structure. Treventis scientists have developed a methodology for targeting misfolding proteins using epitope commonality between multiple misfolded proteins. This information was used to create Common Conformational Morphology (CCM), a patented Treventis methodology for constructing models of the earliest stages of protein misfolding. CCM in silico prediction, coupled with special assays to evaluate speed of misfolding, allows for the identification and optimization of potent, drug-like compounds against targets such as tau.

Under the terms of the agreement, Takeda will have an option to exclusively license the program worldwide for the development and commercialization of the tau program. Subject to the terms of the agreement, Treventis will receive research funding as well as an upfront payment, option exercise and future clinical and commercial milestones of up to $372.5 million if all milestones are achieved over the course of the partnership plus tiered royalties on potential net sales of any commercial product resulting from the license. Under this collaborative relationship, we seek to identify a pre-clinical and ultimately a clinical candidate as a tau inhibitor for the therapeutic disease modification of AD.

Treventis employs computer-aided drug design to design novel small molecules capable of binding to tau protein and inhibiting its misfolding

Treventis utilise la conception de médicaments assistée par ordinateur pour concevoir de nouvelles petites molécules capables de se lier à la protéine tau et d’inhiber son repliement

Enfin, il s’agit de mieux comprendre la maladie d’Alzheimer. S’agit-il d’une seule maladie ou d’un ensemble de maladies liées entre elles? Nous devons mieux cerner la maladie d’Alzheimer en tant qu’entité clinique, afin de mieux concevoir des médicaments susceptibles d’être adaptés à des soustypes cliniques spécifiques.

LA COLLABORATION ENTRE TREVENTIS ET TAKEDA

QUELS OBJECTIFS VOUS ÊTES-VOUS FIXÉS POUR VOTRE COLLABORATION AVEC TAKEDA ET COMMENT

ENVISAGEZ-VOUS CE PARTENARIAT EN CE QUI A TRAIT À LA RÉALISATION DU POTENTIEL DE VOTRE PRODUIT QUI CIBLE LA PROTÉINE TAU ET AUX PROGRÈS DE NOUVEAUX PROJETS PROMETTEURS?

Treventis Corporation a conclu un accord de levée d’options, de collaboration et de licence avec Takeda pour la poursuite de la recherche, du développement et de la commercialisation de petites molécules qui ciblent la protéine tau, une protéine clé de la maladie d’Alzheimer. Cette stratégie thérapeutique vise à réduire les problèmes liés au mauvais repliement de la protéine tau et pourrait agir sur la maladie d’Alzheimer et d’autres tauopathies. Il s’est avéré difficile de cibler la protéine tau à l’aide d’une petite molécule, car il s’agit d’une « protéine intrinsèquement désordonnée »; en effet, les protéines de la catégorie des tau présentent de nombreuses conformations, et leur structure tridimensionnelle est difficile à cerner. Les chercheurs de Treventis ont mis au point une méthode pour cibler les protéines mal repliées, plus précisément les épitopes communs à plusieurs d’entre elles. Ces données ont servi à créer la plateforme Common Conformational Morphology (CCM), une technologie brevetée par Treventis qui permet de construire des modèles des protéines mal repliées à leurs premiers stades. La détection in silico offerte par la plateforme CCM, associée à des essais spéciaux d’évaluation de la vitesse de repliement des protéines, permet de découvrir des composés-médicaments efficaces et de les optimiser de façon à pouvoir les utiliser contre des cibles telles que la protéine tau.

Selon les dispositions de l’accord, Takeda aura l’exclusivité de l’octroi de la licence de développement et de commercialisation du programme tau dans le monde entier. Dans le cadre de l’accord, Treventis bénéficiera d’un financement de recherche ainsi que d’un paiement initial, d’une levée d’options et d’étapes cliniques et commerciales futures pouvant atteindre 372,5 millions de dollars si toutes les étapes sont franchies au cours du partenariat, ainsi que de redevances progressives sur les ventes nettes potentielles de tout produit commercial lié à la licence. Dans le cadre de cette collaboration, nous cherchons à identifier, pour les essais précliniques, puis pour les essais cliniques, un candidat apte à inhiber la protéine tau, et ce, en vue de la modification thérapeutique de la maladie d’Alzheimer.

The journey from academic lab to biotech industry is long and arduous, requiring patience, more patience, and a capacity to absorb failure with a smile. One has to be passionate about their research, and passionate about telling their story and why they believe in their research approach.

BRIDGING ACADEMIA AND INDUSTRY

YOU’VE SUCCESSFULLY TRANSITIONED RESEARCH FROM THE ACADEMIC LAB TO THE BIOTECH INDUSTRY. WHAT ADVICE WOULD YOU GIVE TO RESEARCHERS LOOKING TO NAVIGATE THIS PATH, AND HOW CAN CANADA BETTER SUPPORT THIS JOURNEY?

The journey from academic lab to biotech industry is long and arduous, requiring patience, more patience, and a capacity to absorb failure with a smile. One has to be passionate about their research, and passionate about telling their story and why they believe in their research approach. It is paramount to remember that your job is not done once a publication has been achieved; rather, it is essential to go further and to pursue the translational tasks of converting research into tangible, useful products. This requires getting out of your comfort zone, learning a lot of new concepts and lessons, and being okay with asking questions. The final product is not an academic paper—it’s a product like a new drug, an innovative diagnostic, or a useful tool. And it’s often tricky, but the importance of intellectual property and patent protection must always be juggled. For academic success, it’s “publish or perish”; for patent success, it might be “perish if you publish”. Talk to others who have taken the journey to biotech. Most will have war wounds about which they are willing to speak. And talk to your tech transfer office, they have likely been down this road many times before. If you are taking the academic to biotech journey in Canada, the road is often bumpier and longer. Canada is strong in basic fundamental science, but does not have the same depth in translational science. There are too few medicinal chemists in Canada, too few scientists translating targets to products. Also, there is an immense need for more funding for translational research and a need for more (and less risk aversive) venture capital, willing to support the development of therapeutics for chronic neurologic diseases.

ÉTABLIR DES PASSERELLES ENTRE LE MONDE UNIVERSITAIRE ET L’INDUSTRIE

VOUS AVEZ RÉUSSI À FAIRE SORTIR LA RECHERCHE DU LABORATOIRE UNIVERSITAIRE POUR LA METTRE EN ŒUVRE AU SEIN DE L’INDUSTRIE BIOTECHNOLOGIQUE. QUELS CONSEILS DONNERIEZ-VOUS AUX CHERCHEURS QUI SOUHAITENT S’ENGAGER DANS CETTE VOIE ET COMMENT LE CANADA PEUT-IL MIEUX LES ACCOMPAGNER?

Le chemin qui mène du laboratoire universitaire à l’industrie biotechnologique est long et ardu, et exige de la patience, encore de la patience, et la capacité à supporter les déconvenues avec sérénité. Il faut être passionné par ses propres recherches, et avoir vraiment à cœur de décrire son approche et les raisons pour lesquelles on croit en celle-ci. Il est essentiel de se rappeler que le travail ne s’arrête pas après la publication des résultats. Au contraire, il est nécessaire d’aller plus loin et de poursuivre les étapes de la mise en application qui consistent à concrétiser la recherche pour qu’elle donne des produits utiles. Pour cela, il faut sortir de sa zone de confort, apprendre beaucoup de nouveaux concepts et se former sans cesse, tout en acceptant de poser des questions. Le produit final est non pas un article scientifique, mais la mise au point d’un produit, par exemple un nouveau médicament, un diagnostic innovant ou un outil utile. Et il faut savoir composer avec les aspects importants de la propriété intellectuelle et de la protection des brevets, ce qui est assez délicat. Lorsqu’on pense à la réussite universitaire, cela se résume souvent à « publier ou périr » alors qu’en matière de brevets, cela pourrait bien se traduire « publier, c’est périr ». Le mieux est souvent d’en discuter avec d’autres personnes qui ont un long parcours en biotechnologie. La plupart d’entre eux n’hésiteront pas à évoquer pour vous leurs blessures de guerre. Parlez-en à votre bureau de transfert de technologie : il est probable qu’il soit déjà passé par là à de nombreuses reprises.

Au Canada, la route qui mène de l’université à une entreprise de biotechnologie est souvent plus cahoteuse et plus longue. Le Canada est solide dans le domaine de la science fondamentale, mais n’a pas la même envergure en matière de mise en application. Il y a trop peu de spécialistes en chimie thérapeutique au Canada, trop peu de scientifiques qui transforment les cibles en produits. Par ailleurs, les besoins de financement sont immenses en recherche translationnelle et plus importants encore en capital-risque (et il faudrait pour cela être moins craintif vis-à-vis du risque).

Nous devons pouvoir compter sur une aide qui permette le développement de traitements pour les maladies neurologiques chroniques.

HEALTHCARE POLICY AND INNOVATION

FROM YOUR EXPERIENCE, WHAT CHANGES IN HEALTHCARE POLICY COULD HELP ACCELERATE THE DEVELOPMENT AND AVAILABILITY OF NEW TREATMENTS FOR NEURODEGENERATIVE DISEASES IN CANADA?

All healthcare systems have strengths and weaknesses. The Canadian system is no different. The primary problem to be confronted when seeking improved availability of new treatments for Canadians is dealing with the issue of cost. Canada has a complex healthcare system spread over federal and provincial jurisdictions with drug cost containment seemingly being a priority at all levels. Treating neurodegenerative disease is not cheap; the therapeutics are going to cost a fair amount. If the treatment requires periodic MRIs, we do not have the capacity for these extra imaging demands. If the treatment requires monthly or biweekly infusions of biologics, we probably do not have the capacity for these extra infusion facilities. If a biologic costs >$30,000 per year, do our provincial healthcare budgets have the ability to sustain these costs?

Another issue I feel needs attention concerns how and where we do our clinical trials. Typically, clinical trials are done in academic teaching hospitals. However, these hospitals provide care for less than 15% of Ontarians. The majority of healthcare is at the community level, and in community-based hospitals. If we did more clinical trials in community-based hospitals, the introduction of new therapies for diseases like AD would be achieved more quickly and efficiently at the community level.

Finally, there is the issue of clinical person-power. There are too few geriatricians/neurologists/psychiatrists involved in dementia care. This is a stumbling block to the implementation of new cutting-edge therapies for diseases like AD.

CHALLENGES IN DRUG DEVELOPMENT

WHAT DO YOU SEE AS THE BIGGEST CHALLENGES FACING DRUG DEVELOPMENT FOR ALZHEIMER’S TODAY, AND WHAT STEPS CAN BE TAKEN TO OVERCOME THESE OBSTACLES, BOTH SCIENTIFICALLY AND WITHIN THE HEALTHCARE SYSTEM?

Although A β and tau are important players in the field of AD, they are not the only show in town. About 15-20 years ago, if you weren’t studying A β, then you weren’t studying AD. Although we now know that this is simply not true, there is still great reluctance in both the academic and industrial sectors to whole-heartedly embrace other innovative approaches to AD. There is probably not going to be a single magic bullet drug for AD. Rather it will require combination therapy involving multiple synergistic agents hitting complementary targets. But inventing these other agents requires our willingness to study new directions and new targets—fully aware of the risk and high

LA RÉGLEMENTATION ET L’INNOVATION EN MATIÈRE DE SOINS DE SANTÉ

D’APRÈS VOTRE EXPÉRIENCE, QUELS CHANGEMENTS DANS LA LÉGISLATION SUR LES SOINS DE SANTÉ POURRAIENT CONTRIBUER À ACCÉLÉRER LE DÉPLOIEMENT ET LA DISPONIBILITÉ DE NOUVEAUX TRAITEMENTS POUR LES MALADIES NEURODÉGÉNÉRATIVES AU CANADA?

Tous les systèmes de soins de santé présentent des forces et des faiblesses. Il en est de même au Canada. La question des coûts est le principal problème auquel il faut faire face en ce qui a trait à la disponibilité des nouveaux traitements pour les Canadiens. Le Canada dispose d’un système de santé complexe réparti entre les compétences fédérales et provinciales, et la restriction du coût des médicaments semble être une priorité pour chacun des ordres de gouvernement. Le traitement des maladies neurodégénératives exige des moyens importants. Il en coûtera toujours assez cher. Si par exemple un traitement nécessite des IRM périodiques, il est clair que l’on n’a pas la capacité de répondre à ces demandes supplémentaires. Ou encore si un traitement nécessite des perfusions mensuelles ou bihebdomadaires de produits biologiques, on ne dispose probablement pas d’installations suffisantes pour offrir ces soins. Lorsqu’il en coûte plus de 30 000 dollars par an pour un produit biologique, nos budgets de santé provinciaux sont-ils en mesure d’assumer ces coûts?

Je pense qu’il faut également se préoccuper de la manière dont nous réalisons nos essais cliniques et de l’endroit où ils sont réalisés. Les essais cliniques sont généralement réalisés dans des hôpitaux universitaires. Or, ces hôpitaux offrent par exemple des soins à moins de 15 % des Ontariens. La majorité des soins de santé sont prodigués par les collectivités locales et les hôpitaux de proximité. Si nous réalisions davantage d’essais cliniques dans les hôpitaux de proximité, les nouveaux traitements pour des maladies telles que la maladie d’Alzheimer seraient proposés plus rapidement et plus efficacement à la population locale.

Enfin, il y a la question du savoir-faire clinique disponible. Il y a trop peu de gériatres, de neurologues et de psychiatres engagés dans la prise en charge de la démence. Cela représente un obstacle à la mise en œuvre de nouveaux traitements de pointe pour des maladies telles que la maladie d’Alzheimer.

LES DÉFIS DE LA MISE AU POINT DE MÉDICAMENTS

QUELS SONT, SELON VOUS, LES PRINCIPAUX ENJEUX RELATIFS À LA MISE AU POINT DE MÉDICAMENTS CONTRE LA MALADIE D’ALZHEIMER AUJOURD’HUI ET QUELLES MESURES PEUVENT ÊTRE PRISES POUR SURMONTER CES DIFFICULTÉS, TANT SUR LE PLAN SCIENTIFIQUE QU’AU SEIN DU SYSTÈME DE SOINS DE SANTÉ?

probability of failure. And there will be many challenges in developing these new drugs. For example, current transgenic animal models are better conceptualized as models of protein misfolding, and not models of AD. We need better animal models of AD. The blood-brain barrier (BBB) is invariably a challenge when devising therapies for CNS disorders. We always need better ways of dealing with the BBB. Compared to other diseases, the preclinical animal testing and ultimate human trials are extremely expensive (both in terms of time and money) for AD. We need support that is patient and more time/ cost tolerant. As stated above, the ultimate therapy will probably be a combination of agents. Typical clinical trial protocols and government approval processes are not well equipped with the notion of combination therapies. We need more progressive thinking in this area.

Donald Weaver MD, PhD, FRCP(C) is co-founder and Chief Medical Officer of Treventis. He is a neurologist and medicinal chemist, and is a Senior Scientist and former Director of the Krembil Research Institute, University Health Network, University of Toronto. He was a founder of NeuroChem Inc. and a discoverer of tramiprosate, which reached Phase III trials for Alzheimer’s disease. He has previously worked at Queen’s University and Dalhousie University.

TREVENTIS™ Corporation is a biotech company spun-out of the academic lab of Donald Weaver in 2008. Treventis is dedicated to TREating and preVENTing protein misfolding diseases. We use a proprietary, patented discovery engine—Common Conformational Morphology (CCM)—to identify druggable active sites in misfolded protein targets. CCM combines unique in silico models with deep expertise in model development (in vitro, ex vivo, in vivo) to enable rational drug design against misfolded protein targets such as tau, TDP isoforms, and other proteins with relevance to neurodegeneration (including in Alzheimer’s Disease, frontotemporal dementia, and Amyotrophic Lateral Sclerosis).

Bien que le peptide Aβ et la protéine tau jouent un rôle important dans la maladie d’Alzheimer, elles partagent la vedette avec d’autres agents. Il y a environ 15 à 20 ans, si vous ne vous intéressiez pas aux peptides Aß, cela signifiait que vous ne travailliez pas sur la maladie d’Alzheimer. Bien que nous sachions aujourd’hui que ce constat est tout simplement faux, les secteurs universitaire et industriel sont encore très réticents à adopter sans réserve d’autres approches novatrices pour traiter la maladie d’Alzheimer. Il est probable que l’on ne trouve pas de médicament miracle pour traiter la maladie d’Alzheimer. Elle nécessitera plutôt une approche thérapeutique mixte faisant appel à plusieurs composés agissant en synergie, chacun sur une cible différente. Pour inventer ces autres composés, nous devons être prêts à explorer de nouvelles directions et de nouvelles cibles, en étant pleinement conscients des risques et de la forte probabilité d’échec. La mise au point de ces nouveaux médicaments présentera de nombreux obstacles. Par exemple, les modèles animaux transgéniques existants sont plutôt des modèles de protéines mal repliées que des modèles de la maladie d’Alzheimer. Nous avons besoin de meilleurs modèles animaux de la maladie d’Alzheimer. La barrière hématoencéphalique (BHE) pose systématiquement problème lorsqu’il s’agit de concevoir des traitements contre les maladies du SNC. Il est nécessaire de trouver de meilleurs moyens de faire face à la BHE. Par rapport à d’autres maladies, les essais précliniques sur les animaux et les essais finaux sur l’homme pour la maladie d’Alzheimer sont extrêmement coûteux (à la fois en temps et en argent). Nous avons surtout besoin en la matière d’un environnement plus tolérant sur le plan du temps et des coûts. Comme nous l’avons déjà dit, ultimement, le traitement consistera probablement en une association d’agents. Les protocoles d’essais cliniques typiques et les processus d’approbation gouvernementaux ne sont pas bien adaptés à la problématique des traitements mixtes. Il est nécessaire d’adopter une approche plus novatrice dans ce domaine.

Donald Weaver, M.D., Ph. D., FRCP(C), est un des cofondateurs et le directeur médical de Treventis. Neurologue et spécialiste en chimie thérapeutique, il est chercheur principal au Krembil Research Institute de l’University Health Network, dont il est aussi l’ancien directeur; l’institut est affilié à l’Université de Toronto. Il a fondé NeuroChem Inc. et a fait partie de l’équipe responsable de la découverte du tramiprosate, qui a fait l’objet d’essais de phase III pour le traitement de la maladie d’Alzheimer. Il a aussi travaillé à l’Université Queen’s et à l’Université Dalhousie.

TREVENTIS™ Corporation est une société de biotechnologie née des travaux du laboratoire universitaire de Donald Weaver en 2008. Treventis se spécialise dans le traitement (TREating) et la prévention (preVENTing) des maladies liées aux protéines mal repliées. Nous utilisons une plateforme de recherche exclusive et brevetée, Common Conformational Morphology (CCM), pour repérer les sites actifs susceptibles d’être utilisés comme protéines-médicaments pouvant se lier aux protéines mal repliées. La plateforme CCM associe des modèles in silico uniques à une expertise approfondie dans le développement de modèles (in vitro, ex vivo, in vivo) aux fins de la conception efficace de médicaments contre des cibles protéiques mal repliées telles que la protéine tau, les isoformes de TDP et d’autres protéines qui jouent un rôle dans la neurodégénérescence (notamment dans la maladie d’Alzheimer, la démence frontotemporale et la sclérose latérale amyotrophique).

Canadian Regenerative Medicine Biotechs: Transforming the Future of Healthcare

CANADA HAS A RICH HISTORY of medical breakthroughs, from creating the world’s first pacemaker to discovering insulin and stem cells. Today, Canadian biotech companies are continuing this legacy by driving innovation and advancing cutting-edge, life-changing therapies and technologies. With over $148M invested into research projects and clinical trials across the country, the Stem Cell Network (SCN) has advanced approximately two dozen biotech companies through research funding— funding that has either enhanced an existing company or resulted in the spin-out of a new company. Among them, Morphocell Technologies and Aspect Biosystems stand out as leaders driving transformative advances in liver disease and type 1 diabetes treatments.

TRANSFORMING THE TREATMENT OF LIVER DISEASE: MORPHOCELL TECHNOLOGIES

In 2016, at the Centre hospitalier universitaire SainteJustine, Drs. Massimiliano Paganelli and Claudia Raggi developed a revolutionary solution for Acute Liver Failure (ALF) patients by creating “mini livers” from stem cells. These liver organoids, combined with a specialized biomaterial, form encapsulated liver tissue that temporarily supports patients while their own liver heals or while they await a transplant. This breakthrough led to the formation of Morphocell Technologies in 2018. With $1 million in research funding from SCN, the company has since raised $8 million and, in April 2024, secured an additional US$40 million in Series A financing to advance its innovative liver cell therapy.

Aspect Biosystems laboratory
Dr. Massimiliano Paganelli
Dr. Claudia Raggi
Photo Credit: Province of British Columbia
A 2024 analysis shows that for every dollar Stem Cell Network commits to research associated with a Canadian biotech, that company raises an additional $30 in private equity.

TOWARDS A CURE FOR DIABETES WITH BIOPRINTED TISSUE THERAPEUTICS: ASPECT BIOSYSTEMS

Aspect Biosystems, a Vancouver-based biotech led by CEO Tamer Mohamed, develops bioprinted tissue therapeutics to replace, repair, or supplement biological functions. In 2020, SCN awarded $500,000 to Dr. Timothy Kieffer at the University of British Columbia to advance Aspect’s 3D-printed cell therapy for delivering insulinproducing cells to treat type 1 diabetes. This collaboration, and the resulting data, helped secure a US$2.6 billion deal with Novo Nordisk in 2023 to develop bioprinted tissue therapeutics that maintain normal blood glucose without immunosuppression—potentially transforming treatment for people with type 1 diabetes.

Powered by two decades of success, SCN is a central driver of Canada’s life sciences ecosystem, and the only national network with a proven track record for continued excellence and impact in regenerative medicine. At the start of the decade, the Stem Cell Network’s objective was to ‘ignite’ Canada’s true potential in regenerative medicine. In the years ahead, the Network’s focus is squarely on ‘accelerating’ this momentum with a focus on delivering life-saving innovations to Canadians. Committed to building a world-class research and training ecosystem, fostering global partnerships, and training the leaders of tomorrow, SCN is redefining what’s possible in regenerative medicine.

Dr. Massimiliano Paganelli and the Morphocell Team
Aspect team with CEO Tamer Mohamed at centre

Harnessing Innovation in the Prairies

How Manitoba’s Bioscience Sector is Pushing Boundaries

MANITOBA’S BIOSCIENCE SECTOR is rapidly emerging as a leader in biotechnology, with local companies harnessing cutting-edge technologies like artificial intelligence (AI) to push boundaries. The Bioscience Association Manitoba (BAM), plays a pivotal role in positioning the province as a key player in Canada’s bioscience landscape by fostering innovation, driving collaboration, and providing essential support to companies adopting transformative technologies. As AI becomes increasingly integral throughout the biosciences, Manitoba’s community is leveraging it to fuel advancements in drug discovery, personalized medicine, and digital health, positioning the province as a hub for biotech innovation. This sector is uncovering the technology and scientific discoveries that will transform how we heal, feed and fuel the world.

FOSTERING LOCAL INNOVATION ON THE GLOBAL STAGE

For AI to truly flourish within Manitoba’s biosciences sector, a supportive, well-coordinated ecosystem is vital. BAM plays an instrumental role in advocating for policies that foster an environment where local bioscience companies can not only remain resilient but also thrive. By collaborating closely with government bodies and policymakers, BAM works to shape a business-friendly climate that encourages strategic investments in advanced technologies, streamlines regulatory processes, and ultimately allows companies to concentrate on driving innovation and boosting productivity.

Manitoba’s biotech companies face distinct challenges, particularly around regulation and securing funding, especially in emerging fields such as AI. Through targeted advocacy, BAM helps companies navigate these obstacles by working to simplify complex regulator frameworks and secure essential funding, empowering businesses to invest in cutting-edge technologies. This support has not only bolstered the competitiveness of Manitoba’s biotech sector on the global stage but also positioned the province as a hub for innovation. By fostering a welcoming investment climate, BAM attracts global investors eager to back AI-powered companies, providing them with the resources needed to scale their operations, enhance their market presence, and contribute meaningfully to advancements in global biotechnology. Through these concerted efforts, Manitoba is solidifying its status as a leader in biotech innovation, with AI-driven solutions making significant contributions to the industry’s future.

Collaboration between academia, industry and government is essential for driving innovation in the bioscience sector, and BAM has positioned itself as a central facilitator of these partnerships.

BUILDING THE FUTURE WORKFORCE

In addition to the technological advancements, the bioscience sector requires a skilled workforce to harness the potential of new technologies. BAM is addressing this need by developing training programs designed to nurture the next generation of bioscience leaders and the workforce. As AI becomes a driving force in bioscience, equipping the workforce with the skills to manage and optimize these technologies is critical to ensuring long-term success. These programs are part of BAM’s broader efforts to close the growing skills gap in bioscience. BAM’s Youth Enrichment Network also plays a role in preparing young talent for careers in bioscience, ensuring that Manitoba has the talent pipeline needed to support innovation.

To further support the industry’s evolving needs, BAM’s AI Summit which took place earlier this year, provided a platform for industry leaders and policymakers to discuss the latest AI trends and applications in bioscience. This summit highlighted ongoing efforts to incorporate AI into the sector.

CROSS-SECTOR COLLABORATION

Collaboration between academia, industry and government is essential for driving innovation in the bioscience sector, and BAM has positioned itself as a central facilitator of these partnerships. The organization works to bridge the gap between research and industry, helping companies leverage AI technologies to accelerate research and development. This collaborative approach is evident in initiatives that bring together universities, startups, and established bioscience companies to explore new AI applications.

By facilitating collaborations, BAM is not only advancing the use of AI in Manitoba’s bioscience sector but also positioning the province as a leader in the global biotech community. These cross-sector partnerships ensure that Manitoba’s companies can stay ahead of the curve, driving forward innovation that has the potential to transform industries worldwide.

PREPARING MANITOBA FOR A TRANSFORMATIVE FUTURE

As AI continues to reshape the bioscience landscape, Manitoba’s companies are well-positioned to lead the charge that to an accessible ecosystem, including BAM. By fostering innovation, advocating for supportive policies, and nurturing the future workforce, BAM is ensuring that Manitoba’s bioscience sector can harness the power of AI to push the boundaries of what is possible in healthcare and beyond.

In the coming years, AI is set to play an even more critical role in biotechnology, and Manitoba’s bioscience community is ready to meet the challenge. The province is poised to make significant contributions to global biotech innovation, demonstrating that the Prairies are not just keeping up with the times—they are leading the way.

BIOSCIENCE ASSOCIATION MANITOBA

Structuring Your Company for Cross Border Opportunities in Life Sciences

ANY SUCCESSFUL CANADIAN LIFE SCIENCE COMPANY will at some point need both U.S. and Canadian entities. There are a different number of factors to consider in structuring these entities. Which entity should hold the IP? Which entity should hire the employees? Which company should be the parent company, in other words, which company will investors fund? A little planning at the beginning will avoid large costs and disruption down the road.

WHERE TO HOLD THE IP?

Unless a company has or expects to have significant tax losses in the U.S., we generally (but not always) recommend that companies hold their intellectual property (including U.S. patents) outside of the U.S. due to higher U.S. corporate tax rates and the difficulty of moving IP outside of the U.S. later. For these reasons, Canada is generally preferable to the United States as an IP holding jurisdiction.

Canada may soon become even more attractive, as the Canadian government is currently considering the implementation of a “patent box” regime that would set lower corporate tax rates for income earned from intellectual property held in Canada.

WHERE TO EMPLOY?

Determining where to hire employees is the easiest issue. Companies should hire employees in the country in which they reside. Otherwise, there will be withholding taxes levied in the country of the employer, and the employees may end up paying a higher overall tax rate than others in their jurisdiction of residence.

WHICH COMPANY SHOULD BE THE PARENT AND WHICH THE SUBSIDIARY?

The main factor to consider is whether the investors seek to invest in a Canadian or U.S. company. There is no one size fits all solution. In determining the preferred structure, a number of factors should be considered, including but not limited to:

• Who are the likely near term and longer-term shareholders? Are they individuals or are they VCs and other institutional investors? Are they Canadian or American?

• Will these investors have geographic preferences or restrictions regarding their portfolio companies?

• What is the best jurisdiction for the tax incentives to shareholders?

Canada offers a number of provincial and federal tax credits. For example, in British Columbia, investors who are individuals can claim a refundable tax credit of 30% of their investment amount, up to $120,000 per year. For corporate investors, the 30% credit is non-refundable, but there is no annual limit. At the federal level, Canadian residents are afforded a Lifetime Capital Gains Exemption of $971,190 per person (2023).

The U.S. also offers similar advantages. The Qualified Small Business Stock (QSBS) regime for U.S. individuals and Trusts (along with investments by individuals through partnerships) allows for capital gains exemptions under certain criteria. To be eligible, the investment in a U.S.-based C corporation must be held for a minimum of 5 years, and it must be made when assets are valued at $50M or less. Eligible capital gains up to the greater of $10M USD or 10x the cost basis of the investment is exempt. This exemption is a big driver for family offices and angels, but less so for the large VC with tax exempt limited partners such as pension funds and universities.

• What government grants and other fiscal incentives are available?

Each jurisdiction offers various grant and tax incentives for the Company. Most notably, Canada offers federal and provincial Scientific Research and Experimental Development (SR&ED) credits which can provide an early-stage Canadian controlled private corporation with reimbursement for more than 50% of certain research expenses.

• Some U.S. investors are most comfortable with Delaware corporate law. However, Canadian corporate law is very similar, and changes to Alberta and Ontario laws have removed the requirement that 25% of directors be Canadian residents.

It is therefore important to consider these and other factors as early as possible and preferably from the get-go. If a company wishes to change its parent company from a Canadian entity to a US entity after the enterprise has real value, it can have costly tax consequences or require a complex structure to avoid such consequences.

Luke Jeagal, Associate
Cheryl Reicin, International Chair of Life Sciences

Unleashing Innovation: Mississauga’s Life Sciences Powerhouse

MISSISSAUGA IS AT THE FOREFRONT of a transformative economic cluster, where exceptional talent and innovative companies converge to propel the life sciences industry into a vibrant future. This dynamic sector is a cornerstone of the city’s economy, with more than 500 companies employing 27,000 skilled professionals dedicated to pioneering breakthroughs that enhance lives globally.

RICH HISTORY OF GROWTH

As Canada’s second largest life sciences cluster, by employment, Mississauga boasts a rich history of evolution, transitioning from a pharmaceutical-centric landscape to a diverse ecosystem that includes medtech, biotechnology, diagnostics, digital health, AI and more. Companies don’t just arrive here; they plant deep roots, fueled by a commitment to grow and innovate.

International companies such as Eurofins CDMO Alphora, AstraZeneca, Roche Canada, Resilience Biotechnologies Inc. and Bora Pharmaceuticals to name a few, continue to announce to the globe their re-investments in Mississauga, further solidifying the city’s reputation as a launchpad for business growth and success.

CONNECTED AND COMPLETE ECOSYSTEM

What truly sets Mississauga apart is its interconnected ecosystem, where collaboration thrives, and innovation knows no bounds. The synergy within this cluster creates an environment that fosters growth, ensuring that Mississauga remains a vital player on the global life sciences stage. This sentiment is further strengthened with the 2023 launch and 2024 opening of the University of Toronto Mississauga‘s SpinUp, an affordable shared wet lab space dedicated to early-stage founders. “SpinUp was created by the University of Toronto Mississauga (UTM) as a solution to pressing challenges faced by early-stage startups in need of wet lab access and entrepreneurship supports,” says Raquel De Souza, Director of Partnerships & Innovation at UTM. SpinUp welcomes promising startups to Mississauga who have spun out from university research, and/or have originated from within the greater region and are developing new life science innovations that have high impact potential for human health outcomes, food and environmental sustainability, and beyond.

What truly sets Mississauga apart is its interconnected ecosystem, where collaboration thrives, and innovation knows no bounds. The synergy within this cluster creates an environment that fosters growth, ensuring that Mississauga remains a vital player on the global life sciences stage.

DeSouza adds, “We accelerate our startups via subsidized access to new, state-of-the-art wet laboratory facilities, entrepreneurship programming, access to our research experts and talent pool, and support from Mississauga’s robust entrepreneurship ecosystem and innovation pipeline.”

To further support life sciences scale-ups in the region, SPEC Labs’ Centre for Advancement of Biomedical Innovation has announced the 2025 opening of a 20,000 sq. ft. co-working wet lab facility. This cutting-edge space will provide an advanced environment for researchers, graduating startups, and established companies to conduct experiments and pursue groundbreaking discoveries.

“We are thrilled to embark on this new venture, creating a collaborative space that will drive scientific breakthroughs and technological innovation,” said Doris Qamar, CEO of SPEC Labs. “This facility will serve not only as a state-of-the-art research and development hub but also as a catalyst for fostering partnerships and knowledge sharing within the scientific community.”

Exciting partnerships, including one between SPEC Labs and SpinUp, are already in place, laying the groundwork for future innovation in Mississauga. Graduating companies from SpinUp will have the opportunity to establish residency at SPEC Labs, where they can continue to thrive in a world-class research and development environment.

“These new innovation assets are a game changer for Mississauga,” said Christina Kakaflikas, Director, Invest Mississauga, “We are growing a complete ecosystem that is further supported by third party services that include regulatory services, specialized logistics as well as contract manufacturing and research organizations.” These services have a vital role in bringing therapeutics from concept to commercialization, ensuring they reach the people who need them most. Easy access to these assets, allow start-up and scale-up companies to grow, and scientists to focus on developing lifesaving therapeutics and healthcare solutions in a well-equipped and a supportive environment. Kakaflikas further shares, “With these powerful new assets, Mississauga isn’t just a location for innovation— it’s a community where the future of healthcare is being built today.”

SUPPORTIVE COMMUNITY

Mississauga companies can also benefit from the steadfast support of Invest Mississauga, the City’s economic development division whose mission is to set companies up for success. By taking a partnership approach, the Invest Mississauga team offers customized service that include site selection assistance, guidance and consultation, access to funding programs and partners, and data to support business decisions and goals.

The growth potential of Mississauga’s life sciences sector is limitless, making it a premier destination for businesses at every stage. Whether you’re a startup, a scale-up, or a global enterprise seeking to expand into the North American market, Mississauga is the ideal choice. With its stable economy, skilled workforce, multicultural community, and robust, diverse supply chain, life sciences companies can thrive and reach new heights.

For more information on starting or locating a business in Mississauga, connect with Invest Mississauga at www.investmississauga.ca

SpinUp Labs at the University of Toronto Mississauga

The PEI BioAlliance: How Canada’s Smallest Province is Leading Bioscience Innovation

WHEN ONE THINKS OF PRINCE EDWARD ISLAND, images of rolling potato fields, fresh lobster, and red-headed orphans often come to mind. However, beneath the surface of these traditional industries, a thriving and rapidly expanding bioscience sector is transforming the Island into a global player in innovation. Bioscience is now PEI’s second-largest industry and its growth is nothing short of remarkable.

Over the years, the PEI BioAlliance has nurtured a bioscience cluster that includes more than 60 companies and generates over $600 million in annual sales.

In the last year, there were five billion-dollar bioscience transactions in Canada. Two of these deals happened in PEI—a testament to the province’s growing influence and capability in this sector.

THE RISE OF A BIOSCIENCE POWERHOUSE

Founded in 2005, the PEI BioAlliance is the ‘innovation intermediary’ of the Island’s bioscience cluster, catalyzing collaboration among private sector companies, investors, research institutions, and government agencies. The BioAlliance has played a pivotal role in aligning strategy, attracting investment, and accelerating the commercialization of scientific research.

Today, PEI’s bioscience companies are leaders in human, animal, and fish health, natural product chemistry, and diagnostics. Recent initiatives like BIOVECTRA’s first-inCanada mRNA vaccine manufacturing facility, the development of the Canadian Alliance for Skills and Training in Life Sciences (CASTL), the Biomanufacturing Incubator, and the BioAccelerator are just a few examples of the exciting projects defining the province as a centre of expertise in biomanufacturing and driving the sector’s growth.

BILLION-DOLLAR DEALS AND EXPANDING HORIZONS

PEI’s bioscience sector recently captured international headlines with two landmark transactions.

In September 2024, Agilent Technologies completed its acquisition of PEI-based pharmaceutical company BIOVECTRA for $925 million (USD). In February 2024, Merck Animal Health acquired Elanco Animal Health’s aqua business for $1.3 billion in cash with PEI fish vaccine manufacturing assets a key part of the transaction.

These landmark deals point to the broader trend of bioscience becoming a driver of economic prosperity in PEI.

FROM COLLABORATION TO COMMERCIALIZATION

What sets the BioAlliance apart is the unique collaboration between industry, government, research, and academic institutions.

Through partnerships with the University of Prince Edward Island, Holland College, and the National Research Council’s Charlottetown-based Aquatic and Crop Resource Development labs, the PEI BioAlliance helps translate academic research into commercially viable products.

Beyond billion-dollar deals, the BioAlliance is dedicated to attracting and supporting local, and global startups and SMEs whose technologies are a fit with cluster expertise and infrastructure offerings. Another key BioAlliance asset in this mission is Emergence, Atlantic Canada’s Bioscience Business Incubator, with over 50 clients across the region and beyond.

NO ‘SMALL POTATOES’

With its expertise, infrastructure, talent, and collaborative spirit, PEI’s thriving bioscience sector proves that a small province can make a big impact, leading the way into a new era of prosperity and global recognition. The second-largest industry on the Island is redefining what is possible in economic diversification, positioning it as a leader in global bioscience innovation.

OBIO® and CATTI Collaborate to Train 280 People, Boosting Canada’s Biomanufacturing Capacity for Cell and Gene Therapies

OBIO® AND THE CANADIAN ADVANCED THERAPIES TRAINING INSTITUTE (CATTI) have partnered to spearhead a comprehensive initiative to address the escalating demand for skilled personnel in the rapidly growing field of cell and gene therapy (CGT) biomanufacturing. CGTs is a distinct area in the biomanufacturing sector requiring specialized skill sets compared to conventional biopharmaceutical manufacturing. Through extensive collaborations with companies in the sector developing CGTs, a focused curriculum was developed and tailored to meet their specialized workforce needs.

Employers with a growing need for talent in biomanufacturing of cell and gene therapies are invited to contact OBIO ® and CATTI to learn more about the graduates of the program.

The program’s curriculum is based on a stackable credentialing approach and tailored to various job roles, focusing on both conceptual and practical skills essential for Advanced

ABOUT OBIO®

Therapy Medicinal Products (ATMPs) development and manufacturing. The core of the program is the Cell and Gene Therapy Bootcamp, a one-week (~40 hrs.) on-site training at CATTI’s Guelph facility. This hands-on experience helps participants master key skills such as cell culture, aseptic techniques, and good documentation practices, with proficiency assessed by experienced trainers. Additionally, part-time courses complement the bootcamp, offering live online and self-paced training in Advanced Therapies GMP, CMC, CGT commercialization, IP and licensing, and professional skills.

This collaboration aims at training 280 people across Canada before the end of March 2026 and will support eligible participants with training subsidies. This program is funded by Upskill Canada (powered by Palette Skills) and the Government of Canada.

“OBIO ® is delighted to partner with Upskill Canada and CATTI to offer the

national Advanced Biomanufacturing for Cell and Gene Therapies training program. Developing a highly skilled biomanufacturing workforce by enabling talent to train for in-demand roles will enable Canadian companies to commercialize cell and gene therapies in Canada and increase domestic biomanufacturing capacity.”

– Dr. Maura Campbell, President and CEO of OBIO ®

“The goal of this exciting funding opportunity from Upskill Canada is to ensure that every participant experiences a professional benefit— whether through a new job or expanded responsibilities—as a direct result of their training,” says Vanessa Laflamme, CEO of CATTI. We are thrilled to collaborate with OBIO ® in providing training in a fully operational lab, emulating GMP environments, where trainees can practice their skills without facing costly consequences, turning every challenge into an opportunity for growth.”

OBIO® is a not-for-profit, membership-based organization engaged in strategy, programming, policy development and advocacy to further the commercialization of human health technologies that position Canada as a leader in the international marketplace. www.obio.ca

About CATTI

The Canadian Advanced Therapies Training Institute (CATTI), delivers hands-on and virtual training for efficient and rapid upskilling of the biomanufacturing workforce required in Canada and internationally, including highly specialized hands-on training to produce cell and gene therapies. www.catti.ca

About Upskill Canada, powered by Palette Skills

Upskill Canada is dedicated to bridging the gap between employers and the talent they need to innovate and grow.

On graduation, our diverse talent pool of mid-career professionals brings industry-specific expertise, transferable and professional skills honed through rigorous training to your workforce. www.paletteskills.org/upskill-canada

CATTI trainees practicing aseptic techniques while performing cell culture

Mitsubishi Tanabe Pharma Canada, Inc. Harnesses the Power of Technology to Help Fuel Earlier Diagnosis and Access to Rare Disease Innovations

SINCE ESTABLISHING ITS CANADIAN HEADQUARTERS in Toronto in 2018, Mitsubishi Tanabe Pharma Canada, Inc. (MTP-CA) has relentlessly focused on bringing innovative treatments and solutions for Canadians facing complex and life-threatening diseases.

The same year the company officially opened its doors, it brought to market the first novel treatment option for Canadians living with amyotrophic lateral sclerosis (ALS), a rare, neurological disease, in nearly 20 years.1  In 2022, following a Priority Review by Health Canada, MTP-CA introduced an oral suspension version of its drug that is formulated with the challenges of people living with ALS in mind.

But for Andy Zylak, President of MTP-CA and his team, there is more to their mission than simply bringing products to market successfully. “In addition to new therapies, MTP-CA has invested heavily in research and development projects, including forward-thinking health solutions so that patients may access therapies earlier on in their diseases, collaborations with partners to generate real-world evidence and one-of-a-kind solutions to help advance the clinical practices of healthcare professionals,” says Zylak.

MTP-CA’s entrepreneurial spirit and patient-first philosophy are deeply rooted in a legacy set by its parent company, Mitsubishi Tanabe Pharma Corporation (MTPC)

in Japan, one of the oldest and most successful pharmaceutical companies in the world. For more than 300 years, MTPC has tirelessly pursued medical breakthroughs and has discovered and produced several first-in-class medicines for serious diseases, including multiple sclerosis (MS), diabetes mellitus (DM), and ALS.

As a wholly owned subsidiary of Mitsubishi Tanabe Pharma America, Inc. (MTPA), MTP-CA is part of the company’s global reach, bringing its commitment to research and innovation and addressing the unmet medical needs of those living with rare, life-threatening diseases to Canada.

“Commitment to patients is at the core of everything we do”, says Louise St-Onge, Director Marketing, Patient Support Programs & Advocacy at MTP-CA. “Early diagnosis for patients is crucially important in getting access to approved medications, clinical trials and the multidisciplinary care and therapies that can potentially extend their lives.”

In 2023, MTP-CA supported the launch of the Process for Progress in ALS: An EMR-based practice enhancement initiative, an important new artificial intelligence (AI) program designed to analyze de-identified electronic medical records (EMRs) and identify individuals for which follow-up investigations for ALS or referral to a specialty centre may be clinically appropriate. The cutting-edge

Looking towards the future, Zylak confirms “We remain dedicated to driving scientific discovery to meet the needs of people suffering from serious and often life-threatening illnesses. Our pipeline is focused on research in therapeutic areas where we believe we have the best opportunity to address the challenges of complex and debilitating conditions.”

technology*, developed by Ensho Health in collaboration with a steering committee of Canadian neurologists, aims to improve early detection of ALS and support healthcare professionals (HCPs) in making timely decisions.2

MTP-CA is also currently working with respirologists and respiratory therapists, who focus on ALS patients, on a virtual Forced Vital Capacity (vFVC) test program as an option for patients living in remote communities, or who may not be able to travel to access an in-person FVC test. FVC is the primary test used to evaluate the breathing of ALS patients and a key criteria for insurance coverage for some ALS drugs. Because the disease can progress quickly, having rapid access to FVC test results can make a difference in a patient qualifying for private or public reimbursement to new, innovative therapies.

“We work closely with federal and provincial governments, along with other partners, to ensure patients have access to, and reimbursement for, life changing therapies,” says Brad Alyward, Director, Pricing, Market Access & Government Affairs at MTP-CA. “A vital part of our innovation process is to identify opportunities for partnerships that provide patients across Canada with the best options for positive health outcomes.”

Neurology Account Specialists Marc Masse and Sophy Olafson have been driving MTP-CA innovation in one-of-akind solutions to help advance the clinical practices of HCPs—such as How to Break the News in ALS/MND: A Primer for Physicians and Allied Health Professionals3 —a program that aims to help HCPs better understand the impact that delivering news of an ALS or motor neuron disease (MND) diagnosis can have on patients, caregivers, and on HCPs themselves. The company further supports HCPs through the sponsorship of educational events including annual Clinical ALS Days in Ontario and Quebec.

In addition, MTP-CA is a critical driver in the advancement of essential therapies for rare diseases. MTP-CA’s commitment to patients and their communities continues with a robust late-stage pipeline of investigational treatments for difficult-to-treat diseases and commercializing products with significant unmet medical needs in Canadian markets.

“To provide Canadians with access to cutting edge treatments for rare disease that can change lives, we support research initiatives and provide grants to the Canadian research network,” says Dung Pham, Medical Affairs Director (Canada) at MTP-CA. “We also collaborate with partners in the rare disease ecosystem to generate real-world evidence (RWE).”

Looking towards the future, Zylak confirms “We remain dedicated to driving scientific discovery to meet the needs of people suffering from serious and often life-threatening illnesses. Our pipeline is focused on research in therapeutic areas where we believe we have the best opportunity to address the challenges of complex and debilitating conditions.”

Speaking about the MTP-CA team, Zylak adds “It is especially rewarding to work with a team that is passionate and motivated to make a difference and we will continue to invest in finding ways to improve time to diagnosis, access to treatment and bringing the latest technologies to this important market.”

To learn more about Mitsubishi Tanabe Pharma Canada, Inc. please visit https://www.mt-pharma-ca.com/ for additional information.

*The MNd-5 algorithm is a process for converting input parameters to a likelihood estimate. It is deployed at the Toronto, Canada data lab of Ensho Health through the MNd-5 CDL Module (“CDL Module”). The CDL Module is comprised of the MNd-5 Likelihood Estimator (“Likelihood Estimator”) which encodes it in software and a graphical user interface called the MNd-5 Controller (“Controller”). The CDL Module was developed to the ISO 13485:2016 standard for medical devices in compliance with Ensho’s Quality Management System. The MNd-5 CDL Module is registered as medical device software in Canada under the Medical Device Establishment License of Ensho Health (license 16208). The software that encodes the MNd-5 algorithm and applies it to EHR data is Class I medical device software in Canada developed and deployed under the Medical Device Establishment License of Ensho Health.

1. Health Canada Drug Database. Available at: https://health-products.canada.ca/ dpd-bdpp/ Accessed on September 9, 2024.

2. Process for Progress in ALS: An EMR-based practice enhancement initiative. Available at: https://www.alsprogress.ca/. Accessed on September 9, 2024

3. International Alliance of ALS and MND Associations. How to Break the News in ALS/MND. Available at: https://www.als-mnd.org/support-for-health-professionals/ how-to-break-the-news-in-als-mnd. Accessed on September 16, 2023.

Made in Canada: How Gene Bio Medical is Pushing the Boundaries of Diagnostics to Deliver Accessible Solutions

BRITISH COLUMBIA-BASED GENE BIO MEDICAL (GBM) is a leader in the diagnostics sector, with innovative solutions, from advanced molecular testing to point-of-care technologies. With a proven track record of commercializing breakthrough healthcare products, GBM collaborates with top universities and global partners to deliver cutting-edge diagnostic tools that meet the needs of patients and healthcare providers worldwide. Committed to quality and sustainability, GBM provides accessible, affordable diagnostic solutions, while minimizing environmental impact through eco-friendly manufacturing processes.

PROVIDING LEADERSHIP AND SUPPORT DURING AND POST-PANDEMIC

During the COVID-19 pandemic, GBM swiftly developed a reliable SARS-CoV-2 rapid test and produced over 48 million antigen tests, becoming one of the few Canadian manufacturers capable of meeting large-scale demand. Their SwiftSwab™ antigen self-test kits—available at retailers like Walmart, Jean Coutu and PharmaChoice— continue to safeguard public health across Canada.

Building on this success, GBM is leading the development of next-generation, ultra-sensitive diagnostics using mRNA technology in collaboration with Canada’s top academic institutions. These RNA-based point-of-care tests deliver precise results in 15 minutes, addressing a wide range of diseases.

GBM has also partnered with leading Canadian research hubs, including the Canadian Biomedical Research Fund (CBRF) PRAIRIE Hub, the Immuno-Engineering and Bio-manufacturing Hub, and the Canadian Hub for Health Intelligence & Innovation in Infectious Diseases. The company supports researchers in advancing their technology readiness, fostering innovation and accelerating the development of groundbreaking diagnostic solutions that benefit healthcare providers and patients.

STRENGTHENING

CANADA’S BIOMANUFACTURING

INDUSTRY

“During the COVID-19 pandemic, our teams supplied 6% of the rapid antigen tests used in Canada, but the crisis revealed gaps in our biomanufacturing capacity,” says GBM CEO Jessica Hu. “Relying on imports leaves us vulnerable in future health emergencies, making it critical to strengthen our domestic capabilities.”

Hu emphasizes that investing in local biomanufacturing is key to emergencies preparedness and to the growth of Canada’s life sciences sector. “By building robust production capacity, we can reduce import reliance, ensure higher quality control, create jobs and drive economic growth.”

ADDRESSING GLOBAL HEALTH CHALLENGES

GBM is addressing global health challenges by leveraging advanced diagnostic technologies, including molecular and AI-driven platforms, to combat diseases like

Jessica Hu (with Robert Piasentin, Partner at McMillan LLP) at Entrepreneurship Immersion Week hosted by entrepreneurship@UBC
Jessica Hu, Founder & CEO Gene Bio Medical

GBM’s proprietary mRNA-based detection technology and BioChip Multiplex platforms revolutionize molecular diagnostics by enabling ultra-sensitive, rapid detection of RNA and DNA biomarkers at femtomolar sensitivity, matching that of PCR diagnostics.

influenza and COVID-19. Their ultra-sensitive rapid testing kits enable early detection and effective disease management. Collaborating with governments, research institutions and global health organizations, GBM ensures scalable, cost-effective and accessible solutions, driving innovations that improve public health and enhance global health security.

RECENT BREAKTHROUGHS IN MOLECULAR DIAGNOSTICS

GBM’s proprietary mRNA-based detection technology and BioChip Multiplex platforms revolutionize molecular diagnostics by enabling ultra-sensitive, rapid detection of RNA and DNA biomarkers at femtomolar sensitivity, matching that of PCR diagnostics. Optimized for early disease detection and multiple pathogen testing, the platform detects one molecule of RNA per microliter at a much lower cost than traditional methods. By improving efficiency and reducing costs, GBM helps healthcare providers respond quickly to outbreaks and empowers patients to make informed treatment decisions.

INTEGRATING AI IN DIAGNOSTIC PLATFORMS

To further improve the reach and actionability of rapid tests, GBM has integrated AI into its diagnostic platform. Their AI-enabled system aims to use multiplexed data obtained from rapid tests to enhance clinical decisionmaking, which will reduce human error and connect patients to the most appropriate healthcare provider. The company’s AI-driven approach is yet another step in improving patient outcomes with more efficient care.

BUILDING A HEALTHIER, MORE CONNECTED WORLD

The GBM team are active participants in national and international events that support biotechnology and global health solutions.

In the past two years, GBM was honoured to take part in the prestigious Team Canada Trade Mission—which was led by the Honourable Mary Ng, Minister of Export Promotion, International Trade and Economic

Development—to the UK, South Korea, Malaysia and Vietnam. Additionally, GBM was selected as a delegate for the Asia Pacific Foundation of Canada’s Women-only Business Mission to Thailand, Taiwan and Vietnam! These opportunities allow GBM to forge new international partnerships and promote gender-inclusive trade while showcasing Canada’s strength in life sciences.

ENVIRONMENTAL IMPACT AND SUSTAINABILITY INITIATIVES

GBM is committed to sustainable operating practices. The company has implemented energy-efficient production processes and is exploring the use of sustainable materials in its diagnostic products. These eco-friendly practices— combined with innovations in wearable biosensors and microfluidic devices—ensure that GBM’s diagnostic solutions remain environmentally responsible while maintaining high performance and accuracy.

Get Involved in the Future of Innovative Diagnostics Learn more about GBM’s innovations and explore collaboration opportunities: www.genebiomedical.com.

Jessica Hu and Sara Wilshaw (Chief Trade Commissioner at Global Affairs Canada, Christine Nakamura(VP of Asia Pacific Foundation of Canada) at Trade Mission Team Canada in Malaysia

Delivering on the Promise of Genetic Medicines

A Conversation with Entos Pharmaceuticals’ CEO

John Lewis and CSO Arun Raturi

ENTOS PHARMACEUTICALS (ENTOS) RECENTLY made a significant contribution to the field of genetic medicine through their research published in Cell1. Their work highlights a breakthrough in the delivery of DNA and RNA using their proprietary proteolipid vehicle (PLV) platform, Fusogenix™. Collaborating with the University of Alberta, Dalhousie University, Oisín Biotechnologies, and Aegis Life, this work showcases a new approach to overcome the limitations of traditional delivery systems, such as adenoassociated viruses (AAV) and lipid nanoparticles (LNPs)

John Lewis, CEO of Entos, emphasizes the importance of this advancement: “While AAV and LNP platforms have paved the way for approved therapies in genetic medicine, they come with limitations in safety, immune responses, and biodistribution. Our FAST-PLV™ platform was designed to overcome these challenges, delivering genetic medicines to a broader range of tissues safely and effectively.”

ADVANCING BEYOND CURRENT LIMITATIONS

Arun Rauri, CSO of Entos, acknowledges the significance of past innovations: “We deeply appreciate the pioneering work of fellow Canadian companies like Acuitas Therapeutics, which laid the foundation for LNP technology, and the groundbreaking success of mRNA therapies demonstrated by Pfizer and Moderna. At Entos, we’re pushing these advancements further by creating a novel proteolipid vehicle (PLV) delivery system that avoids the limitations of traditional approaches like endocytosis. Our platform reduces immune activation while achieving efficient, targeted delivery, which could have transformative implications for gene therapies and next-generation vaccines.

The FAST-PLV platform allows for direct fusion of the PLV platform with the cell membrane, avoiding the toxicity often associated with LNPs and broadening the range of

applications. Unlike other systems, especially in DNA delivery, the Fusogenix PLV platform can accommodate larger genes and target many cell types.

A VISION FOR THE FUTURE

The development of the FAST-PLV platform stems from John Lewis’ academic research. Dissatisfied with the limitations of existing DNA and RNA delivery systems, Lewis collaborated with Dr. Roy Duncan of Dalhousie University, whose discovery of fusion-associated transmembrane (FAST) proteins provided the foundation for the PLV platform.

“Our vision was to create a versatile, non-liver-tropic delivery vehicle that could target tissues beyond the traditional scope of AAV and LNP platforms,” explains Lewis. “This was a crucial milestone, as we work towards making gene therapies accessible and safe for a broader range of conditions.”

DELIVERING ON GENETIC MEDICINE’S FULL POTENTIAL

Where other platforms face immune response challenges or are limited to specific organs like the liver, the Fusogenix PLV platform excels in delivering genetic material to extrahepatic tissues. This was demonstrated in the Cell paper where the platform showed safe and effective delivery of DNA and RNA in mouse and non-human primate models. Its low immunogenicity also allows repeat dosing, crucial in addressing diseases requiring ongoing or multiple interventions.

“The ability to re-dose is a game-changer,” says Raturi. “The minimal immune stimulation and broad

2.

biodistribution of the PLV make it a scalable solution for treating diseases that need repeated interventions.”

LOOKING AHEAD

Entos remains committed to translating these scientific breakthroughs into life-changing therapies. Beyond their COVID-19 vaccine booster program, which is in Phase 1 trials, they are actively pursuing gene therapies for singlegene conditions like Cystic Fibrosis (CF), Juvenile Macular Degeneration, and Muscular Dystrophy. Once considered out of reach due to the size of the genes involved, these diseases may now be curable because of advancements like the PLV platform.

The Cystic Fibrosis Foundation, for example, has been pushing for safer delivery methods with investments in AI-designed gene therapy carriers to overcome the immune challenges associated with traditional viral vectors. “Gene therapy has the potential to treat anyone with CF, including those with rare and nonsense mutations,” noted the senior director of genetic therapy programs at the Foundation 2 .

By addressing the challenges of large-gene delivery, the Fusogenix PLV platform offers a pathway to cures once considered beyond reach for previously untreatable genetic disorders.

“We’re on the cusp of a new era in genetic medicine,” says Raturi. “With our FAST-PLV platform, we’re not just overcoming the limitations of current technologies—we’re opening doors to safer, more effective treatments for a broad range of conditions. Our work in Cell is just the beginning.”

1. Brown, D.W., Wee, P., Bhandari, P., Bukhari, A., Grin, L., Vega, H., Hejazi, M., Sosnowski, D., Ablack, J., Clancy, E.K., et al. (2024). Safe and effective in vivo delivery of DNA and RNA using proteolipid vehicles. Cell 187, 5357-5375.e5324. 10.1016/j.cell.2024.07.023.
Foshay, K., and Howe, K. (2024). Research Overview: Genetic Therapies in Cystic Fibrosis. Cystic Fibrosis Foundation.

Canada’s Healthcare at a Crossroads: Embracing Innovation for a Healthier Future

IN THE RAPIDLY EVOLVING LANDSCAPE of life sciences, Canada faces the challenge of adapting. Breakthrough treatments in areas like gene editing, precision medicine, and vaccines have brought us into a golden era of scientific discovery. Yet, while science advances, Canada’s healthcare system remains rooted in the past, unable to keep up with the pace of innovation.

For Canada to lead in healthcare, we need a system that not only embraces innovation but also ensures timely access to the medicines of tomorrow. Innovative Medicines Canada believes that three key priorities should guide our policymakers: supporting advanced diagnostics and precision medicine, enabling innovation-driven policy, and fostering collaboration across sectors.

First, as personalized treatments become more common, our healthcare infrastructure must evolve to integrate advanced diagnostic testing. Patients deserve the right treatment at the right time, and that requires investment in technologies and data systems to deliver on the promise of precision medicine.

Second, innovation must be the driving force behind healthcare policy. Too often, the conversation focuses on short-term costs rather than long-term value. New healthcare models, such as outcomes-based agreements, ensure that payments for drugs are linked to the results they deliver for patients, providing a sustainable way forward. We should be looking to examples from countries like Germany and France, where innovation is leading to better patient outcomes and system efficiencies.

Finally, collaboration is essential. No single entity can address the challenges of modern healthcare. Governments, healthcare providers, pharmaceutical companies, and patients must co-create solutions that

Innovative Medicines Canada believes that three key priorities should guide our policymakers: supporting advanced diagnostics and precision medicine, enabling innovation-driven policy, and fostering collaboration across sectors.

ensure access to life-saving treatments. Initiatives like Target Zero, which aims to improve access to new medicines by reducing time of review between Health Canada and the Canadian Drug Agency to zero days, demonstrate that when regulatory bodies and industry work together, patients benefit. But we need more of this, and we need it on a larger scale.

As we look ahead, it’s clear that Canada must act now to build a healthcare system that keeps pace with scientific advancements. The future of Canadian healthcare depends on it.

Dr. Bettina Hamelin, President, Innovative Medicines Canada

EMBRACING INNOVATION.

Canada’s healthcare system needs to keep pace with the advances in science. Innovation is transforming treatments and offering new hope for patients.

Let’s accelerate access to life-saving treatments by embracing innovation, shaping impactful policies, and collaborating for better health outcomes.

Accelerating Breakthrough Immunotherapies BioCanRx

From the Lab to Clinical Trials

From 2002-2024 less than 4% (36 out of 948) immunotherapy clinical trials run in Canada were based upon discoveries made in our own laboratories. While this represents a substantial improvement over prior years – fewer that 1% of clinical trials in Canada were based on Canadian innovations between 2002-2015 – it isn’t enough.

The BioCanRx network was created to bring together the world-class science being developed in Canada with existing infrastructure and build an innovative translational research program that could help bring immunotherapy for cancer innovation to Canadians.

Today, BioCanRx is a Canadian network of dedicated scientists, clinician, cancer stakeholders, academic institutions, NGOs and industry partners all working towards the development of leading-edge immune oncology treatments for the benefit of patients. To do

this, we focus on supporting translational research –a cornerstone of modern medical innovation, bridging the gap between basic scientific discoveries and clinical applications that improve patient care and public health

Our goal? Move a portfolio of Canadian discoveries into products available to Canadian cancer patients, embedding GMP biomanufacturing from the very beginning. How? By investing time, financial resources and expertise to support the translation of world-class technologies from the research lab to clinical trials – an area known to lack critical funding. In addition, BioCanRx is committed to cultivating biotherapeutics expertise in Canada. Through professional development programs, internships and partnerships with academic institutions, we are training the next generations of researchers and developing highly qualified personnel skilled in all aspects of clinical translation from the lab bench to the clinic.

The result? BioCanRx network members are contributing to a high-performing and lauded program that is providing curative therapies to Canadian cancer patients today. And this approach to supporting translational research is driving transformational change in the health research ecosystem. In fact, it is a shining example of how to catalyze Canada’s innovation potential and deliver real results for Canadians.

To date, the BioCanRx network has:

■ Successfully advanced 34 novel therapeutics and approaches targeting 40 cancer indications through its translational pipeline, including hard-to-treat and refractory cancers.

■ Treated 400 patients in 12 clinical trials.

■ Enabled the training of over 1,100 HQP, providing many of them with advanced training in translational research, GMP biomanufacturing, and science communication.

■ Worked with 202 companies and other charities.

■ Introduced over 29 new therapies to the CDN ecosystem and created 6 spinouts.

■ Leveraged the initial $40M investment by the Government of Canada into $109.49M.

Economic Development Office

AS ONE OF THE FASTEST-GROWING CITIES IN CANADA , Brampton is home to 700,000 people and 100,000 businesses. People are at the heart of everything we do. We are energized by our diverse communities, we attract investment, and we are embarking on a journey to lead technological and environmental innovation. We partner for progress to build a healthy city that is safe, sustainable and successful.

Visit investbrampton.ca to learn more.

BRAMPTON INNOVATION DISTRICT

Brampton’s award-winning Innovation District—in the centre of Canada’s Innovation Corridor—is a thriving entrepreneurial ecosystem. Home to a network of companies, educational institutions, incubators and accelerators in the heart of downtown, the Innovation District supports tech-enabled businesses at all stages of development.

Visit investbrampton.ca/innovation-district to learn more.

MEDTECH

With new and established companies calling Brampton home, and the recent announcement of Toronto Metropolitan University’s new school of medicine—the first new medical school in the GTA in 100 years—Brampton’s health and life sciences sector is on the cusp of an exciting phase of growth.

Visit www.brampton.ca/mttf to learn more about the MedTech Task Force.

OSLER

RESEARCH

INSTITUTE FOR HEALTH INNOVATION

Established in 2013, the William Osler Health System’s (Osler) research program has experienced remarkable growth and is now advancing to the next level— transitioning into a dedicated research institute.

The Osler Research Institute for Health Innovation’s (ORIHI) main priority is to meet the urgent health needs of our patients and communities by providing practical, real-world solutions derived from applied research.

Excellence in applied research ensures that findings can be easily and quickly translated into practice, leading improvements in patient care, health outcomes and system performance.

Positioned uniquely as a community hospital engaged in cutting-edge research, ORIHI’s approach delivers timely benefits for patients while also shaping future treatments and care strategies.

Visit www.williamoslerhs.ca/research for your invitation to the ORIHI formal launch events during Celebrate Research Week , November 18 to 22, 2024.

TORONTO METROPOLITAN UNIVERSITY (TMU) SCHOOL OF MEDICINE

TMU’s School of Medicine, located in Brampton is designed to shift the paradigm of healthcare delivery and improve the well-being of individuals, families and communities. With a community-driven, intentionally inclusive approach, the new school will train doctors whose cultural awareness and humility are as crucial as their medical skills. The school will welcome 94 medical students and 105 residents in 2025 pending successful preliminary accreditation.

TMU is transforming the former Bramalea Civic Centre into a state-of-the-art medical school featuring functional, flexible learning spaces and the latest simulation and digital anatomy technology. Equity, diversity and inclusion, decolonization and reconciliation will be intentionally infused into the building’s design; this building project is also the first at TMU to integrate the university’s Indigenous Design Guidelines—developed in consultation with Indigenous community members—in the design process.

From

evidence. To engagement. To an entire ecosystem.

We believe “what’s possible” can always go further. That’s why we do things differently at IQVIA – by bringing the science of healthcare together with data science, advanced analytics and expert knowledge. It’s how we look beyond what’s expected in healthcare to see what’s possible.

Others may offer a way forward. IQVIA gives you a way further.

Turn static files into dynamic content formats.

Create a flipbook
Issuu converts static files into: digital portfolios, online yearbooks, online catalogs, digital photo albums and more. Sign up and create your flipbook.